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Introduction
Noonan syndrome (NS) is a genetic disorder, characterised by short stature, 
distinctive facial appearance, congenital heart defects and developmental 
delay (Noonan & Ehmke, 1963).  Its prevalence is estimated between 1 in 1000 
and 1 in 2500 live births (Nora, Nora, Sinha, Spangler & Lubs, 1974), but the 
accuracy of these estimates is under debate. In contrast with other genetic 
disorders such as Down’s syndrome, Noonan syndrome is relatively unknown, 
possibly because patients with NS may not typically experience problems in 
functioning.
 However, the majority of patients with NS have a somatic history with 
frequent hospital visits in childhood, and they were often bullied in youth. 
Although intelligence levels seem to be within the normal range, about half of 
the children with NS need special care and counselling (Shaw, Kalidas, Crosby, 
Jeffery & Patton, 2007). Studies so far have predominantly examined children 
with NS, using limited behavioural and cognitive measures. These contrastive 
findings warrant research and analyses of specific cognitive and other adaptive 
abilities, especially in adults. 
 This thesis focuses on cognitive functioning of adults with NS, taking (inter- 
actions between) genetic, physical, cognitive and behavioural manifestations 
in NS into account.
Noonan syndrome
Noonan syndrome was first described in 1963 by Jacqueline Anne Noonan and 
Dorothy Ehmke, pediatric cardiologists. They reported clinical and genetic 
findings of a group of boys and girls with a pulmonary valve stenosis (a 
thickening of the heart valve that separates the right ventricle from the 
pulmonary artery, resulting in a reduction of flow of blood to the lungs) short 
stature, typical faces and skeletal abnormalities (see Figure 1). Their symptoms 
showed overlap with those of Turner syndrome, but were present in both boys 
and girls, and chromosome analysis was normal. It was human geneticist 
John Opitz who suggested the eponym Noonan syndrome for this newly 
distinguished genetic entity. 
 In retrospect, a student named Kobylinski (1883) gave an earlier description 
of the syndrome when he published his report ‘Ueber eine flughautähnliche 
Ausbreitung am Halse’ [About a flight membrane-like extension in the neck], 
referring to the webbing of the neck which is present in about one quarter of 
the patients with NS (see Figure 2). 
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Genetics of Noonan syndrome
NS is a Mendelian trait, transmitted in an autosomal dominant matter. A 
significant percentage of cases are sporadic, due to de novo mutations. In 1994, 
linkage analysis suggested a gene for NS to be located on the long arm of 
chromosome 12 (Jamieson et al., 1994; Van der Burgt et al., 1994). In 2001 Tartaglia 
and colleagues discovered the major disease gene for the disorder, PTPN11. In 
approximately 50% of the patients with NS, a missense mutation is found in this 
gene. PTPN11 is one of the genes of the Ras-MAPK pathway, a signal transduction 
cascade that has been studied extensively for its role in human oncogenesis. 
This signaling cascade regulates cell proliferation, differentiation and survival. 
PTPN11 encodes the non-receptor protein tyrosine phosphatase SHP2. The 
mutations associated with NS result in a gain of function of SHP2 (Tartaglia & 
Gelb, 2005). These findings establish hyperactive Ras as a cause of developmental 
abnormalities seen in NS (Schubbert, Shannon & Bollag, 2007). To date, germline 
mutations in eight other genes in the Ras-MAPK pathway have been identified 
as causative in NS and closely related disorders: SOS1 (about 10% of the cases), 
RAF1 (5-15%), KRAS (2-5%), NRAS (<2-5%), BRAF (<2%), SHOC2 (<2%), MAP2K1 
(MEK1) (<2%) and CBL (<2%) (Tartaglia et al., 2011). 
 The diagnosis NS is primarily made on clinical grounds, by observation of 
cardinal features. The most recent scoring system was developed in 1994 and 
updated and validated in 2010 (Van der Burgt et al., 1994; The Noonan Syndrome 
Guideline Development Group, 2010). Prenatal screening may detect symptoms 
suggestive of NS, such as cystic hygroma and nuchal lucency in foetuses with 
normal karyotypes (Van der Burgt, 2007; Tartaglia, Gelb & Zenker, 2011). Common 
characteristics of NS are postnatally reduced growth, facial dysmorphisms 
(e.g., wide-spread eyes, drooping eyelids, low-set ears), congenital heart 
disease, skeletal anomalies, and webbing of the neck. Additional features are 
hematologic and ectodermal anomalies, lymphatic dysplasia, cryptorchidism 
and variable cognitive deficits (Tartaglia et al., 2011; see Table 1). Weight and 
length are usually normal at birth. Neonatal feeding difficulties and failure to 
thrive are present in 63% of patients and resolve later in infancy. 
 As to milestones, children with NS demonstrate mild motor delay, which 
may be partly attributed to the muscular hypotony that is often present in 
early childhood. Mean age for sitting is 10 months, for walking alone 21 
months, and for talking 31 months. Articulation abnormalities are frequent in 
childhood (72%) (Sharland, Burch, McKenna & Patton, 1992). Mean adult height 
is about two standard deviations below normal (Otten & Noordam, 2009; 
Ranke et al., 1988). Phenotypic expression is highly variable and often milder 
in adulthood than in youth. 
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Figure 1   Rickey E., the first patient with  
Noonan syndrome studied  
by J.A. Noonan and colleagues;  
republished by Opitz, 1985
Figure 2   Kobylinski’s patient Leisar Eischikmann, possibly the  
first illustration of a patient with NS; published by Opitz  
& Pallister, 1979
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 Genetic testing is available to confirm the diagnosis and can be carried out 
on blood, placenta tissue and amniotic fluid samples. Only in about 75% of the 
patients diagnosed with NS, a mutation can be found. Absence of a mutation 
does not, however, exclude the presence of NS, which is still defined by its 
clinical features. The search for other mutations is still ongoing (Tartaglia, 
Zampino & Gelb, 2010; Tartaglia et al., 2011). 
Noonan-like phenotypes and genotypes
A number of disorders exist with a phenotype resembling that of NS, but with 
a different genotype. Like NS, the aforementioned Turner syndrome (TS) is 
often accompanied by short stature, heart conditions, neck webbing and facial 
dysmorphism. TS, however, only occurs in females and is determined by 
chromosomal abnormalities. Other syndromes with different genotypes but 
with appearances reminiscent of NS are William’s syndrome and Aarskog 
syndrome (Van der Burgt, 2007).    
 As described before, NS itself is a genetically heterogeneous disorder, 
with different mutations promoting upregulation of Ras signalling. There are 
a group of distinguishable syndromes with partially similar phenotypes in 
which mutations are also found in genes of the Ras-MAPK pathway. These 
include cardiofaciocutaneous (CFC) syndrome, Costello syndrome (CS), 
Neurofibromatosis type 1 (NF1), LEOPARD syndrome, Noonan syndrome-like 
with loose anagen hair (NS/LAH), and CBL-mutation associated syndrome 
(Tartaglia et al., 2011; see Figure 3). These syndromes share pathogenetic 
mechanisms and show clinical overlap with NS and they are grouped into a 
single family, the neurocardiofacialcutaneous syndrome family, or the 
Ras-opathies (Tidyman & Rauen, 2009). 
Cognition in Noonan syndrome
Most research on NS focuses on genetic aspects and somatic complications of 
the syndrome. Only limited data are available on cognitive functioning in NS. 
Information about functional or structural brain abnormalities could support 
the development of hypotheses about cognitive representations of NS, but 
imaging studies are scarce. In reviewing previous studies, intelligence appears 
the best-studied mental function with respect to NS (see e.g., Collins & Turner, 
1973; Pierpont et al., 2009), while attention, memory, visuoconstruction and 
planning abilities have only been addressed in a few case studies or in small 
groups of children with NS, usually without inclusion of controls (e.g., 
Horiguchi & Takeshita, 2003). 
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Table 1  Clinical features of Noonan syndrome
Facial dysmorphism 
Epicanthal folds 
Ptosis
		 Down-slanting	palpebral	fissures	
Triangular facies
Low set and/or posteriorly rotated ears
Light colored irises 
Ophthalmologic
Strabismus
Myopia 
Hearing Loss
Dental/Oral 
Malocclusion
High arched palate 
Cardiovascular
   Congenital heart defects 
Pulmonic stenosis 
Atrioventricular septal defects 
Aortic	coarctation
Secundum atrial septal defects 
Mitral valve defects 
Tetralogy of Fallot 
Ventricular septal defects 
Patent ductus arteriosus
   Hypertrophic cardiomyopathy 
Webbed neck with low posterior hairline 
Feeding	difficulties	
Postnatally reduced growth 
Developmental
Delay
Attention	deficit/hyperactivity	disorder	
Skeletal
Pectus	excavatum	and/or	carinatum	
Cubitus valgus 
Scoliosis
  Vertebral anomalies
Cryptorchidism 
Lymphatic
Lymphedema
Lymphangiectasia 
Hematological
Bleeding diathesis 
Thrombocytopenia 
Leukemia
[From: Tartaglia, Gelb & Zenker, 2011]
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depending on small convenience samples, multiple source assessment and 
good external validity of the instruments of choice are essential to allow 
patterns of deficits to emerge and to enable generalization of the results. 
 As a result of the recent grouping of NS and NS-like disorders into 
Ras-opathies, samples now often include more than one clinical syndrome, 
which may facilitate data collection and enhance opportunities to compare 
results between genetically associated subgroups. Research on information 
processing in mixed groups with Ras-MAPK associated dysregulation has up 
to now been focused on intelligence (Cesarini et al., 2009; Pierpont et al., 2009, 
2010a), aspects of visual functions (Alfieri et al., 2008, 2011a), memory (Alfieri 
et al., 2011b) and language (Pierpont et al., 2010b). Samples in these studies 
were mainly comprised of children and young adults, in different stages of 
brain development. In this thesis, cognition in a group of adults with NS is the 
subject of research.
Affective information processing
Besides investigation of the traditional cognitive domains such as intelligence, 
speed of information processing, memory, executive functions and visuocon-
struction, this thesis will also address aspects of affective processing in NS. 
Although emotional processing and cognitive function may be distinguished 
conceptually, they share neural mechanisms that modulate behaviour. The 
concept of affective information processing may be used for the processing of 
all kinds of emotional information, both in intrapersonal and interpersonal 
context (see e.g., Critchley, 2005). Social cognition may be considered a part of 
this broader concept, and relates to the processing of emotions in interpersonal 
situations. Adolphs (2001) has referred to social cognition as “the ability to 
construct representations of the relations between oneself and others, and to 
use these representations flexibly to guide social behaviour” (pp. 231). 
 Different aspects can be distinguished in the processing of affective 
information: the perception, the experience and evaluation, or the expression 
of socio-emotional information (Adolphs, 2009). Hence, affective information 
processing depends on other cognitive functions, such as visual perception, 
attention, memory, and executive functions. Studies in genetic diseases such 
as William’s syndrome, that is characterised by spared social cognition in 
contrast to impaired intelligence and cognitive deficits, illustrate that certain 
sets of genes can contribute disproportionally to social cognition (Bellugi et 
al., 2000).
 Examples of affective processes in an interpersonal context are the 
interpretation of body language, the anticipation of reactions, and recognition 
of emotions of others. Montagne, Kessels, De Haan & Perrett (2007) developed 
 Intelligence assessment in NS shows a broad range of IQ scores, with levels 
varying from mentally retarded to superior (Finegan & Hughes, 1988). In 
general, the level of intelligence falls within the normal range but in about 
one-third of the patients, mild mental retardation is found (Allanson, 2010). 
The more profound the phenotypic expression of NS, the stronger the mental 
capacities in general seem to be compromised (Troyer & Joschko, 1997; Van der 
Burgt et al., 1999).
 Many studies refer to observations of other cognitive difficulties in 
children with NS, especially in the domain of attention (Horiguchi & Takeshita, 
2003; Troyer & Joschko, 1997; Van der Burgt et al., 1999). Most of these studies 
have not included neuropsychological tests to substantiate these clinical 
observations. In the study of manifestations of genetic syndromes, usually 
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Figure 3   The Ras-MAPK signal transduction pathway
Note:	Schematic	diagram	showing	the	Ras-MAPK	cascade	and	affected	disease	genes	in	disorders	of	the	
neuro-cardio-facial-cutaneous syndrome family. The double ovals in dark grey and the light grey ovals 
represent generic dimerised cell-surface receptors binding to their ligand. CFCS: cardiofaciocutaneous 
syndrome	 (OMIM	 115150);	 CS:	 Costello	 syndrome	 (OMIM	 218040);	 LS:	 LEOPARD	 syndrome	 (OMIM	
151100);	NF1:	neurofibromatosis	type	1	(OMIM	162200);	NFLS:	neurofibromatosis	type	1-like	syndrome	
(also	 termed	 Legius	 syndrome;	 OMIM	 611431);	 NFNS:	 neurofibromatosis-Noonan	 syndrome	 (OMIM	
601321);	NS:	Noonan	syndrome	(OMIM	163950);	NS/LAH,	Noonan-like	syndrome	with	loose	anagen	hair	
(OMIM	607721).	[From:	Tartaglia,	Gelb	&	Zenker,	2011]
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specific problems in affective information processing, based on findings in a 
case study of a 19-year old woman with NS and a co-morbid anxiety disorder. 
They noticed impaired emotion expression in this patient, and suggested 
alexithymia to be associated with NS.
an experimental, computer-generated paradigm for the assessment of emotion 
recognition. Actors in video clips, in which the degree of the emotional 
expression is presented in increasing intensities, mimic the six basic emotions. 
After each clip, the participant has to choose the correct emotion (see Figure 4). 
 Alexithymia (‘no words for feelings’) may be considered an example of a 
deficit in affective processing. It refers to impairments in identifying and 
describing ones own emotions, an externally oriented mode of thinking, and a 
restricted fantasy life (Sifneos, 1973). The construct originally stems from 
psychoanalytic research on psychosomatic disorders, and has regained interest 
as a symptom of disturbed affective information processing. As such, alexithymia 
reflects ineffective regulation of emotional cognition and constitutes a major 
risk factor for a range of medical and psychiatric problems, including anxiety 
and depression (Conrad, Wegener, Imbierowicz, Liedtke & Geiser, 2009). 
Neuro scientific research aims at unraveling the neural bases for alexithymia 
in which, for example, corpus callosum and posterior cingulate cortex are 
likely to be involved (Aleman, 2005). 
 A shared observation in NS research concerns impairments in social 
competence and emotion expression. A delay in social-emotional development, 
little interaction with peers, poor insight into social situations and problems in 
verbalising and explaining emotional experiences have been described within 
this context (Lee, Portnoy, Hill, Gillberg & Patton, 2005; Sarimski, 2000; Wood, 
Massarano, Super & Harrington, 1995). Verhoeven et al. (2004) suggested 
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Figure 4   Example from the Emotion Recognition Task
[Montagne	et	al.,	2007]
Figure 5   “Among those left”, Ivan Le Lorraine Albright, 1928-1929;  
Carnegie Museum of Art, Pittsburgh (reprinted with permission)
Note:	 The	blacksmith	depicted	 in	Albright’s	painting	was	suggested	 to	have	Noonan	syndrome	 (Cole,	
1980).	 Indeed,	 genetic	 confirmation	 was	 provided	 by	 studies	 of	 a	 great	 grandson	 of	 the	 portrayed	
blacksmith,	who	also	had	clinical	features	of	the	syndrome,	as	well	as	cardiac	abnormalities	consistent	
with the diagnosis.
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Thesis outline
The objectives of the studies described in the present thesis were to explore 
cognitive functioning and processing of socio-emotional behaviour in adults 
with Noonan syndrome. The thesis starts with a literature review of the neu-
ropsychological profile in NS, mainly based on previous studies in children 
with NS (chapter 2), as well as a literature review on the neural substrates of 
alexithymia (chapter 3). Apart from these theoretical considerations, neuropsy-
chology and psychopathology in NS was explored by means of a pilot study in 
10 adult patients with NS (chapter 4). Then, affective information processing 
was examined empirically in a group of 40 patients with NS and compared 
with that in a group of controls carefully matched on age, sex, intelligence, and 
education level (chapter 5). In addition, chapter 6 describes the differences and 
similarities in other cognitive functions, i.e., speed of information processing, 
memory, executive functions and visuoconstruction of patients with NS versus 
controls. Finally, chapter 7 provides a summary and joint discussion of the 
main findings, and concludes with recommendations for future research.   
Introduction
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Neuropsychological framework 
in genetic research 
While neuropsychology shares a main principle with neurology in considering 
brain function as a frame of reference, the subject matter is always behaviour. 
It is the research discipline that combines neurosciences with social sciences 
and focuses on relations between brain and human cognitive, emotional, and 
behavioural functions. In this respect, cognition can be defined as “the infor-
mation-handling aspect of behaviour” (Lezak, Howieson & Loring, 2004, p.18).
 Because of its interdisciplinary identity, neuropsychology can provide a 
suitable framework for theorising on relations between genetic, neural or 
somatic makeup on the one hand, and cognitive and behavioural manifestations 
on the other. Knowledge about the interplay between these levels of functioning 
is important for our theoretic understanding of Noonan syndrome (NS), for 
diagnosing pathological manifestations on either of the levels mentioned, as 
well as for identifying clinical treatment needs. The neuropsychological 
approach can contribute to the decomposition of symptoms and behavioural 
presentations of genetic disorders, and because of this focus on the cognitive 
level, it is very appropriate in the identification of candidate endophenotypes 
(Gottesman & Gould, 2003).
 Only limited data are available on the (neuro)psychology of NS, leaving 
many questions unanswered. Still, when reviewing the existing research, 
some remarkable patterns in information processing and behaviour emerge, 
which deserve the attention of caregivers, teachers, doctors and psychologists 
who work with children or adults with NS. To facilitate understanding and 
appraisal of the Noonan-specific findings, some brief background information 
on measuring and interpreting behaviour will be presented first.
Measuring cognition and behaviour 
In neuropsychology, interactions between brain and behaviour are analysed 
by systematically evaluating cognitive function domains. These function 
domains are described by theoretical constructs, reflecting the multiple 
aspects of mental processes involved in thinking and experiencing. 
Traditionally, the following domains are distinguished: intelligence, learning 
and memory, attention and information speed, executive functions, verbal 
functions, perception and motor functions/praxis (Lezak et al., 2004). These 
‘cold’ cognitive functions dominated theory and research in the neurosciences 
for a long time. Recently, ‘hot cognition’, i.e., the cognitive processes involved 
Abstract
The current paper introduces concise neuropsychological assessment as an 
essential tool for studying the contribution of cognition and behaviour in the 
expression of genetic syndromes like Noonan syndrome (NS). Cognitive and 
behavioural findings in NS show intelligence scores across a wide range, with a 
mildly lowered average level. Language and motor development are often 
delayed, but no longer dysfunctional in adulthood. Continuing mild problems 
in selective and sustained attention are noted, as well as suboptimal organization 
skills and compromised abilities to structure complex information. These 
problems seem to culminate in learning difficulties, requiring attention for 
special needs in education. It seems that a complex of psychosocial immaturity, 
alexithymia and amenable traits is typical for patients with NS. Consequently, 
psychopathology or psychological problems in leading a self-serving life may 
often remain underreported. This is why the integration of the domain of 
social cognition and personality in NS assessment is advocated.
Published as: 
Wingbermühle, E., Egger, J., van der Burgt, I., & Verhoeven, W. (2009). Neuro-
psychological and behavioral aspects of Noonan syndrome. Hormone Research, 
72(Suppl. 2), 15-23.
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 Neuropsychological findings in NS will be presented per cognitive domain, 
followed by an overview of the literature on psychopathology and personality, 
including the study of quality of life. The findings in people with NS based on 
any of the known genetic mutations (PTPN11, KRAS, SOS1, RAF1) will be 
presented in a mixed form, as a result of the absence of distinctive information. 
Intelligence
Intelligence is not a unitary concept. The intelligence quotient (IQ) refers to a 
composite score, established by summing the results of a variety of subtests, 
each associated with different mental abilities. Nevertheless, the total IQ score 
has proven to be a strong predictor of school performance, and can be considered 
a measure of general intellectual ability. 
 Traditionally, verbal intellectual capacities are distinguished from performance 
capacities. Discrepancies between the verbal and performance levels are too 
often without question accepted as indicative of some sort of cognitive or 
psychological syndrome (e.g. nonverbal learning disorder). Nowadays, battery 
tests discriminating crystallised intelligence (academic skills) and fluid 
intelligence (problem solving abilities) are applied by neuropsychologists 
more and more, as they can offer more relevant information about cognitive 
functioning. 
 Intellectual development and intelligence appears to be the best-studied 
cognitive domain in NS. Almost every non-medical study includes some 
measure indicating the level of intelligence, or at least the level of education of 
the subjects under study. Since the 1970s, studies regarding intelligence in NS 
have shown a broad range of IQ-scores, with the level varying from mentally 
retarded to superior (Chery, Philippe, Worm & Gilgenkrantz, 1993; Collins & 
Turner, 1973; Finegan & Hughes, 1988; Hill, 1992; Lee et al., 2005; Mendez & Opitz, 
1985; Money & Kalus, 1979; Sharland et al., 1992; Van der Burgt et al, 1999). 
 Because of this wide range of individual IQ scores, mean group values are 
not extremely informative. As reported by several authors, in about one-third 
of the patients with NS mild mental retardation is found. In general, however, 
the level of intelligence falls within the normal range (Allanson, 2010), with 
verbal and performance capacities more or less equally divided. Nonetheless, 
there are indications that up to 50% of the patients with NS have special 
educational needs, underlining the importance of the further analysis of 
specific cognitive and other adaptive abilities (Shaw et al., 2007). 
Language 
With respect to language functions, comprehension of spoken or written language 
can be divided from expression (speech and writing).
in social interaction, including affective or emotional experiences, has received 
growing attention. It should be stressed that the segmentation of the cognitive 
domains is only conceptual. In fact, the distinct functions are mutually 
dependent and operate in close harmony.
 A psychologist makes use of several methods and techniques when 
performing a neuropsychological assessment. Such an assessment typically 
comprises structured interviews, informal and formal (test-based) observations, 
and a wide array of tests. Every serious neuropsychological assessment should 
comprise reliable and valid measures of intellectual and other cognitive 
domains, but also inventories and questionnaires to record psychopathology, 
personality and quality of life, alongside some specific scales depending on 
the question under examination (such as rating scales for specific complaints 
and coping styles). Only employing the method of pattern analysis, i.e. 
focusing on consistencies and discrepancies within and between various tests 
and other diagnostic sources, can result in a valid profile of strengths and 
weaknesses that supports clinical decision making. Regarding test interpretation, 
it is important to realise that cognitive impairments can be the result of a wide 
range of medical and psychological conditions, and that low tests scores may 
also occur in healthy people (Lezak et al., 2004).
Neuropsychological profile 
of children with NS
When exploring sources of potentially disturbed cognitive abilities in NS, 
reviewing abnormalities of the central nervous system coinciding with the 
syndrome is an obvious first step. The structural brain abnormalities that have 
been described most often in patients with NS are macrocephaly, hydrocephaly, 
epilepsy and hemangioma, suggesting vascular changes or malformations to 
be a key problem (Fryns, 1997; Gorke, 1980; Hara, Sasaki, Miyauchi & Takakura, 
1993; McAnena, Padilla & Buckley, 1984; Tanaka et al., 1999; Schon, Bowler & 
Baraitser, 1992). A typical abnormality in this respect is the Arnold-Chiari I 
malformation, a structural defect of the cerebellum, associated with balance 
and other motor functions, and possible cognitive problems as well (Heye & 
Dunne, 1995; Peiris & Ball, 1982) In two patients, moyamoya vascular changes 
have been described (Yamashita, Kusaga, Koga, Nagamitsu & Matsuishi, 2004). 
 Aside from a handful of reports about more or less infrequent neural 
complications, systematic research on the structure of the ‘normal’ NS brain is 
lacking. As deduction from the physical to cognition does not yet appear to be 
very fruitful, a bottom up approach in exploring the neuropsychological 
makeup of NS seems expedient.
N
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can occur explicitly or implicitly. When information is only needed to be kept 
active for a very short period of time (e.g. remembering a phone number until 
it is dialed), the memory system involved is referred to as working memory. It 
is often measured by digit-span-tasks. Obviously, working memory and 
concentration, an aspect of attention, are very closely related concepts.
 Learning disabilities are frequently mentioned when discussing the 
educational careers of patients with NS, but memory impairments do not seem 
to play a key role here. Research focussing on aspects of memory in children 
with NS is very scarce, and the few publications available are based on results 
of one or two tests. Nevertheless, the findings are consistent, pointing out 
slight problems in working memory and memorising, but not in storage and 
retrieval functions per se (Horiguchi & Takeshita, 2003; Troyer & Joschko, 
1997; Van der Burgt et al., 1999). Attention problems have been put forward as 
the underlying cause.     
Attention
The following aspects of attention can be distinguished: concentration and 
vigilance/sustained attention (staying focused for a shorter or longer period of 
time), selective attention (resisting interfering stimuli), and divided attention 
(paying attention to more tasks simultaneously). There are tests and tasks for 
each of these functions.
 Several authors have suggested that attention problems can be regarded as 
a key dysfunction in NS, having reached this conclusion mainly on the basis of 
parental evaluations (Sarimski, 2000; Troyer & Joschko, 1997; Van der Burgt et 
al., 1999; Wood et al., 1995). Inattention, in NS literature mostly described as a 
lack of selective or sustained attention, is mentioned frequently, while divided 
attention is generally thought to be intact. Although it should be noted that 
many of these findings are not significant when compared to controls, the 
recurrent observation of inattention is at least conspicuous. Some researchers 
have even suggested that features of children with NS resemble the patterns in 
ADD/ADHD or DAMP (deficits in attention, motor control and perception; a 
subgroup of ADHD in which a disorder in motor coordination has to be 
concomitant) (Horiguchi & Takeshita, 2003; Lee et al., 2005). Aside from the 
conceptual questions that can be raised with regard to these conditions, there is a 
lack of systematic, direct (patient-bound) research to substantiate these ‘diagnoses’.
Executive	functions
Executive functioning is an umbrella term for cognitive processes involved in 
planning, organising, monitoring and flexibly controlling goal-oriented behaviour. 
It is utilised for problem-solving capacities in new situations, and it is important 
 Language skills in children with NS tend to develop slower, which often 
becomes manifest in problems in articulation (75%). Both the increased 
occurrence of hearing loss (15-40%), due to recurrent otitis media, and the 
frequently present feeding problems have been suggested to influence 
language development in a negative manner. Shaw et al. (2007) consider 
feeding problems as an early marker of not only delayed language development, 
but also long-term educational achievement. A few case-reports have been 
written about children with NS with specific spelling and reading impairments 
(Hopkins-Acos & Bunker, 1979; Troyer & Joschko, 1997; Wilson & Dyson, 1982) 
and, in the larger cohort of Wood et al. (1995), 43% of the children showed a 
language impairment. In adulthood, when language is sufficiently overlearned, 
problems in this area seem to resolve.
Perceptual and motor functions
Ophthalmic abnormalities can be part of the NS pattern. Nonetheless, functional 
problems in visual perception (e.g. neglect or agnosia) have not been reported 
as being characteristic of NS.
 Motor function or praxis as a cognitive domain focuses on the processes 
needed to plan and sequentially perform actions, rather than examining the 
actions themselves. Fine and gross (sensori)motor functions can be divided. 
The level of visual-motor integration, often measured by hand-eye coordination 
tasks, is associated with the level of cognitive integration and maturation, and 
can moderate educational outcome (Sorter & Kulp, 2003). 
 Mild motor delay and clumsiness have repeatedly been demonstrated in NS. 
Mostly, they are associated with musculoskeletal changes like hyper extensibility 
and hypotonia, but a correlation with abnormalities of the cerebellum has also 
been suggested (Horiguchi & Takeshita, 2003). The few studies addressing the 
cognitive components of motor functioning indeed revealed below average 
achievement on motor coordination tasks, and a developmental coordination 
disorder has been suggested in half of the children (Horiguchi & Takeshita, 2003; 
Lee et al., 2005; Troyer & Joschko, 1997). When studying the results in more detail, 
impaired motor responses (the handling aspects per se) seem to be more 
explanatory than dysfunctions in visual perception or planning. With increased 
age and practice, motor skills usually improve.
Memory
Memory is a very complex concept, comprising many different aspects, which 
have been discussed by others in great detail (Baddeley, 2002). In short, 
learning demands the encoding, storage, consolidation, and, finally, retrieval 
of information. Information can be episodic or semantic in nature, and storage 
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 Alexithymia, ‘no words for feelings’, refers to an impairment in the ability to 
identify and communicate emotional states (Sifneos, 1973). Historically rooted 
in psychoanalytic research about pathogenesis of psychosomatic disorders, 
this multidimensional concept enjoys itself in renewed attention from a neuro-
psychological perspective, as evidence of a neural basis is growing (Aleman, 
2005). Alexithymia hampers effective regulation of emotion, and constitutes a 
major risk factor for a range of medical and psychiatric problems, including anxiety 
and depression, with prevalence rates up to 10% in the general population.
 Two types of alexithymia can be distinguished. Type I is characterised by the 
absence of emotional experience as well as physical arousal and, consequently, 
by the absence of the cognition (i.e. identifying, verbalising, analysing) 
accompanying the emotion. Type II alexithymia is characterised by a selective 
deficit of cognition with sparing of the affective experience and normal 
physiological arousal (Vorst & Bermond, 2001). In persons with type II alexithymia, 
which seems to be the case in NS, feelings and probably even suffering may be 
present, without the ability to ask for support. Strangely, alexithymia is not 
associated with age, gender, educational level, or intelligence (Parker, Taylor & 
Bagby, 1989). It is usually measured by self-report questionnaires. 
Psychopathology, personality, and quality of life
Given the prevalence of NS, remarkably few reports have been published 
about classical psychiatric syndromes or mental health status in NS. Just a 
handful of reports take note of (mostly adult) patients with psychiatric 
comorbidity (Ghaziuddin, Bolyard & Alessi, 1994; Mahendran & Aw, 1989; Paul, 
Cohen & Volkmar, 1983; Krishna, Abrams, Taylor & Behar, 1977; Verhoeven et al., 
2004).  
 In children, a trend towards an increased risk of behavioural problems has 
been noted, mainly characterised by the before-mentioned social problems, 
but stubbornness, restlessness, impulsivity and mood problems, like irritability 
or excessive happiness, have also been found (Lee et al., 2005; Sarimski, 2000; 
Van der Burgt et al., 1999; Wood et al., 1995). Statistically significant differences 
in comparison with healthy controls (often siblings) or with standardization 
norms are hardly ever found, because of the small study groups and the large 
age span. With respect to personality, research is virtually absent. Collins and 
Turner (1973) typified the children they observed as confident, happy, talkative, 
and reminiscent of the cocktail party manner. 
 In the prospective study of Shaw et al. (2007) with children and adults, the 
subject of quality of life in NS was attended to for the first time. Most patients 
(n=112) felt their quality of life to be satisfactory or good, with only 15% 
reporting it was poor, due to a lack of social life or an inability to fit in. 
for successful adaptation to the social environment. The development of the 
executive functions to their full capacity takes up the entire period of youth, 
and proceeds even in adolescence and early adulthood. Different aspects 
evolve at different ages; at the age of about 4 years, basic theory of mind and 
self-control skills have been established. Because of its complexity and interde-
pendency with other cognitive functions, it is important to employ multiple 
tests to measure executive functioning.
 Executive functioning has not yet been very well studied in NS, which 
may partly result from the fact that this set of cognitive functions did not 
receive much attention until about a decade ago. Van der Burgt et al. (1999) 
were the first to recognise organizational and planning weaknesses in children 
with NS, emphasising their causal effect on poor academic task performance 
and difficulties in school. 
Social	cognition	and	alexithymia
Social cognition encompasses the processing of information necessary to 
adapt to our social environment (Van Rijn, 2007). It incorporates perception of, 
attention to, memory for, and thinking about other people in a way that 
involves emotional and/or motivational processing (Adolphs, 2006).
 Social cognition can for instance be measured by tasks for emotion recognition 
(processing faces or voices), theory of mind tasks (making inferences about 
intentions or interpreting social meaning), and tasks in which planning in a 
social context is required. Another operationalization can be found in the 
construct of alexithymia. Studies on the evolution and development of social 
cognition suggest that this domain can be dissociated from general cognition, 
as there are specific neural substrates involved that subserve different 
functions during different stages of development. At the genetic level, there is 
evidence that specific sets of genes contribute to the development of aspects of 
social cognition within a particular timecourse, as found in genetic diseases 
such as William’s syndrome (Adolphs, 2001).
 A shared observation concerns impairments in social competence in NS. 
Immaturity, a lack of interaction with peers, a diminished insight in social 
situations and problems in verbalising and explaining of experiences have 
been mentioned with respect to this subject (Lee et al., 2005; Sarimski, 2000; 
Troyer & Joschko, 1997; Van der Burgt et al., 1999; Wood et al., 1995). Verhoeven 
et al. (2004) suggested specific problems in affective information processing, 
based on findings in a case-study of an adolescent with Noonan syndrome and 
a comorbid anxiety disorder. 
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(Kendler & Greenspan, 2006; Moore, 2003; Rutter, 2006) Thus, the aetiology of 
behavioural manifestations is likely to be intricate, forcing us to revise our 
view on the phenotypic concept.
 Philosophical and methodological issues need to be addressed to enhance 
future research for (endo)phenotypes in NS. As suggested by Sarimski (2000), 
studies should be based on a developmental model, incorporating genetical, 
biological and environmental influences, with the aim of disentangling the 
interplay between them and gain insights in their effects on cognitive and 
behavioural maturation. Larger prospective group studies have the potential 
to make a meaningful contribution in this area.
Clinical implications
Cognitive and behavioural findings in NS suggest that language and motor 
development are often delayed, but no longer dysfunctional in adulthood. 
Continuing mild problems in selective and sustained attention have been 
described and there are indications for suboptimal executive functioning. 
These cognitive problems may result in learning difficulties. 
 The majority of children with NS will require special care and counseling, 
fitted to their developmental stage. The assessment of developmental 
milestones and monitoring of physical and cognitive characteristics is 
important during youth. One of the tasks of a neuropsychologist may be to 
determine school readiness and to assess intellectual and other cognitive 
capabilities, with special attention on learning difficulties as a result of motor 
delay, language delay, executive dysfunctioning and inattention. A longitudinal 
perspective should be adopted with respect to neuropsychological evaluation 
because of the differences in development of the various cognitive skills. 
Guidance should be given while keeping in mind that NS-related problems 
may be underdiagnosed, and, in the case of alexithymia, it is important to help 
patients to give words to their experiences and possible complaints.
 The paucity in published cases with psychiatric syndromes might be an 
expression of a real lower incidence, or of an underreport in psychopathology 
in adult patients with NS. Since patients with NS may have an increased 
vulnerability to develop anxiety disorders due to the co-occurence of 
alexithymia in adulthood, maintenance treatment with an antidepressant 
should be considered in such conditions (Verhoeven & Tuinier, 2005).
 Given the subtlety of symptoms and their broad variation within the NS 
population, most reports conclude that a well-defined, separate phenotype has 
not emerged yet. Moreover, the pattern of cognitive and personal characteris-
tics that has emerged may not be exclusive to NS, but also at least partly fits a 
profile that is common in mixed developmental disorders. A complex interplay 
of feeding difficulties with medical complications, alongside the psychosocial 
consequences of short stature and frequently being bullied because of 
dysmorphia, may add to pervasive alterations in (neuro)biological, cognitive 
and psychological development in Noonan syndrome. 
 Advances in understanding gene-environment interaction reveal a deeply 
intertwined interdependency and synergy, going well beyond the outdated 
common sense models of both sources adding together in producing disease 
liability. Even single-gene disorders can present with substantial variation. 
Genetic expression may vary as a result of exposure to different kind of 
environments, and, moreover, vary in different phases of development 
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The	neurocognition	of	alexithymia
In 2004, Taylor and Bagby reviewed the relations between alexithymia and 
emotional processing as known until then, discussing the achievements of 
broad, interdisciplinary developments in alexithymia research. With rapid 
advances in technology and a still growing interest in social cognition, 
alexithymia research has continually expanded ever since without, however, 
definitive clarification. Both theoretical (top down) and empirical (bottom up) 
guidance is mandatory to further the understanding of the concept. Therefore, 
with a social-cognitive focus and evaluating both early neuropsychological 
and more recent imaging studies, this article reviews the evidence on the 
neural correlates of alexithymia.
 Some conceptual issues with respect to the character and definition of 
alexithymia will be discussed first, followed by a short introduction to social-
cognitive theory and a summary of widely used instruments to measure 
alexithymia. The neural correlates will be highlighted following primarily the 
lines of research history, moving from low-tech to high-tech experiments, 
from first indications of the involvement of large, hardly specified brain areas 
to identifying specific (parts of) structures and functional networks concerned 
with alexithymia. The article will end with a social-cognitive reappraisal of 
the alexithymia concept.
Alexithymia	from	1973	to	date
The alexithymia concept was first introduced by Sifneos in 1973, as an ‘absence 
of words for emotions’. It refers to difficulties in identifying and describing 
emotions, to an externally oriented mode of thinking, and to a restricted 
fantasy life. Disturbances in the processing of emotions may lead to 
psychosocial problems and even to severe psychopathology (Cole, Michel & 
O’ Donnell-Teti, 1994). Having difficulties in identifying feelings has been 
shown to be a significant predictor of psychopathology, e.g. major depression 
and anxiety disorders (Conrad, Wegener, Imbierowicz, Liedtke & Geiser, 2009; 
Sifneos, 1967). With prevalence rates up to 10% in the general population and 
indications of diminished levels of quality of life in relation to alexithymia, the 
importance of disentangling the aetiology is important Mattila, Poutanen, 
Koivisto, Salokangas & Joukamaa, 2007; Taylor, Bagby & Parker, 1997). 
 Alexithymia as a construct stems from clinical observations of patients 
with psychosomatic disorders. It is originally rooted in psychodynamics, in 
the beginning explained as a defence mechanism to repress unconscious 
conflicts (Den Hollander, Bruijn & Trijsburg, 1991; Ruesch, 1948; Shands, 1958). 
In the early 1960s, French psychoanalysts suggested a lack of fantasy and a 
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Alexithymia refers to an ineffective regulation and expression of emotions. It 
constitutes a major risk factor for a range of medical and psychiatric problems, 
including chronic pain, somatisation, anxiety and depression. Alexithymia is 
a multi-faceted concept, described in terms of cognitive and affective aspects. 
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cortex appear to be implicated as mediators, because of their broader 
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impairments are obvious in the interpersonal domain as well as in the 
intrapersonal or self-referential domain: autistic features are associated with 
poor mentalising capacities and with increased levels of alexithymia. In fact, 
the ability to understand our own feelings modulates empathic behaviour, 
and disturbances in both qualities may share the same functional cortical 
impairment (Bird et al., 2010; Lombardo, Barnes, Wheelwright & Baron-Cohen, 
2007). 
 A recurrent issue in alexithymia research is the question whether it should 
be considered a primary and permanent condition, caused by a structural 
deficit in the regulation of emotions, or rather a secondary, state-dependent 
phenomenon. Alexithymia is more prevalent after head injury; state-depend-
ent alexithymia induced by head trauma is often referred to as ‘acquired’ or 
‘organic’ alexithymia (Becerra, Amos & Jongenelis, 2002; Henry, Philips, 
Crawford, Theodorou & Summers, 2006; Wood & Williams, 2007). However, 
people with severe physical illnesses or post-traumatic stress disorder (PTSD) 
may also manifest alexithymic features as a state-bound reaction, mostly 
understood as a way of dealing with profound stress (Fukunishi, Kikuchi, 
Wogan & Takubo, 1997; Groot, Rodin & Olmsted, 1995; Hendryx, Haviland & 
Shaw, 1991). Others describe alexithymia as a constant disposition or 
personality trait, relatively independent from fluctuating stress levels (Martin-
ez-Sanchez, Ato-Garcia, Adam, Medina & España, 1998; Martinez-Sanchez, 
Ato-Garcia & Ortiz-Soria, 2003; Mikolajczak & Luminet, 2006; Salminen, 
Saarijärvi, Aäirelä & Tamminen, 1994). The time-window is essential in 
defining a characteristic to be state- or trait-like. While not completely trait-like, 
alexithymia cannot be regarded as entirely state-like either (Freyberger, 1977).
 Although the state-versus-trait discussion has received much academic 
attention, both the theoretical and clinical relevance of differentiating 
alexithymia on this basis can be debated. With respect to susceptibility to 
change, the state-trait differentiation has in fact not been very helpful so far. 
While it is clear that absolute levels of alexithymia may vary within persons 
over different situations, no prospective studies have been conducted focussing 
on the (in)stability of relative differences between persons over shared 
situations (e.g.: is the degree to which soldiers display differences in alexithymic 
features equal before and after a joint mission?).
 If the ultimate aim is to understand alexithymia, it should probably be 
considered the result of cumulative and complex brain-behaviour-environ-
ment interactions. Interestingly, this is not discordant with earlier theories, 
which is illustrated by the study of Swart, Kortekaas and Aleman, who showed 
that alexithymic people use less efficient emotion-regulation strategies and are 
characterised by suppressive rather than reappraisal strategies (2009). This 
proneness to practical and action-oriented thinking to be typical traits for 
patients with psychosomatic diseases. They called their style of communication 
‘la pensée opératoire’, which can be seen as the precursor of the alexithymia 
concept of Sifneos. Five aspects emerged repeatedly: (1) a reduction or 
incapacity to experience emotions; (2) problems in verbalising emotions; (3) an 
inability to fantasise; (4) an absence of tendencies to think about or analyse 
one’s emotions; and (5) difficulty in identifying, primarily one’s own, emotions 
(Taylor, Ryan & Bagby, 1985).
 With the rise of the Object Relations and Self Psychology concepts in the 
second half of the 20th century, the influence of the conflict model decreased, 
and another aspect of psychoanalytic theory was accentuated: ‘failing ego 
functions’ were introduced as the key problem in alexithymia. In this deficit 
model, an early disturbance in the parent-child relationship was suggested to 
predispose inadequate ego functions, resulting in deviances in the awareness, 
the experience, the regulation and the expression of emotions. Developmental 
principles were applied and alexithymia was theorised to be the result of a 
stagnation in the development of differentiation of emotions and in the shift of 
the so called ‘concrete operational’ to the ‘formal’ stages of thinking, according 
to the theories of Werner and Piaget (Lane & Schwartz, 1987; Piaget, 1962; 
Salminen, Saarijärvi & Aäirelä, 1995; Taylor et al., 1997).
 Alexithymia, in the last decade redefined as an impairment in affective 
information processing, has triggered neuroscientists to search for a neural 
basis. Neuropsychological research in this area may build upon theories of 
social cognition, i.e. the ability to construct representations of the relations 
between oneself and others, and to use these representations flexibly for 
guiding social behaviour (Adolphs, 2001). Social-cognitive skills encompass (a) 
the perception of social-emotional stimuli, such as facial expressions or verbal 
reactions of others, or interoceptive information about the state of one’s own 
body, (b) the evaluation of these stimuli and (c) the modulation and regulation 
of social-emotional behaviour (Adolphs, 2009). Although alexithymia primarily 
describes problems in the experience and expression of one’s own feelings, it 
often co-occurs with impairments in the recognition of emotions in others, in 
mentalising and empathising abilities, resulting in problems in social 
interactions (Lee et al., 2011). Studies of psychosocial functioning in psychiatric 
diseases such as schizophrenia and autism illustrate the close relation of the 
alexithymia concept with social-cognitive constructs. It is well known that 
patients with schizophrenia have higher levels of alexithymia. Apart from 
these problems in affective responsiveness to one’s own emotional experiences, 
patients with schizophrenia are characterised by impairments in emotion 
perception and in perspective taking (Derntl et al., 2009). In autism too, 
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subscale scores of the BVAQ are expected to be lowered, while in type II 
alexithymia subscale scores on Emotionalizing should be normal.
 Factor analyses of the BVAQ-items have indeed provided support for a 
two-factor structure, differentiating an affective dimension (including 
Emotionalizing and Fantasizing) from a cognitive dimension (including 
Identifying, Analyzing and Verbalizing) (Vorst & Bermond, 2001; Bermond, 
Vorst & Moormann, 2006). The scales making up the cognitive dimension of 
the BVAQ correlate significantly (r=0.80) with the corresponding factors of the 
TAS-20 (Müller et al., 2004). 
 Subtyping alexithymia has been helpful in understanding schizophrenia. 
Patients with schizophrenia display specific impairments in the cognitive 
components of emotion regulation (type II), coexistent with a disposition for 
higher levels of subjective emotional arousal. Difficulties in identifying and 
expressing their own emotions may very well contribute to the deficits in 
social functioning observed in patients with schizophrenia (Van ‘t Wout, 
Aleman, Bermond & Kahn, 2007).
 Other, less frequently employed instruments in the measurement of 
alexithymia are the Levels of Emotional Awareness Scale (LEAS), the Beth 
Israel Psychosomatic Questionnaire (BIPQ), and the Observer Alexithymia 
Scale (OAS). BIPQ and OAS, unlike TAS-20, BVAQ and LEAS, are observer-based 
questionnaires. As self-report inherently demands reflection on one’s own emotions, 
precisely the quality under measurement, one would expect observer ratings 
to be used more often in alexithymia studies to counterbalance for potential 
bias. An extensive overview of alexithymia questionnaires can be found in 
Kooiman (2003).
Neural substrates
Involvement of the right cerebral hemisphere and the corpus callosum will be 
first discussed, as these two brain areas have historically been linked to 
alexithymia and they have been studied most extensively in this area of 
research. Subsequently, evidence for the involvement of other, more specific 
subcortical and cortical structures traditionally linked to emotional processing 
will be discussed: the amygdala, as well as the cingulate, insular and orbito -
frontal cortices.
neuropsychological interpretation again highlights the original psychodynamic 
background of the construct.
Measuring	alexithymia
Alexithymia is a conceptually diverse concept. This diversity is also reflected 
in the variety of instruments that are being used to measure the construct. The 
latest version of the Toronto Alexithymia Scale (TAS-20) is internationally 
accepted as the gold standard to evaluate alexithymia. The TAS-20 is a self-report 
questionnaire consisting of three subscales: Difficulties in Identifying Feelings 
(DIF), Difficulties in Describing Feelings (DDF) and Externally Oriented 
Thinking (EOT). Although reliability and validity of the TAS-20 have been 
shown to be sufficient, the scale has been criticised for ignoring affective 
aspects of the alexithymia concept (Müller, Bühner & Ellgring, 2004). 
 A more differentiated operationalisation of alexithymia can be found in 
the 40-item self-report Bermond-Vorst Alexithymia Questionnaire (BVAQ), 
covering both affective and cognitive aspects. This questionnaire contains five 
subscales: Emotionalizing, Fantasizing, Identifying, Analyzing and Verbalizing 
emotions. Emotionalizing refers to the degree to which a person is emotionally 
aroused by emotion inducing events, and Fantasizing to the degree to which 
someone is inclined to fantasise, imagine, and daydream. Identifying, 
Analyzing and Verbalizing respectively refer to the degree to which someone 
is able to define, explain and describe one’s own arousal states and emotional 
reactions (Vorst & Bermond, 2001). 
 Bermond extensively studied alexithymia from a neuropsychological 
point of view and suggested a distinction into two main subtypes, following 
two neural mechanisms (Bermond, 1995). Type I alexithymia, understood as a 
dysfunction of the right cerebral hemisphere, is characterised by the absence 
or constriction of the emotional experience and, consequently, by the absence 
or constriction of cognition accompanying the emotion. A decreased 
physiological arousal would cause this type of alexithymia. Type II alexithymia, 
understood as a dysfunction of the corpus callosum, is defined by a selective 
deficit of emotional cognition (i.e. Identifying, Analyzing and Verbalizing 
emotions), accompanied by an intact emotional experience and a normal 
physiological arousal.
 According to this disconnection model, the emotional information present 
in the right hemisphere cannot be transferred to the left hemisphere, resulting 
in physiological arousal that cannot be reduced by cognitive ways of coping. 
Consequently, in type I, both the affective and the cognitive components of 
emotion regulation are disturbed, whereas in type II the affective aspects are 
spared while the cognitive ones are impaired. In case of type I alexithymia, all 
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for electrodes over the left compared to the right hemisphere in a scalp electro-
encephalography (EEG) performed to record the P300 response. The results 
suggest that, at least in some women, the left hemisphere is involved in 
alexithymia (Bermond et al., 2008). 
 In sum, most findings underline the idea of substantial right-hemisphere 
involvement in alexithymia, at least in males. Still, regarding the aetiology, 
these findings are not very specific, neither with respect to location nor to 
function. Moreover, many of these lateralisation findings need replication. If 
there is a reduced activity in the right hemisphere in a male alexithymic, then 
how does this explain the alexithymic features? As a consequence of the non-
specificity of the contribution of the right hemisphere to alexithymia, both 
type I and type II aspects may be associated with dysfunctions of this brain 
area. In terms of social cognition, main problems may be expected with regard 
to the perception or interoception of social-emotional signals, but certainly not 
exclusively.  
Corpus callosum
Adequate interhemispheric communication is required for adequate regulation 
of emotions. When it is impeded, type II alexithymic features can emerge 
(Bermond, 1995). The left hemisphere is known to be more specialised in a 
verbal, conscious and analytic mode of information processing, whereas a 
non-verbal, unconscious, and more holistic mode of information processing is 
predominantly associated with the right hemisphere (Joseph, 1982; Miller, 
1986; Galin, 1974). To consciously experience and verbalise emotions, perceptual 
information of the right hemisphere has to be transferred to the left hemisphere. 
The corpus callosum accounts for this transfer of information. 
 An interhemispheric communication deficit as a neural explanation for 
alexithymia stems from observations in split-brain patients, who had been 
treated for severe types of epilepsy for which they underwent complete 
cerebral commissurotomy (Den Hollander et al., 1991). Hoppe and Bogen (1977) 
studied 12 patients before and after split-brain surgery and showed that after 
surgery all were highly alexithymic according to the BIPQ and that they 
experienced problems with the verbal expression of emotions. In addition, 
there was a decrease in their ability to fantasise, to symbolise and to dream. 
Ten Houten, Hoppe, Bogen and Walter (1986) performed a similar study with 
eight patients who underwent commissurotomy, and eight matched controls. 
Participants were shown a three-minute film with the purpose to evoke 
emotions and fantasies by symbolically representing death and loss. After 
watching the film, the participants were asked to give comments, verbally and 
in writing, and answer questions about the film. The results of the study 
Hemispheric and interhemispheric structures
Right cerebral hemisphere
The right hemisphere is well known for its involvement in the perception and 
coordination of emotional behaviour (Den Hollander et al., 1991; Joseph, 1982; 
Miller, 1986). Bermond (1995) indeed described several clinical studies of 
patients with right-hemisphere lesions, who showed mixed alexithymic 
features, presenting combined affective and cognitive deficiencies. Moreover, 
the ability to recognise facial expression of emotions is reduced in alexithymic 
patients (Berenbaum & Prince, 1994; Jessimer & Markham, 1997; Kano et al., 
2003; Lane, Ahern & Schwartz, 1997; Mann, Wise, Trinidad & Kohanski, 1994; 
Parker, Taylor & Bagby, 1993). 
 Jessimer and Markham (1997) indirectly explored the involvement of the 
right hemisphere in healthy participants with high and low levels of 
alexithymia by chimerical tasks. The chimeras consisted of pictures of faces 
made of conjoined emotive and non-emotive halves, as well as asymmetrically 
distributed stars and whole faces, expressing different emotions. Results 
indicated that participants with high levels of alexithymia had less leftward 
perceptual preference, suggesting reduced right hemisphere responding, 
although only the asymmetry scores on one task (sad/neutral chimerical 
photographs) reached the level of statistical significance. In addition, they 
were worse in recognising facial expressions of emotions than subjects with 
low levels of alexithymia. Differences were not emotion-specific. 
 An imaging study using Positron Emission Tomography (PET) analysed 
brain activity in a non-clinical sample of 12 participants with and 12 without 
alexithymia according to the TAS-20, while these participants were viewing a 
range of emotional face expressions. The alexithymia group exhibited lower 
regional cerebral blood flow in the right hemisphere than the non-alexithymia 
group. In addition, the alexithymics showed higher regional cerebral blood 
flow in the left hemisphere when compared with the non-alexithymic 
participants (Kano et al., 2003).
 Some authors have suggested that sex differences exist with respect to left- 
and right-hemisphere involvement in alexithymia (Bermond, Righart, Ridderinkhof 
& Moormann, 2008; Lumley & Sielky, 2000; Spaletta et al., 2001). In stroke 
patients with right unilateral lesions in various regions, high TAS scores were 
more frequent in men than in women, despite the variety in lesion localisation. 
In women, both a left-hemisphere and a right-hemisphere stroke resulted in 
higher levels of alexithymia (Spaletta et al., 2001). A recent event related 
potential (ERP) study also showed sex differences regarding lateralisation in 
alexithymia. Females showed higher P300 amplitudes compared with males. 
Moreover, females with low levels of alexithymia showed enhanced amplitudes 
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information. Only a right-to-left relationship between alexithymia and inter-
hemispheric communication was found, in contrast with the findings of Zeitlin 
et al. (1989), who found a bidirectional relationship.
 Parker, Keightley, Smith and Taylor (1999) tried to replicate Zeitlin’s findings 
in a non- clinical sample. The efficiency of interhemispheric communication 
was assessed in 14 alexithymic and 15 non-alexithymic, right-handed male 
students using the tactile finger localisation task. The non-alexithymic participants 
were significantly more efficient at transferring information between the 
cerebral hemispheres than the alexithymic subjects in a bidirectional way. 
These findings suggest that an alexithymic cognitive style reflects poor 
integration of the information processing of both hemispheres. Lumley and 
Sielky (2000) also used the tactile finger localisation task to assess the inter-
hemispheric communication in a non- clinical sample of 47 men and 58 women. 
Among the men, the TAS-20 scales ‘difficulty identifying emotions’ and 
‘difficulty describing emotions’ were correlated with reduced interhemispheric 
transfer of information. However, among the women, alexithymia was completely 
unrelated to interhemispheric functioning. The authors concluded that 
deficiencies in interhemispheric communication may contribute to alexithymia 
in men, but not in women. Again, in both studies note that the tactile finger 
localisation task involved the transfer of sensorimotor information only.
 In 2008, after more than 30 years of research on the interhemispheric 
transfer deficit in alexithymia, more direct evidence was provided by a 
transcranial magnetic stimulation study (Romei et al.). Functional differences 
were found in transcallosal interactions in 16 high alexithymic as compared to 
16 low alexithymic male and female students, according to the Italian version 
of the TAS-20. This supports the conclusion of Bermond et al. (2006), that 
although not enequivocal, experimental results suggest that ‘alexithymia 
could be related to a “functional commissurectomy”’. 
 In conclusion, there is supporting evidence for the hypothesis of an inter-
hemispheric communication deficit underlying alexithymia, particularly in 
alexithymic men. According to Bermond’s subdivision (1995), this deficit 
would result mainly in type II alexithymia, implying that the cognitive aspects 
of alexithymia would be impaired, whereas emotional arousal ought to be 
present. In social-cognitive terms, mainly the facets modulating and regulating 
social-emotional information may be implicated in callosal dysfunction. That 
is, the conscious awareness and expression of emotions is impaired because of 
the inability to verbally interpret the right-hemisphere arousal. Nevertheless, 
none of the aforementioned studies has yet revealed the precise nature and 
directionality of the transfer deficit sufficiently (Tabibnia & Zaidel, 2005).
clearly indicated that the patients used fewer affect-laden words and fewer 
adjectives in their descriptions of the film, compared to their matched controls. 
In short, patients were more alexithymic than the controls in this study. 
Unfortunately, only the use of language was taken into account in this study, 
while the subjective emotional experience was not examined.
 In a corpus callosum agenesis case study of Buchanan, Waterhouse and 
West (1980), the patient demonstrated severe alexithymia as measured by the 
BIPQ. Another corpus callosum agenesis case study, using the TAS-20, showed 
that the adolescent patient, who also had chronic pain, appeared to have flat 
affect, a restricted fantasy life and was unable to recall dreams, all character-
istics of alexithymia (Ernst, Key & Koval, 1999). 
 Additional support for the interhemispheric communication deficit 
hypothesis of alexithymia was provided by Zeitlin, Lane, O’Leary and Schrift 
(1989), who used a tactile finger localisation task to assess the efficiency of in-
terhemispheric communication in participants without neurological damage. 
In such a task, the researcher simultaneously touches one, two, three or four 
fingers of the participant with a pencil. Then, he or she has to state which 
fingers were touched, by touching them again with the thumb of the same 
hand (uncrossed condition) or with the thumb of the other hand (crossed 
condition). For the crossed condition, interhemispheric communication is 
required. Interhemispheric communication of patients with and without 
alexithymia (TAS-20) suffering from PTSD secondary to combat in Vietnam 
was compared with the interhemispheric transfer of control subjects without 
alexithymia. The results indicated a strong association between alexithymia 
and an interhemispheric communication deficit. In addition, the deficit in in-
terhemispheric communication was bidirectional. It was concluded that at 
least some forms of alexithymia may be mediated by a functional disconnection 
of both hemispheres. The reason for this prudent conclusion is the fact that the 
localisation task measures the transfer of sensorimotor information, but not 
necessarily the transfer of emotional information. 
 Dewaraja and Sasaki (1990) used a visual lateralisation matching task with 
linguistic (words) and non-linguistic (line drawings) emotional stimuli as 
variables. Right-handed university students were identified as either 
alexithymic or non-alexithymic with the Schalling-Sifneos Personality Scale, 
an incidentally used 20-item self-report questionnaire with suboptimal 
psychometric properties (Taylor et al., 1997; Sifneos, 1986). Differences in 
ipsilateral and contralateral hand reaction times were used to indicate speed of 
callosal transfer. The alexithymic group was significantly slower than the non-
alexithymic group in the interhemispheric communication of non-linguistic 
information, but the groups did not differ in the speed of transferring linguistic 
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Cortical structures
Anterior cingulate cortex
The anterior cingulate cortex (ACC) appears to be involved in initiation, 
motivation, and goal-directed behaviour and is also recognised to have a 
function in attention processing, pain, response selection, as well as maternal 
and skeletomotor behaviour (Devinsky, Morrell & Vogt, 1995). In 1937, Papez 
was the first to propose involvement of the ACC in the regulation of emotions. 
In the 1940s and 1950s, animal and human studies on the ACC clearly showed 
the involvement of the cingulate cortex in motor and autonomic control. 
Lesions in the ACC have also been related to changes in affect and personality. 
Patients with ACC lesions have been described as indifferent after making 
mistakes (Eslinger & Damasio, 1985; Rylander, 1947). Hornak et al. (2003) 
described patients with ACC lesions whose subjective emotional experiences 
changed and who developed deficits in the recognition of emotional face 
expressions. 
 The ACC has been further subdivided into a dorsal ‘cognitive’ part, 
engaged in response selection associated with motor activity, and an anterior-
ventral ‘affective’ part, dedicated to autonomic activity and internal emotional 
responses. The cognitive subpart has strong reciprocal interconnections with 
the lateral prefrontal cortex and motor areas, while the affective subpart is 
connected to the amygdala, hypothalamus, hippocampus and the orbitofrontal 
cortex. Regarding alexithymia, it is important that these two subparts show 
reciprocal suppression and that cognitive and emotional information may be 
processed separately (Bush, Luu & Posner, 2000; Devinsky et al., 1995). 
However, rather than considering the subregions of the ACC as two separable 
entities, Critchley et al. advocated an integrative approach in explaining the 
functions of this structure. The authors showed integration of mental and 
bodily processes in the ACC and suggested that the production of autonomic 
responses that signal the requirement for adaptive control of behaviour is the 
core task of the ACC: the ACC as an autonomic, executive regulator.  
 There is supporting evidence for a dysfunction of the ACC in relation to 
alexithymia. Lane et al. (1998) observed significantly deviant activation of the 
ACC in response to watching emotion-inducing films. In their PET study, they 
explored the neural correlates of emotional experience in 12 healthy women. 
They measured regional cerebral blood flow during film- and recall-induced 
emotion and correlated changes in the blood flow attributable to emotion with 
the scores on the LEAS. The LEAS measures the level of emotional awareness, 
varying from awareness of physical sensations to complex emotions in social 
situations. Their findings imply that the degree to which the ACC is activated 
during emotion varies across individuals. Positive associations between LEAS 
Subcortical structures
Amygdala
The subcortical brain structure that is best known for its contribution to 
emotion processing is the amygdala. The amygdala receives, together with the 
prefrontal cortex (PFC), highly processed sensory information from all 
modalities. It has extensive reciprocal connections with a large number of 
other brain structures, such as the ventromedial frontal cortices, the 
hypothalamus and the hippocampus, whose functions can be modulated by 
emotion. The amygdala is considered to be a part of what was described by 
McLean as the limbic system, a functionally interconnected set of subcortical 
and cortical structures involved in emotional processing, motivation and 
emotional association with memory (McLean, 1949). It is particularly known 
for its involvement in the evaluation of valence of emotions in social situations, 
such as those related to reward and fear. Furthermore, the amygdala is 
important in emotional conditioning and in the consolidation of emotional 
memories (Adolphs & Damasio, 2000; Adolphs, Tranel & Damasio, 1998; 
Dalgleish, 2004; LeDoux, 1992).
 Many studies have indicated that the amygdala is involved in evaluating 
emotional significance (Adams, Gordon, Baird, Ambady & Kleck, 2003; Breiter 
et al., 1996; Davidson & Irwin, 1999; Ono, Nishijo & Nishino, 2000; Philips, 
Drevets, Rauch & Lane, 2003) and in the recognition of facially communicated 
threat (Adolphs et al., 1999; Adolphs & Tranel, 2003; Whalen et al., 2001), two 
features associated with alexithymia. Surprisingly, studies directly examining 
whether the amygdala is involved in alexithymia are scarce. Results tend to 
reveal no differences between alexithymic and non-alexithymic participants 
with respect to brain activity in limbic structures in general (Berthoz et al., 
2002; Kano et al., 2003; Mantani, Okamoto, Shirao, Okado & Yamawaki, 2005). 
 As the amygdala is important in the detection of emotional significance, as 
well as in the recognition of emotions in facial expressions, it could be 
hypothesised that the alexithymia features ‘Emotionalizing’ (type I) and 
‘Identifying’ (type II) may be compromised in people with amygdala lesions. 
Concerning the magnitude and frequency of emotions, Anderson and Phelps 
(2002) found no differences between patients with unilateral and bilateral 
amygdala lesions and controls. Patients with amygdala lesions were able to 
report emotional feelings of normal intensities, pleading against involvement 
of the amygdala in affective aspects of alexithymia (type I).
 In sum, the amygdala is undisputedly an essential structure with regard 
to emotional processing, but there is no convincing evidence that it is 
dysfunctional in alexithymia. Specific research of amygdala functioning in 
alexithymic subjects is however still lacking.
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be fitted for ‘evaluative’ purposes (Vogt, Finch & Olson, 1992). The PCC has 
shown to be involved in both memory and emotion processing. Emotional 
stimuli have been reported to consistently activate this area, and it is speculated 
that the PCC is active in the modulation of episodic memory (Maddock, 1999). 
The PCC does indeed have strong reciprocal connections with regions engaged 
in memory processing, such as the hippocampus and the thalamus. It also has 
reciprocal projections to the ACC and the orbitofrontal cortex (Mantani et al., 
2005). 
 Based on fMRI findings, Mantani et al. (2005) were the first to propose the 
PCC to play a crucial role in alexithymia, especially in alexithymia-related 
imagery disturbance. People with alexithymia are known to have limited 
ability to fantasise. The regional cerebral activation of 10 participants with and 
10 without alexithymia according to the TAS-20 was compared during various 
imagery conditions. Participants were instructed to image a past and future 
happy event, a past and future sad event and a past and future neutral event. 
The results revealed significantly reduced activation of the PCC in alexithymic 
people during happy imagery. Given the projections of this brain structure, 
this result may be related to a dysfunction of episodic memory retrieval during 
happy imagery in subjects with alexithymia. The authors suggested that while 
people without alexithymia can easily use memories of emotional events to 
imagine future events, this process is compromised in individuals with 
alexithymia. Why the reduced activation in the PCC was specific for the future 
happy event remained uncertain, but the authors suggest that the specific 
difficulty of imagining future happy events could reduce motivation and hope. 
In line with these findings with respect to PCC involvement in alexithymia, 
the before mentioned fMRI study of Frewen et al. (2006) showed not only 
decreased activity of the ACC in alexithymic patients performing a trauma 
imagery task but also positive correlations between TAS-20 scores and 
increased activation in the PCC. Although Miyake et al. (2009) reported 
covariation of PCC activation and alexithymia levels, their findings did not 
equivocally replicate those of Frewen et al. (2006) and Mantani et al. (2005).
 Maddock, Garrett and Buonocore (2003) conducted an fMRI study to 
determine if activation of the PCC by emotional stimuli can be attributed to 
the memory enhancing effects of non-emotional stimulus features. In a va-
lence-decision task, pleasant and unpleasant words were matched with neutral 
words on non-emotional features known to influence memory. They reported 
heightened activation of the PCC in healthy participants during the processing 
of emotional words; these results confirmed that the PCC mediates interactions 
of emotional and memory-related processes. Although alexithymia was not a 
variable in this study, the results suggest that a dysfunction of the PCC may 
scores and regional cerebral blood flow in the ACC were found during film- 
induced negative emotions. 
 Kano et al. (2003) found similar results in the PET study described already 
in the discussion of the involvement of the right cerebral hemisphere. They 
showed that people with alexithymia showed less ACC activation compared to 
the volunteers without alexithymia, as a response to angry faces. Berthoz et al. 
(2002) conducted a functional magnetic resonance imaging (fMRI) study in 
eight men with alexithymia and eight men without alexithymia. They observed 
stronger ACC activation in men with alexithymia than in men without 
alexithymia in response to highly positive emotional pictures, and they found 
reduced activation in the left ACC in men with alexithymia in response to 
negative emotional pictures. Another fMRI study confirmed this once more 
(Frewen, Pain, Dozois & Lanius, 2006). Twenty-six patients with PTSD and 16 
trauma-exposed controls completed a trauma script imagery task. In the PTSD 
group as well as in the controls, TAS-20 scores correlated negatively with 
activation in the ACC. More recently, Karlsson, Näätänen and Stenman (2008) 
found alexithymia to be related with less activation in the ACC, in their PET 
study with 10 TAS-20-alexithymic adult female students, watching emotion-
inducing films with positive, neutral or negative valence. With respect to 
structural differences, a magnetic resonance imaging (MRI) study of Gündel et 
al. (2004) showed a significant positive relation between the size of the right 
ACC and the extent of alexithymia in male university students, as measured 
by the TAS-20. In women, a prominent ACC was associated with a tendency to 
withdrawal-behaviour (harm avoidance). The authors suggested the ACC to be 
involved in a suppression mechanism that pushes unwanted associations out 
of awareness. This explanation is consistent with the findings of Bush et al. 
(2000), in which the cognitive and emotional parts of the ACC show reciprocal 
suppression. 
 In conclusion, the ACC takes part in emotion regulation processes and less 
ACC activation is associated with negative emotions. Furthermore, the ACC 
has been linked to affective as well as cognitive aspects of alexithymia. Thus, 
dysfunction of the ACC may result in type I alexithymia. From a social-cogni-
tive perspective different aspects can supposedly be affected by ACC 
dysfunction, including the evaluation, modulation and regulation of social-
emotional stimuli.  
Posterior cingulate cortex
The posterior cingulate cortex (PCC) can be differentiated from the ACC on the 
basis of cell architecture and patterns of projection, as well as function. The 
ACC has been characterised as ‘executive’ in function, whereas the PCC would 
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 The before-mentioned PET-study of Karlsson, Näätänen and Stenman 
(2008) also showed higher levels of activation in the (left) insula and in sensory 
and motor cortices, in alexithymic women watching films that evoked empathic 
reactions. The authors suggested this over-activation of  ‘bodily brain regions’ 
as an explanation for the tendency of alexithymic patients to experience 
physical symptoms rather than emotions, supporting the hypothesis of 
somatosensory amplification in alexithymia.
 Others have found deviant activity levels in the AIC in alexithymic 
participants as well. In an fMRI study with Asperger patients watching 
emotion inducing pictures, Silani et al. (2008) demonstrated low levels of 
emotional awareness, i.e. high TAS-20 and BVAQ-scores, to be correlated with 
hypoactivity in the anterior insula. Support for the shared role of the insular 
cortex in both alexithymia and empathy was confirmed by the work of Bird et 
al. (2010), who performed an fMRI study with an ‘empathy for pain-paradigm’ 
in 18 males with autism spectrum conditions and 18 controls, matched on 
TAS-20 scores, sex, age and IQ. They found an increased activation of the left 
AIC in reaction to the observation of pain in closely related others. The strength 
of the signal was predictive for the degree of alexithymia in both autistic 
patients and controls. In sum, the interoceptive cortex, especially that of the 
left anterior insula, is associated with alexithymia. The ability to reflect on 
one’s own emotions modulates empathic brain responses, in which the insula 
is involved as well. One would expect type I alexithymia to occur in focal 
injuries of the insula, or redefined in social-cognitive terms, the processes of 
both perceiving and evaluating social-emotional information.
Orbitofrontal cortex 
The PFC is the part of the cortex that is situated in front of the motor and 
premotor cortices in the frontal lobe. The PFC can be divided into the lateral, 
medial, and the orbitofrontal cortex (Rolls, 2002). This area of the brain is 
thought to be involved in higher cognitive and emotional functions, such as 
decision-making, planning complex cognitive behaviours, moderating appropriate 
social behaviour and impulse control (Angrilli, Palomba, Catagello, Maietti & 
Stegagno, 1999; Bechara, 2004; Larsen, Brand, Bermond & Hijman, 2003). 
Involvement of the PFC in alexithymia has predominantly been studied in 
patients with head trauma, as acquired brain injury often involves damage to 
the PFC.
 In 1948 Freeman first introduced the transorbital method, a surgical 
procedure in which the orbitofrontal parts of the PFC were isolated from the 
rest of the brain, with the purpose to reduce suffering in patients with 
overwhelming emotions. In 1970, Trigg described several cases of patients who 
contribute not only to the diminished affect-related imagery in alexithymia, 
but also to problems in verbalising emotions. Subsequently, Aleman (2005) 
proposed that compromised interactive processing in hippocampal-amygdala 
circuits during the development of associations between affective states and 
words may underlie the problem of verbalising feelings in alexithymia. In 
their recent fMRI study, Swart et al. (2011) showed alexithymia, in particular 
difficulties with verbalising emotions, to be positively related to a catechol- 
O-methyltransferase (COMT)-genotype variation (COMT Val158Met poly-
morphism), which in turn results in a decrease of neural activation in the PCC. 
As PCC is one of the cortical midline structures, they therefore suggested PCC 
functionality to be with connected with self-awareness.
 Thus, the PCC takes part in alexithymia-related (self) imagery disturbances, 
as well as in emotional learning and in problems in verbalising emotions. 
Dysfunction of the PCC can be expected to result in type I alexithymia, as 
problems in imagining and fantasising may constrict emotional experience, 
including emotional awareness. According to the description of social-cogni-
tive processes of Adolphs, the evaluative or interpretative aspect of social 
cognition may be impeded in alexithymia associated with PCC malfunction.
Anterior insular cortex
The insular cortex is the part of the cerebral cortex situated in the centre of the 
brain, folded within the lateral sulcus; it can be divided into a smaller posterior 
part (PIC) and a larger anterior part (AIC).  The AIC, also referred to as the 
‘interoceptive cortex’, is involved in a bottom-up process, mapping internal 
body states and integrating them in conscious representations of feeling states, 
as Damasio first suggested in 1994 (see also Craig, 2009; Critchley, 2005; Critchley, 
Wiens, Rotshtein, Ohman & Dolan, 2004; Singer, Critchley & Preuschoff, 2009). 
It is often studied because of its involvement in the social-cognitive processes 
of empathy, in particular pain-related empathy. However, to affectively share 
feelings of other people, intact cognitive capacities to make self-other 
distinctions are mandatory. Shared network models of empathy suggest that 
the neural networks involved in the representations of one’s own feelings are 
the same as those underlying the representations of feelings of others (Singer 
et al., 2009). 
 In the already cited study of Kano et al. (2003), alexithymic participants 
displayed decreased insular activity in response to angry faces. The same 
research group found heightened activity in the right insula of TAS-20 
alexithymics in response to visceral stimulation (Kano, Hamaguchi, Itoh, 
Yanaki & Fukudo, 2007), as did Frewen et al. (2006) in response to trauma 
imagery. 
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emotional stimuli. Frewen et al. (2006) found conflicting results in their fMRI 
study with 26 PTSD patients and 16 controls, who completed a trauma script 
imagery task with negative emotional stimuli. In the controls, TAS scores 
correlated positively with activation in the bilateral medial PFC, suggesting 
alexithymia to be related to increased activation in these parts of the PFC. 
Mantani et al. (2005) observed no differences between persons with and 
without alexithymia in activation of the orbital PFC. 
 Although most research focuses on the orbital part of the PFC, Bermond 
suggested involvement of the dorsolateral part in ‘pseudo-alexithymia’ 
(Bermond, 1995). The dorsolateral PFC has a function in motivational aspects 
of emotion regulation, such as planning, initiating and adapting behaviour to 
the demands of the environment. Selective lesions in this area may therefore 
prevent a person from reflecting upon their feelings and from actively 
responding to them, while the emotional experience and emotional cognition 
per se are intact.
 In conclusion, there is general agreement about the contribution of the 
PFC, particularly the orbital part, to the experiencing of emotions, but the 
relation with alexithymia is more inconclusive. PFC dysfunction may be 
related to the features ‘Emotionalizing’ (the orbital PFC as a thermostat, 
initiating or inhibiting emotions with a certain intensity), ‘Fantasizing’ 
(imagery, memory and emotion), and ‘Analyzing’ (integrating, reflecting on 
emotions, making decisions). The orbital PFC may especially be involved in 
the affective aspects of alexithymia (type I), including problems in perceiving 
and evaluating emotions, while the dorsolateral part has been associated with 
pseudo-alexithymia.
Alexithymia	redefined	as	an	impairment
in social cognition
Alexithymia is considered a neuropsychological concept, which means that it 
has a neural basis, but is expressed through and measured by social-emotion-
al behaviour. It can be defined as a disturbance in affective information 
processing, but as it is inherently linked with social impairments, it may 
be considered a disturbance in social-cognitive functioning as well and 
consequently as a disturbance in social-cognitive functions. 
 Traditional approaches as BVAQ type I and type II alexithymia reflect no 
absolute or dichotomous entities. Problems in affective and cognitive aspects 
seem to occur in different degrees. This is in line with recent findings of Bagby 
et al. (2009), who performed confirmatory factor analyses and model-based 
cluster analyses on a large BVAQ database, showing that decomposition into 
underwent frontal lobotomy. Generally, after removing the PFC, patients 
reported fewer complaints, they experienced a flatness of affect and an absence 
of spontaneous emotional reflection, known as features of alexithymia. 
However, emotional cognitions remained unchanged. This type of surgery 
could also induce a disinhibition of emotional behaviour, resulting in short 
periods of violent emotional behaviour. 
 The orbitofrontal part of the PFC is especially important in the regulation 
of emotions. This brain region is involved in emotion-related learning and in 
the regulation of facial expressions (Angrilli et al., 1999; Larsen et al., 2003). It 
projects to the hypothalamus and has strong reciprocal connections with the 
amygdala (Bechara, 2004; Bermond et al., 2006; Bechara, Damasio & Damasio 
2000; Davidson, Jackson & Kalin, 2000). Lesions in the orbital PFC can impair 
voice and facial expression identification (Hornak et al., 2003; Rolls, 2002). 
Furthermore, they may lead to a reduction in emotionalising and to deficiencies 
in emotional decision-making, whereas the emotional cognitions may still be 
intact (Bechara, 2004; Bechara et al., 2000). Patients with frontal lesions may 
lack the internal drive to reflect upon their emotional cognitions, but they will 
do so if stimulated by others (Damasio, Tranel & Damasio, 1990). This lack of 
spontaneous reflection may underlie the disrupted emotion decision- making. 
 In a case study of Angrilli et al. (1999), the orbital PFC proved to play an 
important role in retrieval of emotional information, particularly information 
with a negative valence. The patient, who had a right orbitofrontal lesion, 
showed reduced recall of unpleasant stimuli. During a task focusing on 
imagery of emotional situations, facial expressions to unpleasant imagery 
scripts were impaired. Hence, orbitofrontal lesions may be related to 
alexithymia, because people with alexithymia are known to have constricted 
imaginative capacities and impaired recognition of facial expressions. 
Constricted imagination and a reduction in facial expressions have been found 
repeatedly in patients with prefrontal lesions (McDonald & Prkachin, 1990; 
Sifneos, 1975; Taylor et al., 1985). The results of the study of Angrilli et al. are 
in line with the view that the orbital PFC is important in integrating past 
emotional physiological patterns, reactivated by the amygdala and the 
hippocampus, and current or ‘online’ information, kept in the working 
memory situated in the frontal cortex. The integration of information from 
these two systems is in turn essential for adequate decision-making and 
planning.
 To date, only a few studies have directly addressed the role of the PFC in 
alexithymia. The PET study of Kano et al. (2003) showed that alexithymic 
subjects exhibited decreased activation in the inferior and superior frontal 
cortex and the orbital PFC of the right hemisphere, in reaction to negative 
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 For instance, since the development of imaging techniques, more structures 
have been pinpointed for their implications in alexithymia. The cingulate 
cortex takes part in emotion regulation processes, with the ACC being 
especially equipped for experiencing and controlling emotions (I + II), and the 
PCC specifically fit for imagery-related aspects of emotion (I). Findings with 
respect to the role of the cingulate cortex in alexithymia are not completely 
unambiguous, but a double dissociation between a diminished activation of 
the ACC together with an increased activation of the PCC does provide support 
for its involvement. The insular cortex is crucial in the represention of feeling 
states of the self and of others. Furthermore, the amygdala is obviously 
involved in affective information processing, but not evidently responsible for 
alexithymia. Likewise, the orbitofrontal PFC undoubtedly contributes to 
emotional experience, but it is not clearly involved in alexithymia per se, 
although it does seem to mediate affective aspects of alexithymia. Some brain 
structures probably derive their share in alexithymia from their projections to 
other brain structures, making them important, but not crucial. 
 With respect to the differentiation of alexithymia, the reputed clinical 
subdivision cannot be downsized to strictly separable cerebral roots. However, 
corpus callosum and prefrontal cortical structures, in particular the ACC and 
AIC, seem to be implicated more prominently.
Conclusion
Alexithymia is associated with a diffuse neural substrate, in which the corpus 
callosum and the cingulate and insular cortex seem to be explicitly involved, 
whereas the amygdala and (orbito)PFC are involved as mediators of the 
affective process in general. The relative contribution of these brain areas to 
the aetiological understanding of alexithymia remains to be quantified. A 
further analysis of the methodology followed in the various studies, including 
axiomas on the dimensional or taxonic nature of alexithymia, would be 
necessary. For future studies, the inclusion of more observer-based alexithymia 
questionnaires should be encouraged.
 Refining our knowledge of the neural substrates is important, but adopting 
a contextual perspective is essential for furthering our understanding of 
alexithymia. In fact, alexithymia should be considered a social-cognitive 
impairment, in the explanation of which developmental, neurobiological, neu-
ropsychological and behavioural theories have to be combined to enable a 
better understanding of the construct. This, in turn, is a prerequisite for the 
development of targeted interventions to prevent or diminish complaints and 
to enhance the quality of life in people with alexithymia.
two types of alexithymia is not a just representation of the alexithymia 
construct. They state that the latent structure of alexithymia is dimensional 
rather than taxonic and they advocate the development of measures that use a 
continuous scale. Theoretically, Bermond and colleagues (2006) suggested 
dimensionality as well. They considered it possible that, due to experiences in 
childhood, the system for emotion regulation becomes fixated at different 
stages of maturity of the brain, resulting in extreme or intermediate personality 
types with respect to tendencies in emotionalising and expressing feelings. 
Affective-neuroscientific research concerning brain plasticity in early 
childhood provides confirmation for such a developmental explanation. The 
neural circuits of emotion (i.e. hippocampus, amygdala, PFC) might, as a result 
from plasticity, be influenced by stressful life events, which in turn shape 
patterns of emotional reactivity and change the risk for psychopathology later 
in life (Davidson et al., 2000).
 According to Adolphs (2009), social-cognitive skills can be subdivided into 
the aspects: (a) perceiving, (b) evaluating and (c) modulating and regulating 
social-emotional stimuli. Theoretically, alexithymia has been subtyped in an 
affective (I) and cognitive (II) factor (Bermond, 1995). Considering this 
distinction in the light of Adolph’s interpretation of social cognition, type I 
alexithymia would be the result of constrictions in the perception of social-
emotional situations and/or in the experience of emotions (a+b), while type II 
alexithymia can be regarded as a disturbance in expressing emotions (c). 
 Roughly, two neurocognitive models regarding hemispheric and inter-
hemispheric disturbances have been extensively described to account for 
alexithymia. The first postulates a non-specific dysfunction of the right cerebral 
hemisphere, resulting in equally non-specified alexithymia (type I + II). 
Considering the contemporary state of knowledge, the right-hemisphere 
model with its broadband character is in fact of limited use in modern 
alexithymia research. Nevertheless, lateralisation is still an important variable 
in unravelling sex differences in alexithymia. The second influential model 
identifies the corpus callosum as dysfunctional, assuming an interhemispher-
ic communication deficit, associated predominantly with impairments in the 
cognitive, expressive aspects of alexithymia (type II). Although this may be 
the best-studied structure with respect to the origins of alexithymia, the 
nature and directionality of the functional transfer deficit have not been 
cleared up in detail yet. In fact, the amount of literature on hemispheric and 
callosal structures as compared to the other structures, may erroneously 
suggest their greater involvement in alexithymia. This however, may be the 
reflection of a historical bias caused by the development of neuroscientific 
methods over the last decades.
The neurocognition of alexithym
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Introduction
Noonan syndrome (NS) is an autosomal dominant genetically heterogeneous 
disorder with an estimated incidence of 1 in 1500 live births, although 60% of 
cases are reported to be sporadic (Shaw et al., 2007). The description of the 
syndrome dates back to 1883 when Kobylinski reported on a male patient with 
several phenotypical characteristics. In 1963 Noonan and Ehmke were the first 
to define a specific group of patients, both male and female, with congenital 
heart defects, small stature, hypertelorism, skeletal malformations and mild 
mental retardation (Noonan & Ehmke, 1963). As proposed by Opitz, this 
disorder was called Noonan syndrome (Opitz, Summitt & Sartro, 1965). The 
diagnosis of NS is primarily clinical and can be made by using a scoring 
system listing major and minor congenital and morphological anomalies (see 
Table 1) (Duncan et al., 1981; Van der Burgt et al., 1994).
 NS should be considered when typical facial features are present as well 
as short stature, a variety of heart defects, particularly pulmonic stenosis 
and hypertrophic cardiomyopathy and skeletal deformations like pectus 
excavatum and carinatum. Additional features are cryptorchidism, lymphatic 
dysplasias, abnormal bleeding and a lower level of IQ (Tartaglia & Gelb, 2005; 
Van der Burgt, 2007).
 In 1994 linkage analysis demonstrated that the gene for NS is located on 
the distal part of chromosome 12q (Jamieson et al., 1994). Some years later it 
was found that missense mutations in the PTPN11 gene (12, q24.1) account for 
Abstract
Although Noonan syndrome (NS) is a disorder with a relatively high 
prevalence, virtually no information in adult patients is available about the 
psychological and psychopathological profile. In the present clinical report the 
first series of 10 patients with NS from an ongoing project is presented. The 
purpose of the study is to investigate the psychopathology, social cognition 
and adaptation as well as the quality of life in patients with NS aged 16 years 
or more. PTPN11 mutations were present in six patients and KRAS and SOS1 
in one patient respectively. In two patients no known mutation was found. The 
results demonstrate a variable level of intelligence and suggest moderately 
impaired social cognition in terms of emotion recognition and alexithymia. In 
some patients mild signs of anxiety and lowered mood are found that, however, 
do not meet the criteria for a specific psychiatric disorder. It is concluded that 
NS in adults is associated with a behavioural phenotype in which deficiencies 
in social and emotional recognition and expression may be key elements.
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Table 1  Diagnostic criteria for Noonan syndrome (NS)
Feature A = major B = minor
1. Facial Typical face Suggestive	face
2. Cardiac Pulmonary Valve Stenosis and/or 
typical ECG
Other defect
3. Height <3rd	centile <10th	centile
4. Chest wall Pectus	carinatum/excavatum Broad	thorax
5.	Family	History First	degree	relative	definite	NS First	degree	relative	
suggestive	NS
6.	Other All	3	(males):	mental	retardation,	
cryptorchidism,	lymphatic	dysplasia
One	of	mental	retardation,	
cryptorchidism,	lymphatic	
dysplasia
*	Definite	NS:	1A	plus	one	of	2A-6A	or	two	of	2B-6B;	1B	plus	two	of	2A-6A	or	three	of	2B-6B
[Adapted	from:	Van	der	Burgt	et	al.,	1994]
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group of 26 children, problems in social interactions were noticed (Sarimski, 
2000). In a group of 48 children aged 4-16 years, inattention and emotional 
problems could be observed (Lee et al., 2005). Finally, Shaw et al. (2007) 
reported qualitative data on 112 adult Noonan patients, showing lack of social 
life, or an inability to fit in, although overall quality of life was evaluated to be 
satisfactory. Psychiatric disorders are rarely found and are described only in 
single case reports on patients with lower intelligence (Table 2). Given the 
prevalence of NS, it is remarkable that virtually no reports have been published 
about classical psychiatric syndromes and that hardly any information is 
available about the cognitive and mental health status of adult patients with 
NS. As suggested earlier, this lack of information and the frequently described 
impaired social capacities may be the result of a relative deficit in the 
comprehension and expression of emotions (Verhoeven et al., 2004). This can 
be illustrated as follows. Several authors have noticed difficulties with social 
competence, especially the emotional perception of self and others in patients 
with NS (Lee et al., 2005; Mahendran and Aw, 1969; Sarimski, 2000; Wood et al., 
1995). These phenomena are associated with social cognition, an umbrella 
term in which cognitive, emotional and motivational processes are involved to 
flexibly guide social behaviour (Adolphs, 2001). Examples can be found in the 
decoding of affective expressions in faces, voices and body postures, attribution 
of mental states to others (e.g., believes, desires, and intentions), and regulation 
of emotions (Van Rijn, 2007). These processes can also be found in the concept 
of alexithymia, a historical, originally psychoanalytic concept, that gained 
renewed attention in neurocognitive research.  “Alexithymia”, or “no words 
for feelings”, refers to an impairment of the ability to identify and communicate 
one’s emotional state, in addition to diminished affect-related fantasy and 
imagery. There is rising evidence for a neural basis for this multidimensional 
construct (Aleman, 2005).
 The present study was designed to investigate the psychiatric profile, 
cognitive qualities, social cognition and adaptation, as well as the quality of 
life in adult patients with NS. 
Materials and Methods
The study is part of an ongoing multidisciplinary project with the purpose to 
assess neuropsychological characteristics, social cognition, psychiatric 
symptoms and quality of life in patients with NS, aged 16 years or more. 
Patients volunteered after being invited by the Department of Human Genetics 
of the Radboud University Medical Centre or the Dutch Noonan Syndrome 
about half of the patients with NS (Tartaglia et al., 2001, 2002). Apart from this 
autosomal dominant form an autosomal recessive form, in which hypertrophic 
obstructive cardiomyopathy is more frequent, was suggested (Van der Burgt & 
Brunner, 2000). 
 Given the overlap in congenital anomalies between NS and both cardio-
faciocutaneous syndrome (CFCS) (Roberts et al., 2006a) and Costello syndrome 
(CS) (Hennekam, 2003), shortly after the discovery of mutations in the HRAS 
gene in the majority of patients with CS (Aoki et al., 2005) and in the KRAS 
gene in CFCS (Niihori et al., 2006), germline mutations in KRAS gene were 
reported in a minority of patients with severe forms of NS (Carta et al., 2006; 
Schubbert et al., 2006; Zenker et al., 2007). Most recently, a novel mutation in 
another gene involved in the Ras-MAPK pathway was discovered in a subset 
of patients with NS, the SOS1 (Roberts et al., 2006b; Tartaglia et al., 2007). 
 These disease gene discoveries have established NS and related traits 
(CFCS and CS) as disorders of unregulated Ras-MAPK signaling (Tartaglia et 
al., 2007). The Ras-MAPK pathway is implicated in growth-factor mediated 
cell proliferation and differentiation or cell death (Malumbres & Barbacid, 
2003; Narumi et al., 2007).
 Only limited data are available on the psychological and psychiatric 
characteristics of patients with NS. As reported by several authors, in about 
one-third of the patients mild mental retardation is found. In most patients, 
however, the level of intelligence falls within the normal range (Allanson, 
2010). In 21 children with NS, aged 3-16 years, mood disturbances as well as 
social and communication problems have been found (Wood et al., 1995). Van 
der Burgt et al. (1999) described lowered intelligence and planning problems in 
a group of 35 children. In a case report, inattention-resembling features of an 
attention-deficit/hyperactivity disorder were suggested to be a key problem 
(Horiguchi & Takeshita, 2003). By using a postal survey, in at least 30% of a 
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Table 2  Psychiatric syndromes in patients with Noonan syndrome 
Author, year Age, sex, IQ Diagnosis
Krishna	et	al.,	1977 37,	male,	63 Schizophrenia
Paul	&	Volkmar,	1983 4,	male,	18months* Autistic	disorder
Mahendran	&	Aw,	1989	 30,	female,	68-70 Bipolar	affective	disorder
Ghaziuddin	et	al.,	1994 13,	male,	69 Autistic	disorder
Verhoeven et al., 2004 19,	female,	low Panic	disorder,	alexithymia
*developmental age
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Results
At present, 28 patients are referred. In Table 3, the clinical characteristics of the 
first series of 10 patients are depicted. The mean age and length (range) of the 
patients were 29.6 years (range: 16-59 years) and 164 cm (range: 152-183 cm) 
respectively. As can be inferred from Table 3, PTPN11 mutations are present in 
six patients, KRAS and SOS1 in one each, whereas in two patients (2 and 6) 
neither of the known mutations could be demonstrated. In these two patients, 
the diagnosis was clinically confirmed by a geneticist, according to the 
diagnostic criteria proposed by Van der Burgt et al. (1994). With respect to the 
level of intelligence, total IQ (WAIS-III) varied between 65 and 121. In six 
patients, a significant difference between verbal and performal IQ was found. 
Verbal capacities were better than performal in two patients and in the other 
four the reverse was found.
 In one patient (1), a diagnosis of obsessive-compulsive disorder was made 
previously and he was successfully treated elsewhere. In some patients, on a 
symptom checklist, mild signs of anxiety and lowered mood were found that, 
however, did not reach the intensity of a specific psychiatric disorder. None of 
the patients met the DSM-IV-criteria for Attention Deficit/Hyperactivity 
Disorder or Pervasive Developmental Disorder, albeit that in some patients 
subtle deficits in attention and concentration were demonstrated. 
 The results of the psychological test battery are depicted in Table 4. Social 
cognition, in terms of emotion recognition and alexithymia, appeared to be 
moderately impaired. Test results were suggestive for alexithymia, especially 
for its cognitive aspects (inadequate verbalisation). A tendency was found 
towards an indirect expression of emotions during social interaction. In 
contrast with their self-report of psychological problems on the earlier 
mentioned checklist, and the evaluation of social functioning by significant 
others, patients reported average level of quality of life in terms of the LQoL 
domain satisfaction. 
Foundation, and were subsequently referred to the outpatient Department for 
Neuropsychiatry of the Vincent van Gogh Institute for Psychiatry, Venray, the 
Netherlands. All patients and their primary caregivers signed written 
informed consent to participate in this clinical project and to collect all data 
from the medical history. Screening for mutations was performed previously 
in the laboratory for DNA-diagnostics of the University Medical Center 
Nijmegen, the Netherlands.
 During the first phase of the project, 10 patients were enrolled in whom 
the diagnosis NS was confirmed. Thereafter, a multidisciplinary evaluation 
took place in order to ascertain whether the research procedure was adequate 
to collect the required data. 
 In all patients an extensive neuropsychological assessment was performed 
followed by a neuropsychiatric examination using all available data from 
medical, developmental, and family history. Intelligence was measured using 
the Wechsler Adult Intelligence Scale (WAIS-III) (The Psychological Corporation, 
1997), and the National Adult Reading Test (NART) (Nelson, 1982). The Theory 
of Mind Test (TOM) was used to check if patients were able to interpret simple 
actions and intentions of other people (Steerneman, Meesters & Muris, 2003). 
In addition, Perrett’s Emotion Recognition Task (ERT) was administered. This 
is a computer-generated paradigm for measuring the recognition of six basic 
facial emotional expressions (anger, disgust, fear, happiness, sadness and 
surprise) presented at different intensities. Video clips of increasing length are 
presented, starting with a neutral face that changes into a facial expression of 
different intensity levels (Montagne et al., 2007). Furthermore, because of the 
conceptual overlap between social cognition and alexithymia, we used two 
alexithymia questionnaires. The Toronto Alexithymia Scale (TAS-20) is an in-
ternationally used instrument to measure the ability to give words to feelings 
(Bagby, Taylor & Parker, 1994b). The Bermond Vorst Alexithymia Questionnaire 
(BVAQ) was developed in the Netherlands. It offers the possibility to 
disentangle the so-called affective (arousal per se) and cognitive (recognising, 
verbalising and analysing emotions) aspects of alexithymia (Vorst & Bermond, 
2001).
 In order to gather psychometric information on the existence of psychopa-
thology, the Structured Clinical Interview for the DSM-IV (SCID-I and SCID-II) 
(First, Spitzer, Gibbon & Williams, 1997; First, Spitzer, Gibbon, Williams & 
Benjamin, 1997), and a Symptom Check List (SCL-90-R) (Arrindell & Ettema, 
2003) were administered. Finally, the Lancashire Quality of Life Profile (LQoL) 
was included, an interview widely used in Europe to measure health related 
quality of life variables (Van Nieuwenhuizen, Schene, Koeter & Huxley, 2001).
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Table 4  Neuropsychological profile of patients with Noonan syndrome (n=10)
Measurement  
domain
Scale Mean SD Performance
Intelligence
WAIS-III Total IQ 90 18.8 Low Average
WAIS-III Verbal IQ 88 20.6 Low Average
WAIS-III Performance IQ 93 18.6 Low Average
NART-IQ 90 11.8 Low Average
Social cognition and adaptation 
Emotion	Recognition	Task 2.1 0.3 Low Average
TAS-20 Total Score 45.3 8.6 Average
BVAQ Total Score 120.9 12.5 Low
BVAQ-Affective	scale 45.4 9.2 Low Average
BVAQ-Cognitive	scale 75.4 12.0 Low
TOM 70.8 3.5 Low Average
Psychopathology 
SCID One	classification
SCL-90-R	Psychoneuroticism 153.4 37.3 High Average
SCL-90-R	Anxiety 17.7 4.4 High Average
SCL-90-R	Depression 29.7 11.9 High Average
Quality of Life
LQoL	Satisfaction	with	Leisure	&	
Social	participation
5.5 0.7 Average
LQoL	Satisfaction	with	Health 5.5 0.8 Average
LQoL	Satisfaction	with	Family	
relations	
6.0 0.5 High Average
LQoL	Satisfaction	with	Fulfilment	
of Life-goals 
4.8 0.7 Average
Performance	classification	follows	a	five-point-scale	in	which	each	step	represents	one	standard	
deviation;	e.g.,	“low”	means	2	standard	deviations	from	the	normative	mean	of	healthy	subjects.
In	the	absence	of	applicable	norms,	TOM	and	LQoL	performance	classification	represents	clinical	
judgment.
WAIS: Wechsler Adult Intelligence Scale
NART:	National	Adult	Reading	Test
TAS:	Toronto	Alexithymia	Scale
BVAQ:	Bermond-Vorst	Alexithymia	Questionnaire
TOM: Theory of Mind Test
LQoL:	Lancashire	Quality	of	Life	Profile
66 67
Discussion
The results of the first phase of this project confirm the genetic and somatic 
heterogeneity and the variability in IQ scores in patients with NS. With respect 
to the SCL-90-R, a self-report instrument, high average scores (+1 SD) were 
found on complaints reflecting psychoneuroticism, anxiety and depression. 
The quality of life questionnaire, however, showed an average to high 
satisfaction with different aspects of life. Social and emotional recognition 
appeared to be slightly impaired which implies that some form of alexithymia 
is present.
 An observation, never mentioned in publications on patients with NS, but 
made by all participating investigators of this project, is that they are in general 
remarkably friendly, cooperative and very willing to please. These are all 
aspects of a social desirable attitude. Social desirability can be defined as 
behaviour guided by the environments’ expectations (Paulhus, 2002). As to the 
behavioural phenotype of NS, this could be a relevant neglected aspect of it. 
This may be reflected by the contrasting scores on the SCL-90-R and the LQoL, 
which suggest a tendency towards desirable answering. The SLC-90-R could 
be a trigger for these patients to admit problems since its format only asks for 
confirmations of complaints. Inherently, alexithymia and problems in social 
cognition, that is, in the ability to recognise and verbalise emotions, can lead 
to inadequate results on this kind of self-report measures, because they impose 
these very demands on the subjects studied. 
 In conclusion, although no behavioural phenotype has been suggested for 
NS, the results of the present project show that deficiencies in social and 
emotional recognition and expression may be key elements. The paucity in 
published cases with psychiatric syndromes might be an expression of a real 
lower incidence, or of an underreport in psychopathology in adult patients 
with NS.
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Introduction
Noonan syndrome (NS) is an autosomal dominant congenital disorder, first 
described in the 1960s (Noonan & Ehmke, 1963). Although relatively unknown, 
NS is fairly common, with an estimated incidence between one in 1000 and 
one in 2500, and a presumably higher prevalence of milder expressions 
(Allanson, 2007). Different activating germline mutations in genes encoding 
participants of the Ras mitogen-activated protein kinase (MAPK) pathway 
have been found to cause NS. At present, genetic testing reveals a mutation in 
approximately 70% of Noonan cases. Research aimed at the identification of 
other NS-causing genes is ongoing and the diagnosis is still established 
primarily on clinical grounds, by observation of key features such as short 
stature, heart defects and facial dysmorphology. Typical facial appearance 
involves ptosis, wide-spaced eyes, low-set and posteriorly rotated ears with a 
thickened helix, and a broad or webbed neck. 
 Although cardinal characteristics are well described, there is a large 
variability in expression and, with increasing age, the phenotype often 
becomes less pronounced. Diagnosis is generally made in early childhood 
because of congenital heart disease, feeding problems or other somatic 
complications. In otherwise healthy adults, the diagnosis may only be 
ascertained after the birth of a more significantly affected child. Life expectancy 
is mildly reduced, predominantly by serious cardiac defects (Allanson, 2007; 
Van der Burgt, 2007). The pathogenesis of NS has been associated with tissue 
disruption or displacement by lymph-oedema during (congenital) development 
(Witt et al., 1987). Furthermore, vascular changes and malformations may 
occur slightly more frequently in NS, but there is limited evidence for structural 
abnormalities of the central nervous system. 
 At a cognitive level, a low average IQ and learning difficulties are 
considered to be typical for NS and deviations in social adaptation have been 
suggested repeatedly (Verhoeven, Wingbermühle, Egger, Van der Burgt & 
Tuinier, 2008; Wingbermühle, Egger, Van der Burgt & Verhoeven, 2009). In the 
majority of publications on clinical features of NS, authors refer to anecdotal 
evidence from clinical observation regarding the social competence of their 
patients. For example, children with NS are often said to mature more slowly, 
have a diminished insight into social situations and have problems in 
verbalising and explaining emotions (Lee et al., 2005; Sarimski, 2000; Wood et 
al., 1995). In adults, a tendency towards a socially desirable attitude has been 
reported (Verhoeven et al., 2008). In a case study of an adolescent with NS, a 
specific problem in the expression of emotions was demonstrated, in 
combination with an anxiety disorder (Verhoeven et al., 2004). Moreover, in a 
Abstract
Noonan syndrome (NS) is a common genetic disorder, characterised by short 
stature, facial dysmorphia, congenital heart defects, and a mildly lowered IQ. 
Impairments in psychosocial functioning have often been suggested, without, 
however, systematic investigation in a clinical group. In this study, different 
aspects of affective processing, social cognition and behaviour, in addition to 
personal well-being, were assessed in a large group of patients with NS. Forty 
adult patients with NS were compared with 40 healthy controls, matched with 
respect to age, sex, intelligence and education level. Facial emotion recognition 
was measured with the Emotion Recognition Task (ERT), alexithymia with 
both the 20-item Toronto Alexithymia Scale (TAS-20) and the Bermond-Vorst 
Alexithymia Questionnaire (BVAQ), and mentalising with the Theory of Mind 
test (TOM). The Symptom Checklist-90 Revised (SCL-90-R) and the Scale for 
Interpersonal Behaviour (SIB) were used to record aspects of psychological 
well-being and social interaction. Patients showed higher levels of cognitive 
alexithymia than controls. They also experienced more social distress, but the 
frequency of engaging in social situations did not differ. Facial emotion 
recognition was only slightly impaired. Higher levels of alexithymia and 
social discomfort are part of the behavioural phenotype of NS. However, 
patients with NS have relatively intact perception of emotions in others and 
unimpaired mentalising. These results provide insight into the underlying 
mechanisms of social daily life functioning in this patient group.   
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Z=0.23, p=0.82). No differences were found between patients with NS and 
controls with respect to overall intelligence [Wechsler Adult Intelligence Scale 
III (WAIS-III; Wechsler, 1997) Full-Scale IQ NS: M=91.2, SD=14.5, range=67-124; 
controls: M=91.4, SD=8.3, range=73-109; F(1,78)=0.007, p=0.93; National Adult 
Reading Test (NART; Nelson, 1982) IQ NS: M=87.65, SD=13.62, range=55-123; 
controls: M=87.90, SD=8.79, range=68-111; F(1,77)=0.009, p=0.93], verbal 
intelligence (WAIS-III VIQ NS: M=90.3, SD=15.9, range=64-127; controls: 
M=91.7, SD=9.3, range=72-110; F(1,78)=0.248, p=0.62) or performance intelligence 
(WAIS-III PIQ NS: M=93.8, SD=14.4, range=61-120; controls: M=93.4, SD=9.4, 
range=73-114; F(1,78)=0.017, p=0.90). Finally, there were no differences in 
education level (mode NS=5, mode controls=5, U=694.5, Z=1.12, p=0.26), which 
was scored using seven categories, category 1 being the lowest and 7 the 
highest (Duits & Kessels, 2006). Table 1 shows the genetic subtypes of the 
patients with NS. 
Materials and procedure
The Emotion Recognition Task (ERT) was administered to examine emotion 
perception. This is a computer-generated paradigm for the recognition of six 
basic facial emotional expressions: anger, disgust, fear, happiness, sadness and 
surprise. The emotions are mimicked by actors (two males, two females) and 
they are presented at different intensities. The degree of expression is 
incrementally increased from 20% to 100% (Montagne et al., 2007). After each 
video clip, the participant is asked to make a forced choice between the six 
emotional expressions, displayed in labels on the test computer. Each emotion 
in each intensity is presented four times. This task provides a static measure of 
pilot study (n=10) an increased incidence of alexithymia and higher levels of 
mood and anxiety problems were found in adult patients with NS compared 
to clinical cut-off scores (Verhoeven et al., 2008). However, a case-control study 
in a larger sample to substantiate these findings has not been performed yet. 
Hence, the aim of the current study was to examine different aspects of 
affective information processing and social cognition in adults with NS. Social 
cognition reflects a neuropsychological approach and definition of social- 
emotional processes. The perception, experience, and expression of emotions 
were evaluated, in addition to social interaction and psychological well-being.
Methods
Participants
Eighty participants were enrolled in this study; 40 of these were Dutch adults 
(17 males) with NS who volunteered after being invited either by the human 
genetics department of a university medical centre or by the Dutch Noonan 
Syndrome Foundation. All were referred to the out-patient neuropsychiatry 
clinic of the Vincent van Gogh Institute for Psychiatry, Venray, the Netherlands. 
The other 40 participants were matched healthy Dutch adults (16 males) 
recruited for control purposes. The study was approved by the local 
Institutional Review Board in accordance with the Declaration of Helsinki. 
After full explanation of the procedures, written informed consent was 
obtained from all participants and their caregivers, where appropriate. 
 In all patients, a clinical diagnosis of NS was confirmed by a clinical 
geneticist with a special expertise in NS (I.vdB.). Genotyping resulted in 
ascertainment of a mutation in 29 patients. In five patients no known mutation 
was found, and in another six the mutation was unknown (one patient did not 
wish to undergo DNA testing and the DNA of five patients was still under 
examination to test for the most recent mutations). Five of the patients with NS 
were on psychotropics [selective serotonin reuptake inhibitors (SSRIs)/ mood 
stabilizers in all cases, additional methylphenidate in one case], mainly 
because of current anxiety and mood symptoms. The control participants 
neither had a history of neurological or psychiatric disorder, nor were they 
diagnosed with a genetic disorder, according to self-reports. Two of them used 
psychotropic drugs (SSRIs), because of mood complaints in an earlier period in 
their lives. All patients had normal or corrected-to-normal vision.
 The control group was carefully matched. The two groups did not differ 
with respect to age (NS: M=29.1 years, SD=13.4, range=16-61; controls: M=33.8 
years, SD=14.0, range=18-54; F(1,78)=2.34, p=0.13) and sex distribution (U=780.0, 
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Table 1  Genetic subtypes of the patients with Noonan syndrome
Genotype n %
PTPN11 22 55.0
SOS1 3 7.5
KRAS 2 5.0
BRAF 0 0.0
MAP2K1/2 1 2.5
NRAS 0 0.0
SHOC2 1 2.5
No	mutation	found 5 12.5
Unknown 6 15.0
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of getting involved in a variety of interpersonal behaviours and for the level of 
distress accompanying assertive responses. The SIB consists of 50 items, to be 
evaluated on two separate five-point scales by the participant; one for the 
frequency of engagement in a specific social situation (Performance) and one 
for the degree of discomfort experienced (Distress). The index provides four 
subscales, based on factor analyses: Negative Assertion (disclosure of negative 
feelings), Insecurity (expression of and dealing with personal limitations), 
Initiating Assertiveness (social assertiveness and expressing one’s own opinion) 
and Positive Assertion (praising others and the ability to deal with compliments). 
Data analysis
ERT data of both groups were compared using a general linear model (GLM) 
repeated-measures analysis, with Emotion type (six levels: anger, disgust, 
fear, happiness, sadness and surprise) and Intensity (nine levels: 20-100%) as 
within-subject factors, and Group (patients with NS versus healthy controls) as 
the between-subject factor. A one-way ANOVA was used to reveal significant 
differences between patients and controls in their performances on the 
ToM-test and on all questionnaires (TAS-20, BVAQ, SCL-90-R, SIB). For all 
analyses, α was set at 0.05. 
Results
Affective information processing
Table 2 shows the results for both groups on measures for affective information 
processing. Figure 1 depicts the mean ERT-performance for the patients with 
NS and the control group for all emotion types, and for the different intensity 
levels.
 A small, yet significant, overall group effect was found on the ERT, 
indicating that the patients with NS performed slightly worse than the controls 
(F(1,78)=4.52, p<0.05). Overall main effects were found for Emotion 
(F(5,74)=227.26, p<0.0005) and Intensity (F(8,71)=114.94, p<0.0005) . This indicates 
that, as usual, some emotions were harder to recognise than others and 
performance improved when faces with a higher level of emotion intensity 
were presented. A significant interaction between Emotion and Intensity was 
found (F(40,39)=5.99, p<0.0005), indicating that the intensity did not affect each 
emotion in the same way, in line with previous findings (Montagne et al., 
2007). None of the other interactions was significant (all F values < 0.91). 
 According to the TAS-20, patients with NS scored significantly higher on 
alexithymia than the healthy controls (F(1,76)=4.65, p<0.05). A stronger externally 
accuracy with respect to emotion recognition and also is a sensitive measure 
for the assessment of emotional expressions of lower intensities. The ERT has 
been validated in several clinical groups (Montagne et al., 2006).
 To assess emotion experience and individual habits in emotion expression, 
two alexithymia questionnaires were completed by the participants. The 
Toronto Alexithymia Scale (TAS-20) is the standard instrument for evaluating 
alexithymia, with 20 items and three factor-based subscales, measuring 
difficulties in identifying feelings (DIF), difficulties in describing feelings 
(DDF) and a tendency to externally oriented thinking (EOT) (Bagby, Parker & 
Taylor, 1994a). The Bermond Vorst Alexithymia Questionnaire (BVAQ) consists 
of 40 items and it differentiates between affective and cognitive dimensions of 
alexithymia (Vorst & Bermond, 2001). Increased scores on the affective 
dimension would reflect problems in the conscious experience of arousal that 
accompanies emotions (factor-derived scales Fantasizing and Emotionalizing), 
whereas a heightened score on the cognitive dimension is presumed to refer to 
difficulties in Identifying, Verbalizing and Analyzing emotions (analogous to 
factor and subscale names). In both the TAS-20 and the BVAQ, respondents are 
asked to rate the applicability of statements about alexithymic features to 
themselves on a five-point scale. The factor structure of both instruments has 
been confirmed in clinical and non-clinical samples (Bagby et al., 1994b; Müller 
et al., 2004; Vorst & Bermond, 2001). 
 To evaluate mentalising capacities, a basic Theory of Mind (ToM) test was 
included. This test comprises tasks to assess precursors of ToM, in addition to 
general ToM-abilities such as first-order belief, false-belief and second-order 
belief, using stories and images based on the ToM paradigm (Steerneman et al., 
2003; Baron-Cohen, Leslie & Frith, 2007).
 The Dutch version of the Symptom Checklist-90 Revised (SCL-90-R), a 
multidimensional questionnaire based on self-assessment of recent complaints, 
was used to estimate general psychological, somatic and cognitive well-being 
(Arrindell & Ettema, 2003). The 90 items of the SCL-90-R are rated on a 
five-point scale. The Dutch translation includes eight subscales: Agoraphobia, 
Somatization, Anger-Hostility, Depression, Interpersonal Sensitivity and 
Paranoid Ideation, Anxiety, Cognitive-Performance Difficulty, and Sleep 
Disturbance. The total scale Psychoneuroticism indicates the general level of 
distress. Additionally, the subscale Somatization can be used as an indicator of 
the level of the physical symptoms and the subscale Cognitive-Performance 
Difficulty can be considered an indicator of cognitive complaints.
 As an index for engagement in social behaviour and the associated 
experience of stress, the Scale for Interpersonal Behaviour (SIB) was administered 
(Arrindell et al., 2001). This questionnaire was validated for both the likelihood 
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Figure 5   Mean performance (proportion correct and standard error of the 
mean) for the different levels of intensities (20-100%) of the six basic 
emotions in the NS patient group (circles) and the healthy controls 
(triangles).
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oriented mode of thinking in the participants with NS contributed most to this 
difference. The BVAQ revealed no statistical differences with respect to the 
total score (F(1,76)=1.38, p=0.24), but the cognitive composite core was 
significantly higher in the patients (F(1,76)=4.37, p<0.05), again referring to 
more alexithymic features. Subsequent analysis showed that problems in 
Verbalizing emotions had a large part in this (F(1,76)=4.80, p<0.05). These 
results suggest problems in the cognitive processing of emotions in NS, in the 
presence of an intact affective experience. Mentalising abilities (TOM total 
score) did not differ significantly between the groups (F(1,78)=1.37, p=0.25). 
Psychological well-being and social interaction 
Table 3 demonstrates the results of the questionnaires addressing aspects of 
psychological well-being and social interaction. There was no group difference 
in the general level of personal complaints on the Psychoneuroticism scale of 
the SCL-90-R (F(1,76)=1.61, p=0.21). However, the patients with NS manifested 
significantly more complaints on Anger-Hostility (F(1,76)=4.63, p<0.05), and 
they reported significantly higher levels of Cognitive-Performance Difficulty 
(F(1,76)=5.32, p<0.05). There was no group difference on the Anxiety subscale 
(F(1,76)=0.27, p=0.60), nor did the patients show different avoidance tendencies, 
given the results on Agoraphobia (F(1,76)=1.00, p=0.32).
 The SIB results indicate a significant difference between the groups with 
respect to Distress experienced during the execution of social behaviour; 
patients with NS reported substantially higher levels of distress (F(1,75)=8.08, 
p<0.01). The results on the Performance scale show that frequencies of actual 
engagement in social situations did not differ (F(1,75)=0.39, p=0.53). 
Discussion
This is the first case-control study to examine affective processing, social 
cognition and interpersonal behaviour, as well as psychological well-being, in 
NS. To objectify previously reported anecdotal problems in these domains, 
relevant measures were chosen and findings of adult patients with NS were 
compared with those of matched controls. 
 First, our findings demonstrate that the perception and labeling of 
emotional facial expressions was lowered in patients. However, the effect size 
was small and no selective deficits were found in the perception of any specific 
emotions. These findings suggest that patients with NS do not fundamentally 
lack the ability to correctly perceive and label emotions. Second, difficulties in 
the subjective experience and expression of emotions were noticeably more 
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rely heavily on executive control processes, such as integration, control and 
guidance, impairments in executive functioning could be the core deficit in 
NS, resulting in secondary problems in social cognition. Although dysexecutive 
symptoms have been suggested in NS, this domain has not been empirically 
studied yet (Wingbermühle et al., 2009). 
 Considering psychosocial aspects contributing to alexithymia in NS, 
heightened levels of social distress may underlie deficits in emotional 
expression. Experiencing social discomfort may result in social withdrawal or 
in a lack of confidence to express oneself. Individuals scoring high on cognitive 
aspects of alexithymia have been shown to be more prone to suppressive 
emotion regulation strategies, rather than to apply reappraisal strategies 
(Swart et al., 2009). Consequently, alexithymia may be considered as the 
reflection of an inadequate coping strategy. However, the reverse may be the 
case as well; the inability to express emotions may lead to feelings of frustration 
and discomfort. It is plausible that emotion regulation is altered by deviating 
interpersonal experiences, for example in relation to the frequent medical 
interventions in early childhood, or because of experiences with being bullied. 
 As mentioned earlier, these explanations are likely to interact and thus 
may not be mutually exclusive. Alexithymia in NS is probably the manifestation 
of a complex interaction between genetic, neurocognitive and psychosocial 
influences. Deficits in affective information processing or social cognition, 
notably alexithymia, may result in unrecognised discomfort and a lower 
quality of life in many patients (Mattila et al., 2007). 
 The strengths of this study lie in the novelty of the findings and the 
inclusion of a high quality, matched control group. A limitation is in the 
relatively small sample size, although it is the largest behavioural study yet. 
Previous studies were either single cases or small groups or lacked a control 
group. Nevertheless, studies in larger samples are required to replicate our 
findings and to compare NS subgroups, for example based on mutation type, 
sex, age group, or age of diagnosis. Moreover, future studies may be able to 
clarify whether neurocognitive impairments in other domains, in particular 
in the executive functions, are related to alexithymia in NS. Research should 
also address the question of specificity of the social-cognitive problems found 
in NS by comparing the performances of patients with NS with those of 
Noonan-like phenotypes, such as Turner syndrome. 
 In conclusion, this study demonstrates that cognitive alexithymia and 
elevated levels of psychological and social distress are part of the behavioural 
phenotype in adults with NS. Adopting a longitudinal, developmental 
perspective may elucidate the variability of the behavioural phenotype during 
the process of ageing. 
prevalent in the patient group, in agreement with the concept of alexithymia. 
In particular, cognitive aspects of alexithymia, that is problems in verbalising 
emotions, were problematic for individuals with NS. Although several studies 
report that alexithymia often underlies concurrent objective deficits in facial 
emotion recognition (Jessimer & Markham 1997; Karlsson et al., 2008; Parker, 
Taylor & Bagby, 1993), such an association was not apparent in our study as 
only a small difference between NS and controls was found with respect to 
emotional perception. Third, basic TOM or mentalising abilities were found to 
be satisfactory in all participants.
 At the level of social participation and psychological well-being, patients 
with NS reported experiencing significantly higher levels of distress during 
interpersonal behaviour. Levels of general anxiety were, however, comparable 
to controls and social interaction was not avoided. Furthermore, most patients 
had a significant medical history related to somatic conditions as part of NS. 
Consequently, higher scores were expected on the somatic subscale of the 
symptom checklist, as it also contains items that could refer to somatic aspects 
of NS. However, on this subscale, the patients reported a similar extent of 
somatic complaints as the controls.
 The origins of alexithymia may be found on three interacting levels: the 
genetic, the neurocognitive, and the psychosocial level. A first explanation for 
the occurrence of alexithymia in NS could be found in the direct influence of 
syndrome-specific genetic mutations on the development of the brain, and, as 
a result, on cognitive development. From the 1970s onwards, heightened levels 
of alexithymia, more in particular on the externally oriented mode of thinking 
(as represented in the TAS-20 EOT-subscale), have been associated with genetic 
influences (Heiberg & Heiberg, 1978; Valera & Berenbaum, 2001). In our study, 
patients with NS showed marked problems specifically in this aspect of 
alexithymia. In recent years, research has shifted from a classical behavioural-
genetics approach to a more specific focus on molecular genetics. Recent 
studies focus upon the cognitive and behavioural consequences of dysfunctions 
in the Ras-MAPK pathway, which is affected in NS and in phenotypically 
associated syndromes, such as cardiofaciocutaneous syndrome (CFCS). Here, 
for example, correlations have been found between mutations in Ras-MAPK 
and adaptive functioning in NS and CFCS (Pierpont et al., 2010). Likewise, 
dysfunctions in this pathway may be related to the occurrence of alexithymia.
 An alternative explanation at the neurocognitive level may be that lowered 
verbal intellectual abilities could have been the cause of problems in the 
expression of emotions. However, the patients in this study did not have 
specific deficits in verbal intelligence. Patients with NS reported more cognitive 
complaints compared with controls. As emotion regulation and social adaptation 
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Introduction
Noonan syndrome (NS) is a worldwide reported genetic disorder with an 
autosomal dominant inheritance pattern that was first described by Noonan 
and Ehmke in 1963 and further elaborated upon by Noonan (1994) and Noonan 
and O’Connor (1995). The prevalence of NS is estimated to be between 1 in 1000 
and 1 in 2500 live births (Allanson, 2010; Mendez & Opitz, 1985; Noonan, 1994). 
Although clinical features may vary, NS is typically characterised by mild 
facial dysmorphisms including hypertelorism, ptosis, strabismus, down - 
slanting palpebral fissures, low-set ears, and a broad and sometimes webbed 
neck. In addition, NS is frequently associated with congenital heart defects 
and short stature (Allanson, 2007; Van der Burgt, 2007). Up to 90% of the 
patients have cardiac defects, particularly pulmonic valve stenosis (PVS), 
hypertrophic cardiomyopathy, and atrial septal defects. Reported adult heights 
are about –2 SD, due to postnatally reduced growth (Noonan, Raaijmakers & 
Hall, 2003; Otten & Noordam, 2009; Ranke et al., 1988). Other phenotypical 
characteristics include chest and spine deformities, cryptorchidism, lymphatic 
dysplasia, and delayed pubertal development (Tartaglia et al., 2002; Van der 
Burgt, 2007). Nowadays, the diagnosis is mostly established soon after birth 
and is based on a set of clinical criteria (Van der Burgt et al., 1994). 
 NS is caused by germline mutations (mutations in gametes) in the  Ras- 
mitogen-activated protein kinase (Ras-MAPK) pathway. This signal transduction 
pathway is involved in cell-cycle control processes (Boutros, Chevet & 
Metrakos, 2008; Zenker, 2009). At present, while research in NS continues to 
identify new causative mutations, in approximately 75% of the patients a 
causative mutation is found in one of the following genes: PTPN11, SOS1, 
RAF1, KRAS, NRAS, BRAF, SHOC2, MEK1 (MAP2K1), and CBL (Tartaglia et 
al., 2011). Mutations in the PTPN11 gene are most common, accounting for over 
50% of the cases. As the disorder is caused by germline mutations, it is 
inheritable (Allanson, 2010). In 60% of the cases, mutations occur spontaneously 
(de novo) (Fakouri & Fakouri, 1998; Shaw et al., 2007).
Cognitive functioning in Noonan syndrome
Recently, problems in affective information processing were demonstrated in 
patients with NS (Wingbermühle, Egger, Verhoeven, Van der Burgt & Kessels, 
2012). Little is known, however, about the performance of patients with NS 
on cognitive domains such as memory, executive function, and speed of 
information processing. To date, studies have mainly focused on somatic 
complications and only incidentally address intellectual (dis)abilities or 
behavioural characteristics. Also, studies have mostly examined children or 
Abstract
This is the first study in which functioning within the major cognitive domains 
is systematically evaluated in a group of adults with Noonan syndrome (NS) 
and compared with a control group. Extensive neuropsychological assessment, 
including the domains Intelligence, Speed of Information Processing, Memory 
(Working Memory, Immediate Recall and Delayed Recall), Executive Function, 
and Visuoconstruction, was performed in a sample of 42 patients with NS and 
42 healthy controls, matched on age, sex, and education level. In addition, 
subjective cognitive complaints were assessed with self-report questionnaires. 
On the domain speed of information processing patients performed worse 
than controls (p<0.05). Furthermore, except for slightly better results on 
Delayed Recall in the patients with NS (p<0.05), none of the other cognitive 
domains showed between-group differences. On the questionnaires, patients 
reported substantially more complaints about their own cognitive abilities 
than controls (p<0.05). A lowered speed of information processing and 
relatively intact functioning in other cognitive domains characterises the 
cognitive profile of adult patients, in contrast to previous findings in children 
with NS, who seem to have more generalised cognitive deficits. 
Published as: 
Wingbermühle, E., Roelofs, R.L., Van der Burgt, I., Souren, P.M., Verhoeven, 
W.M.A., Kessels, R.P.C., & Egger, J.I.M. (2012). Cognitive functioning of adults 
with Noonan syndrome: A case-control study. Genes, Brain & Behavior, 11, 785-793. 
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adolescents with NS. Moreover, if cognitive functioning is reported, evaluations 
often result from single-case studies using only one or a few assessment 
instruments, mostly questionnaires completed by parents or teachers. In the 
occasional group studies, age ranges are usually wide, including both infants 
and adolescents, although cognitive performance develops and differs over 
age stages. Table 1 summarises sample sizes and age ranges of previous studies 
on cognitive and behavioural functioning in patients with NS that have 
included some kind of neuropsychological assessment. Overall, these studies 
suggest a mildly lowered average intelligence, a delay in language and motor 
development, mild problems in selective and sustained attention as well as 
suboptimal executive function to be present in patients with NS (Wingbermühle 
et al., 2009). These kinds of cognitive problems may explain an increased need 
for special education in young patients with NS (Shaw et al., 2007). However, a 
systematic, controlled and multiple-sourced assessment of cognitive functioning 
in adults with NS has not been performed as yet. 
Genetic, cardiac and psychosocial influences 
NS results from point mutations in genes encoding upstream components of 
the Ras-MAPK pathway. Since this signalling cascade affects metabolic 
functioning, including cell and tissue growth and placement, dysfunction 
may very well result in abnormalities in brain development and function. 
Manifestations of NS in the human central nervous system have, however, not 
extensively been studied. Potential neurological disorders that have been 
described in NS are epilepsy, craniosynostosis, hydrocephalus, and Arnold 
Chiari Malformation (Wingbermühle et al., 2009). Animal studies have showed 
abnormal central nervous system development and mental retardation to be 
linked to signalling disturbances in the Ras-MAPK pathway (Gauthier et al., 
2007; Samuels, Saitta & Landreth, 2009). In humans, lowered intellectual and 
adaptive functioning has been associated with dysregulation of the Ras-MAPK 
cascade, with mutations more downstream resulting in more severe impairments 
than mutations in upstream components of the pathway (Cesarini et al., 2009; 
Pierpont et al., 2010a). Cardiac defects associated with NS may also influence 
cognitive functioning. The aetiology of cognitive deficits in congenital heart 
disease (CHD) is thought to be multi-factorial and includes preoperative, 
operative, and postoperative factors. The most profound intellectual and 
cognitive impairments, in particular with respect to executive functions such 
as set shifting, planning, problem solving, and calculation, have been described 
for cyanotic conditions (Daliento, Mapelli & Volpe, 2006). Nonetheless, acyanotic 
cardiac disorders, which are more common in NS, may also reduce cognitive 
performance (Mahle, 2001; Miatton, De Wolf, François, Thiery & Vingerhoets, 
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 The patient group is to be considered as a convenience sample, composed 
of consecutively referred patients with NS. Inclusion criteria for the patients 
were a confirmed clinical diagnosis of NS (scoring system Van der Burgt et al., 
1994) and an age of 16 years or older. The age of the included patients ranged 
from 16 to 61 (M=30.67, SD=13.38; 24 females). The education level ranged from 
2 (only primary school completed) to 7 (academic degree), according to the 
Dutch educational system (see Duits & Kessels, 2006).
 With respect to genetic subtypes, 22 patients had a confirmed mutation in 
the PTPN11 gene, five in SOS1, one in KRAS, and one in SHOC2. In seven 
patients, no known mutation could be found and in six patients, mutation 
analyses had not been performed or completed yet. 
 A heart defect was present in 21 out of 40 patients (in two patients, no 
information was available about cardiac condition). Twenty-one patients had a 
PVS, of whom five had PVS combined with another heart condition (minor 
septal defects). Five patients had a non-PVS heart condition only, i.e., 
hypertrophic cardiomyopathy (1), arrhythmia (1), or atrial septal defect (3). 
Eighteen patients with NS reported a history of or current need for special 
education and 35 reported a history of being bullied.
 A control group was included consisting of community-dwelling volunteers, 
who were recruited via the network of the researchers involved in the process 
of data collection. Control participants were recruited based on education 
level primarily, and subsequently matched to the group of patients with NS 
on education level, age, and sex using the patients’ group characteristics 
(supported by statistical between-group testing of these variables). Exclusion 
criteria for controls were: a diagnosis of a genetic or neurological disorder, and 
the presence of a current psychiatric disorder. Their age ranged from 18 to 56 
(M=34.19, SD=14.28; 25 females). The level of education ranged from categories 
3 to 6. No significant differences were found on age (t(82)=1.17, p=0.25, d=0.25), 
sex (U=861.0, Z=0.22, p=0.83), or education level (U=722.5, Z=1.54, p=0.12) 
between patients with NS and control participants. None of the controls 
reported a history of or current need for special education and 17 reported a 
history of being bullied. Minor cardiac insufficiencies were present in two 
controls. 
Materials
Neuropsychological testing
Neuropsychological tests were selected to assess the major cognitive domains. 
In total, 14 measures were obtained, covering five cognitive domains: 
Intelligence, Speed of Information Processing, Memory (with the subdomains 
Working Memory, Immediate Recall and Delayed Recall), Executive Function 
2006; Snookes et al., 2010). However, the only study about cardiac involvement 
in cognitive function in NS, Pierpont et al. (2009) did not find a significant 
relation between the severity of heart disease and both verbal and nonverbal 
abilities in 65 children with NS.
 Given the somatic history of most patients with NS, with frequent hospital 
visits during their childhood, higher stress levels and an increased prevalence 
of psychopathology (i.e., mood and anxiety disorders) might be expected, 
which in turn may be associated with cognitive impairments. Depressive 
symptoms are known to occur more frequently in patients with CHD, and 
increased severity of cardiac problems has been associated with more anxiety 
and fears (Green, 2004; Gupta, Mitchell, Giuffre & Crawford, 2001; Lip, Lane, 
Millane & Tayebjee, 2003). Older children and adolescents with CHD seem to 
be more vulnerable for internalising and, to a lesser extent, externalising 
behavioural problems than younger children (Karsdorp, Everaerd, Kindt & 
Mulder, 2007).  
 In children and adolescents with NS, short stature and deviant physical 
appearances may increase the risk of being bullied by peers, which, in turn, 
may result in increased levels of psychological distress. In their study of 
healthy sixth graders, Nishina, Juvonen & Witkow (2005) found frequent peer 
harassment to result in higher levels of depression, anxiety, loneliness and a 
lower self-esteem. Kumpulainen (2008) described bullying as a clear predictor 
of both concurrent and future psychiatric disorders, with heightened levels of 
anxiety in (male) bully-victims in young adulthood. 
 In summary, both genetic and somatic make-up, as well as psychosocial 
aspects may affect cognitive functioning in NS. Therefore, this study aims to 
systematically examine the cognitive profile of adults with NS, using both 
extensive neuropsychological assessment methods as well as self-report 
measures of cognitive complaints.
Materials and Methods
Participants 
In this study, 42 adult patients with NS and 42 control participants were 
included. The Department of Human Genetics of the Radboud University 
Nijmegen Medical Centre referred patients for cognitive and behavioural 
evaluation. Participation was voluntary and written informed consent was 
obtained from all participants and/or from their legal representatives. The 
study was approved by the Institutional Review Board of Vincent van Gogh 
Institute for Psychiatry in accordance with the Declaration of Helsinki.  
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Executive Function
To measure the ability to inhibit a prepotent response, an interference score 
derived from the Stroop CWT test was used. Performance on the third trial 
(naming the colour of the ink of colour names printed in incongruent colours) 
was compared with performance on the previous trials by computing a ratio 
score (the time used to complete card III divided by the average of the time 
used to complete card I and II). Furthermore, the Tower of London, a multistep 
executive task, was included to assess strategy planning and problem solving 
behaviour (Ganzevles, De Geus & Wester, 1994; Shallice, 1982). In this task a 
participant is asked to transfer beads on three pegs, according to a set of rules. 
The total score was used in this study.
Visuoconstruction
The raw score on the copy trial of the Rey CFT described earlier was used as 
an outcome measure to assess the domain of Visuoconstruction.
Assessment of subjective cognitive functioning
To gain insight into the experience of patients with NS of their own cognitive 
status, two self-report questionnaires were included. To assess perceived 
ability to plan, organise and monitor behaviour in daily life, the Dysexecutive 
Questionnaire (DEX) was administered. The DEX is a 20-item questionnaire 
containing items that address everyday executive problems that have to be 
rated on a five-point scale (Wilson, Alderman, Burgess, Emslie & Evans, 1996).
 The Symptom Checklist-90-Revised (SCL-90-R) is a self-report questionnaire 
that consists of 90 items, rated on a five-point scale (Arrindell & Ettema, 2003). 
Two indices were used. First, the total score provides an estimate of the global 
level of psychological stress of the participant. Second, the subscale Cognitive-
Performance Difficulty specifically addresses cognitive complaints. 
Statistical analyses 
For each cognitive domain, raw test scores were transformed into standardised 
Z scores based on the total group’s distribution (taking together controls and 
patients with NS; see e.g., Brands et al., 2006). Subsequently, domain scores 
were derived by calculating the mean of the standardised test scores that 
contributed to each of the cognitive domains. To examine differences between 
patients with NS and controls, domain scores were compared by General 
Linear Model (GLM) multivariate analyses of variance and standardized effect 
sizes (partial eta squared) were computed. For significant domains, subsequent 
analyses were performed on the separate subtests in the domain (Bonferroni-
corrected; effect-size: Cohen’s d). Additionally, the performance of individual 
and Visuoconstruction. Trained assessors administered the tests. The order of 
the tests was not fixed, but depended on clinical logistics and patient charac-
teristics. In most cases, testing took place on two consecutive days.
Intelligence
The Full Scale IQ of the third edition of the Wechsler Adult Intelligence Scales 
(WAIS-III) and the estimated IQ of the Dutch version of the National Adult 
Reading Test (NART) were used as measures of intelligence (Schmand, 
Lindeboom & Van Harskamp, 1992; Wechsler, 2005).
Speed of Information Processing
To test information processing speed, three tasks were included. The raw score 
on the WAIS-III subtest Digit Symbol Coding (DSC) served as an index of 
motor and mental speed. During this test, the subject is asked to pair numbers 
and symbols in accordance with presented examples. In addition, the raw 
score of the WAIS-III subtest Symbol Search (SS) was included, a task in which 
target symbols have to be detected in a stimulus set as quickly as possible. 
Both DSC and SS have to be performed under time pressure, and the combined 
scores of these tests constitute the Processing Speed Index of the WAIS-III 
(Wechsler, 1997). Furthermore, two of three parts of the Stroop Color Word 
Test (CWT) were used to measure mental speed. To this end, the average time 
used to complete part I (quickly reading of colour names) and part II (quickly 
naming of colours) was computed (Stroop, 1935).
Memory
Memory was divided into three subdomains: Working Memory, Immediate 
Recall, and Delayed Recall. To assess Working Memory, Digit Span and 
Letter-Number Sequencing (LNS) of the WAIS-III were administered. In Digit 
Span, series of numbers of increasing length have to be repeated in forward 
and backward order. In LNS a string of combined letters and numbers has to 
be repeated, while placing them in numerical and alphabetical order. Episodic 
memory was measured by the immediate and delayed recall conditions of 
both the Rey Auditory Verbal Learning Test (RAVLT) (Rey, 1941; Van der Elst, 
Van Boxtel, Van Breukelen & Jolles, 2005) and the Rey-Osterrieth Complex 
Figure Test (Rey CFT) for visual memory (Rey, 1964). In the RAVLT, the 
participant is asked to repeat a word list, presented in five trials. Subsequently, 
the information has to be recalled after 15 minutes. In the Rey CFT, the 
participant is asked to copy a complex geometrical figure, followed by an 
immediate recall condition and a delayed recall trial after 10 minutes. 
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 Patients with NS reported significantly more subjective executive problems 
on the DEX (NS: M=26.5, SD=14.0; control: M=20.5, SD=9.6; t(70.6)=2.25, p=0.028, 
d=0.50). They also reported significantly higher levels of complaints on the 
subscale Cognitive-Performance Difficulty of the SCL-90-R (NS: M=18.4, 
SD=7.4; control: M=15.0, SD=4.6; t(66.9)=2.52, p=0.014, d=0.55). No significant 
difference was found between the group with NS and controls on the SCL-90-R 
Total Score (NS: M=146.1, SD=41.8; control: M=132.6, SD=34.2; t(77.0)=1.60, 
d=0.35). Correlations between DEX or Cognitive-Performance Difficulty 
SCL-90-R and the domain score Speed of Information Processing were not 
statistically significant (r=-0.14 and r=-0.16, respectively).
patients and controls was compared with available normative data (age and/or 
education corrected), expressed in standardized Z scores (normative mean=0, 
SD=1). Subsequently, individuals were classified as impaired on a specific subtest 
if their performance was more than 1.5 Z score below the normative mean 
(Lezak et al. 2004). Nonparametric Mann-Whitney U tests were performed to 
compare the frequency of impaired participants in both groups. Furthermore, 
the levels of cognitive complaints of the two groups were compared with 
independent t-tests. Finally, Pearson’s correlations were computed between 
the score on the DEX and the domain score Speed of Information Processing, 
and between Cognitive Performance Difficulty SCL-90-R and Speed of Information 
Processing.  
Results
Table 2 presents the mean raw scores, the cognitive domain scores, as well as 
the normative Z scores of the two groups. One patient was not able to complete 
the SCL-90-R; she was admitted to a psychiatric hospital elsewhere towards 
the end of the assessment and was not able to finalize all the questionnaires. 
Finally, one control did not complete the SCL-90-R and the DEX was not 
administered in two controls, due to time restrictions. 
 GLM multivariate analyses of variance showed an overall worse performance 
in the patient group (F(7,76)=2.49, p=0.023, ηp2=0.19). A significant difference 
was found in two domains, Speed of Information Processing (F(1,82)=5.15, 
p=0.026, ηp2=0.059) and Delayed Recall (F(1,82)=4.80, p=0.031, ηp2=0.055). No 
significant group differences were found for the domains Intelligence (F(1,82)= 
0.120, ηp2=0.001), Working Memory (F(1,82)=0.051, ηp2=0.001), Immediate Recall 
(F(1,82)=3.19, ηp2=0.037), Executive Function  (F(1,82)=1.31, ηp2=0.016) or Visuo-
construction (F(1,82)=1.21, ηp2=0.015) (see also Figure 1).
 For the significant domains Speed of Information processing and Delayed 
Recall, separate between-group comparisons on the individual neuropsycho-
logical measures were performed (independent t-tests; Bonferroni-corrected). 
Regarding Speed of Information Processing, a significantly worse performance 
of the patient group compared with controls was found on the Stroop CWT 
(t(82)=2.81, p=0.006, Cohen’s d=0.61), but not on WAIS-III Digit Symbol Coding 
(t(71.65)=1.32, d=0.29) or WAIS-III Symbol Search (t(82)=1.74, d=0.38). With 
respect to Delayed Recall, post-hoc analyses did not reveal any significant 
differences on the two subtests in the domain (Rey CFT-Delayed Recall 
(t(78.10)=1.80, d=0.40; RAVLT-Delayed Recall (t(82)=2.06, d=0.45). 
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Figure 1   Performance on the different cognitive domains for patients with 
Noonan syndrome and Controls
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Table 2   Cognitive domain scores, mean raw test scores, normative  
Z scores and % impaired for patients with Noonan syndrome (NS)  
and controls
Cognitive domain and tests Patients with NS Controls
Mean 
domain/ 
raw score
SD  
domain/ 
raw score
Mean 
normative	 
Z scorea
n	(%)	 
impaired  
(i.e., Z<1.5)
Mean 
domain/ 
raw score
SD  
domain/ 
raw score
Mean 
normative	 
Z scorea
n	(%)	
impaired  
(i.e., Z<1.5)
Intelligence 0.02 1.11 -0.65 9 (21%)* -0.05 0.64 -0.70 2 (5%)
  WAIS-III FSIQ 92.19 14.65 -0.52 9	(21%) 91.14 8.65 -0.59 4	(10%)
  NART-IQ 88.36 13.80 -0.78 9	(21%) 88.40 8.22 -0.77 3	(8%)
Speed of Information Processing -0.21* 1.01 -0.66 5 (12%) 0.21 0.64 -0.21 1 (2%)
  WAIS-III Digit Symbol Coding 66.12 17.37 -0.46 7	(17%)* 70.38 11.64 0.08 1	(2%)
  WAIS-III Symbol Search 30.71 9.96 -0.59 10	(24%)* 34.19 8.30 -0.28 2	(5%)
  Stroop I, II 58.37** 12.46 -0.93 8	(19%) 52.02 7.70 -0.44 3	(7%)
Working Memory 0.00 1.06 -0.33 3 (7%) -0.04 0.76 -0.38 2 (5%)
		WAIS-III	Letter	Number	Sequencing 10.20 3.10 -0.11 3	(8%) 9.12 2.18 -0.46 6	(14%)
  WAIS-III Digit Span 13.55 3.44 -0.48 9	(21%) 14.29 3.04 -0.29 3	(7%)
Immediate Recall 0.14 0.91 -0.26 5 (12%) -0.17 0.69 -0.57 5 (12%)
  RAVLT – Immediate Recall 50.05 10.38 -0.02 4	(10%) 44.74 10.31 -0.65 10	(24%)
  Rey CFT - Immediate Recall 19.54 7.60 -0.45 9	(22%) 18.31 5.81 -0.49 9	(21%)
Delayed Recall 0.18* 0.85 -0.11 5 (12%) -0.21 0.77 -0.51 8 (19%)
  RAVLT - Delayed Recall 10.69 2.97 -0.11 6	(14%) 9.31 3.17 -0.59 9	(21%)
  Rey CFT - Delayed Recall 20.42 7.34 -0.06 10	(24%) 17.73 6.20 -0.43 9	(21%)
Executive functioning 0.10 0.91 0.01 1 (2%) -0.10 0.60 0.30 1 (2%)
  Tower of London 27.83 4.20 - - 25.71 3.06 - -
  Stroop Interference 1.78 0.36 0.01 1	(2%) 1.72 0.24 0.30 1	(2%)
Visuoconstruction 0.12 1.10 -0.73 12 (29%) -0.12 0.88 -0.90 14 (33%)
  Rey CFT – Copy 30.39 5.37 -0.73 12	(29%) 29.23 4.30 -0.90 14	(33%)
Notes. Negative	values	indicate	worse	performance.	
*	p<0.05,	**	p<0.01 
WAIS-III	=	Wechsler	Adult	Intelligence	Scale	–	Third	Edition;	NART	=	National	Adult	Reading	Test;	RAVLT	
=	Rey	Auditory	Verbal	Learning	Test;	Rey	CFT	=	Rey-Osterrieth	Complex	Figure	Test.	FSIQ	=	Full	Scale	IQ;	
Stroop I, II = mean part I and part II of the Stroop Color Word Test. 
a	Normative	data	for	WAIS-III	(n=588)	from	Wechsler	(2005),	NART	(n=601)	from	Bouma	et	al.	(2012),	
RAVLT (n=1680)	from	Van	der	Elst	et	al.	(2005),	Rey	CFT	(n=117)	from	Gallagher	&	Burke	(2007),	Stroop	
Color Word Test (n=585)	from	Schmand	et	al.	(2003),	and	Tower	of	London	(no	normative	data	for	this	
version	available).
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and the hypothesis of energetic limitations as a cause of speed problems is still 
highly speculative.
 Apart from speed of information processing, the patients with NS did not 
perform worse than controls on any of the other cognitive domains, in contrast 
to previous studies in children. For example, mild decrements in working 
memory and learning have been reported in children with NS (Horiguchi & 
Takeshita, 2003; Troyer & Joschko, 1997; Van der Burgt et al., 1999). Although 
measures of episodic memory function are usually thought to be intact in 
these children, Alfieri et al. (2011b) recently showed reduced verbal recall 
memory performance and normal recognition in a group of children with NS 
or LEOPARD syndrome. In the adults examined in this study, no differences 
were found between patients with NS and controls with respect to working 
memory or immediate recall on episodic memory tasks. The performance on 
the subdomain delayed recall was even slightly better in the patients with NS 
than in controls, although subsequent analyses did not show any subgroup 
differences on the individual subtests in this domain. These findings regarding 
memory functions seem to be in contrast with those of Alfieri and colleagues 
(2011b), and with animal studies that have shown recall problems in relation to 
activations in the Ras-MAPK cascade (Sweatt, 2001; Sweatt, 2004). 
 Van der Burgt et al. (1999) reported weaknesses in planning and organisation 
abilities in children with NS, using an extensive intelligence battery. Again, 
these results could not be corroborated in our adult sample, as our patients 
with NS performed at control level on measures of working memory or 
executive function (planning and response inhibition). Interestingly, although 
no differences were found in the performance on executive tests, patients 
reported more subjective executive problems than controls on questionnaires. 
It could be argued that these complaints are associated with executive 
impairments that were not addressed by the current tests, such as a deficit in 
concept shifting. However, as our aim was to investigate all major cognitive 
domains, we could not examine every aspect in detail because of time limitations. 
Furthermore, in a previous study from our group in a smaller sample of 
patients with NS (n=33) that included the Wisconsin Card Sorting Test, a 
widely used concept shifting task, no deficits were found compared with 
normative data (Wingbermühle et al., 2009).  Maybe, the mental slowness we 
found underlies the experience of executive problems in daily life. Also, it has 
been shown that subjective estimates of people’s own cognitive status are 
often incongruent with objective measures (e.g., Goverover et al., 2005; Koerts 
et al., 2012). 
 Finally, no differences were found between patients and controls on a test 
for visuoconstructive ability. In children with NS, research with cognitive-
Discussion
This is the first study to examine the performance of adults with NS on all 
major cognitive domains, compared with that of matched controls. Patients 
with NS showed a significantly worse performance in the domain Speed of 
Information Processing. No between-group differences were found on any of 
the other cognitive domains, except for a slightly better performance of 
patients with NS on the subdomain Delayed Recall. The level of complaints 
concerning their own cognitive capacities was significantly higher in the 
patients compared with controls. Patients with NS experienced more cognitive 
problems in their daily lives than controls, although the overall level of distress 
did not differ between the two groups. Also, no relation was found between 
the performance on measures of speed of information processing and the level 
of subjective complaints of distress. Concerning the background variables, 
slightly lowered intelligence levels were found in the adults with NS as 
compared with the average population, which is consistent with results of the 
majority of previous studies.  Moreover, a higher need for special education 
was noted in our sample (43% of the patients with NS versus 0% of the controls), 
which has been reported by others as well (Shaw et al., 2007; Van der Burgt et 
al., 1999; Wood et al., 1995). 
 Patients showed a lower speed of information processing than the control 
group. This finding was mainly driven by a highly significant and medium to 
large sized difference in performance on the Stroop CWT (reading and naming 
speed on part I and part II), a task that does not require psychomotor responses. 
Moreover, a significantly higher proportion of patients than controls 
demonstrated impairments on the other two subtests for processing speed, 
WAIS-III-DSC and WAIS-III-SS, compared with the normative mean. 
Occasionally, lowered scores have been reported on time-limited tests in 
children with NS (Horiguchi & Takeshita, 2003; Troyer & Joschko, 1997; Van 
der Burgt et al., 1999), which have typically been interpreted as manifestations 
of attentional impairments. Notably, a lack of selective or sustained attention 
has been observed in children with NS, mainly by their parents (Lee et al., 
2005; Sarimski, 2000; Wood et al., 1995). Our adult group did not demonstrate 
deficits in selective attention as part of cognitive control (response inhibition 
as measured with the Stroop CWT interference score), and observation during 
testing did not show any signs of inattention. Possibly, the mental slowness 
may be associated with metabolism, in particular with the energetic limitations 
due to mitochondrial dysfunction that is reported to be manifest in syndromes 
of the Ras-MAPK pathway, including NS (Kleefstra et al., 2011). So far, however, 
the exact pathophysiological mechanisms for this association remain unclear, 
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experimental paradigms has suggested visuomotor difficulties to be present 
(Horiguchi & Takeshita, 2003; Lee et al., 2005; Troyer & Joschko, 1997). 
Specifically, within the perceptual domain, the study of Alfieri et al. (2011a) 
demonstrated impairments in form coherence in children with NS of varying 
age.  It could be speculated that visuoconstruction is only compromised in NS 
during childhood, but no longer in adulthood. However, Alfieri used cognitive 
paradigms that are not applicable in clinical practice yet and their findings 
should be replicated with a dedicated multi-method assessment to objectify 
cognitive functioning of adults with NS in the domain of visuoconstruction.
 In addition to the previously suggested, speculative energetic limitations, 
there are alternative explanations for the underlying deficit in information 
processing speed. For instance, heart defects may result in an increased risk 
for circulatory problems, with cognitive slowness as a result. In NS, however, 
the associated heart defects are usually fairly mild and, unless complications 
occur, largely asymptomatic. In line with this, Pierpont et al. (2009) did not 
find severity of heart defects to be associated with mental capacities in children 
with NS. Another, indirect, explanation for the speed problems may be in an 
effect of being bullied on cognition. The high rates of a bullying history in 
patients with NS can lead to anxiety, which may moderate cognitive 
development. However, recent research comparing the same patients and 
controls as examined in the current study, did not show any differences in 
general levels of ‘anxiety’ (SCL-90-R subscale), although levels of social distress 
were significantly higher in the patients with NS (Wingbermühle et al., 2012).
 Comparison of the performances of our groups with normative means 
shows a large number of impaired performances in various domains. It should 
be noted, however, that this is the case for both patients and controls, which is 
related to the fact that norms do not always adjust for schooling effects (Lezak 
et al., 2004).  This emphasizes the need for the inclusion of specific control 
groups matched with respect to age and education level, to prevent over-
estimation of cognitive deficits in patients with lower intellectual ability.
 Strengths of our study are the extensiveness of the neuropsychological 
assessments, evaluating all relevant cognitive domains, as well as the inclusion 
of a carefully matched control group. While a larger sample size would 
possibly have allowed for even more detailed subgroup analyses, it should be 
noted that neurobehavioural studies in NS are typically performed in smaller 
samples (see Table 1). Also, inspection of the effect sizes of the non-significant 
findings indicate that our study had sufficient statistical power resulting in 
reliable (non)results. Besides replication studies, preferably including more 
cognitive domains such as language and perception, future studies should in 
particular focus on the aetiological mechanisms of the mental slowness in 
adults with NS, which may be related to factors such as genetic influences on 
brain development (e.g., neuroimaging of cortical thickness and white-matter 
integrity) or somatic aspects (for example heart disease). As our sample 
consisted of patients with varying IQ levels from below average to higher 
ability, it would be interesting to stratify patients with NS on IQ level in future, 
larger studies. Moreover, there is a need for longitudinal studies to evaluate 
developmental change across the lifespan in NS.  Systematically comparing 
specific patients groups with different NS mutation types is also recommended. 
Finally, future control groups should also include patients with other genetic 
disorders, preferably with Noonan-like genotypes and phenotypes (e.g. cardi-
ofaciocutaneous syndrome, Turner syndrome), as well as young adults with a 
history of heart disease.
 In conclusion, cognitive functioning in adults with NS is characterized by 
impaired speed of information processing, but not in any of the other cognitive 
domains, taking age and education level into account. Despite the relatively 
intact cognitive profile in adults with NS, patients frequently report cognitive 
complaints, indicating that neurocognitive and psychological assessment is 
important in clinical management of patients with NS. The extent and profile 
of cognitive impairment in adults with NS seems to be different from that of 
children with NS, who appear to have more generalized cognitive deficits. 
This may point towards a developmental delay rather than impairments that 
remain present during the lifespan. 
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Summary and discussion
The aim of this thesis was to investigate cognitive functioning in adults with 
Noonan syndrome (NS), focusing not only on traditional neuropsychological 
domains of functioning, but also on affective processing and social cognition. 
In this last chapter, the main findings of the previous chapters will be 
summarised and reflected upon. Also, strengths and limitations will be 
discussed. Finally, suggestions for future research and recommendations for 
clinical practice will be provided. 
Main findings
The literature on the neuropsychological profile in NS was reviewed in chapter 2. 
Research in this area proved to be limited. Previous studies have shortcomings 
with respect to study design and sample size (case studies or small groups, 
mostly without comparison subjects), age range (focusing mainly on children 
and adolescents with NS), and assessment methods (parental interviews and 
questionnaires). Notwithstanding these limitations, general findings on 
cognition and behaviour in NS suggested on average a mildly lowered 
intelligence level, a developmental delay in language and motor functions, 
deficits in selective and sustained attention, suboptimal planning and 
organisational skills as well as impairments in social competence and in the 
experience and communication of emotions. These cognitive impairments 
might explain the anecdotally reported ‘learning problems’ and the high 
percentage of patients with NS that attend special education. The above 
findings, indicating multiple cognitive deficits in the NS profile in childhood 
and adolescence, prompted questions about the neurocognitive profile of 
adults with NS. 
 With respect to the underlying mechanisms of the cognitive problems in 
NS, abnormal development of the central nervous system may be assumed, but 
structural brain abnormalities have not been investigated in NS in much detail. 
As described in chapter 2, the experience and communication of emotions 
seems to be a problem of patients with NS. The concurrent presence of problems 
in experiencing and communicating one’s own emotions is typically described 
by the alexithymia construct. Although not studied in patients with NS yet, 
there is a growing amount of research on the neural correlates of alexithymia. 
These were reviewed and discussed in chapter 3, with the purpose to gain 
more insight into this construct and its aetiology. Abundant evidence for 
reduced general activity in the right hemisphere is present in (male) alexithymic 
individuals. Furthermore, lesions in the corpus callosum were associated with 
inter-hemispheric communication, which supposedly results in disconnection 
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processing, memory, executive functioning and visuoconstruction; chapter 6), 
and affective information processing, including measures of social interaction 
and psychological well-being (chapter 5). For the first time, cognitive functioning 
of adults with NS was characterised and compared with that of a control 
group, carefully matched on age, sex, and education level. In short, results 
demonstrated between-group differences in the speed of information processing 
and in affective information processing. Significantly higher levels of alexithymia 
and social discomfort were found in patients with NS versus controls, whereas 
emotion recognition was only slightly worse in the patient group. Patients with 
NS did not perform worse in any of the other cognitive domains and general 
levels of psychological complaints did not differ between the groups. However, 
patients with NS reported more cognitive complaints on questionnaires. 
Contrary to expectation, these cognitive complaints and the established so-
cial-emotional problems were not likely to be associated with dysexecutive 
symptoms, since patients and controls did not differ in their performance on 
executive tests. It was concluded that alexithymia and psychosocial distress in 
NS are probably manifestations of a complex interaction between genetic, 
neurocognitive, and psychosocial influences. Frequent medical interventions 
and experiences of having been bullied are part of the childhood of many 
patients with NS. This may result in a different development of emotion 
regulation and coping strategies. With respect to mental slowness, energetic 
limitations due to an altered metabolism may potentially be involved (Kleefstra 
et al., 2011). Alternatively, the frequently present heart defects in NS can be 
hypothesised to be of influence on cognitive performance. 
 In sum, from the combined analysis of the present findings and those of 
previous studies concerning neurobehavioural aspects of NS it can be concluded 
that 1) diffuse cognitive problems seem to be present in childhood; 2) a lowered 
speed of information processing is found in adult patients with NS compared 
with controls matched on age, sex and education level; 3) social problems are 
repeatedly observed in childhood; in adulthood, the expression of one’s own 
emotions is limited and social interaction is associated with higher stress 
levels.
Strengths and limitations
This is the first comprehensive study of cognition and emotion in NS, focussing 
on the abilities of adults, while previous research has mainly been limited to 
the study of children and adolescents. A major strength of the present research 
is the inclusion of a control group matched on age, sex, and education level. 
Since available normative data are often of mixed quality, especially within 
the Dutch-language domain, these do not always provide adequate adjustments 
of emotional experiences and their ‘cognitive’ counterpart (i.e., verbalising, 
analysing). In relation to activation of the anterior cingulate cortex, impairments 
have been described in emotion induction, emotion recognition, and in 
emotion regulation, the latter in the sense of diminished adaptive control. 
Finally, functioning of the (left) anterior insular cortex, involved in the 
integration of body signals and conscious representations of feelings, was 
described in relation to alexithymia. Lesions in the insular cortex can result in 
the combined presence of alexithymia and other impairments in empathising. 
From this description of involvement of neural structures, it was concluded 
that alexithymia is diffusely represented in the brain. The adoption of a 
developmental, neuropsychological perspective was advocated, in order to 
enhance the understanding of alexithymia.
 Main impetus for the current empirical research was given by a pilot study 
of psychological and psychiatric aspects in a first series of 10 adult patients 
with a confirmed diagnosis of Noonan syndrome (chapter 4). Its aim was to 
explore cognitive qualities, including some measures for affective information 
processing and psychopathology, in order to test the validity of the hypothesis 
that adults with NS may be characterised by problems in verbalising emotions 
and a heightened risk for anxiety disorders. This notion was based on an 
earlier single-case description of a deficit in the comprehension and expression 
of emotions in a young adult with NS and a comorbid anxiety disorder 
(Verhoeven et al., 2004), as well as on careful review of studies on the NS 
phenotype and the literature on alexithymia. The results were compared with 
normative data, using established clinical cut-off scores. In this sample, a 
broad range of full-scale WAIS-III-IQs was demonstrated, with a low-average 
mean. Additionally, patients reported more alexithymic traits. Furthermore, 
performance on an emotion recognition task was of low-average quality. 
Cognitive aspects of alexithymia were particularly impaired in these patients, 
notably inadequate verbalisation of self-experienced emotions. With respect to 
psychopathology, mild signs of depression and anxiety were reported. Only in 
one patient a DSM-IV classification was established, but self-report of quality 
of life was judged to be satisfactory. Finally, the assessors observed a socially 
desirable attitude. 
 Based on these pilot data, it was concluded that deficiencies in emotion 
recognition and expression might indeed characterise the neurobehavioural 
profile of adult patients with NS, confirming the need for further controlled 
empirical study in a larger group. 
 Chapters 5 and 6 describe the case-control studies on cognitive functioning 
in a group of adults with NS. Extensive assessment was performed, covering 
both the traditional neuropsychological domains (i.e., speed of information 
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abilities. Future studies in larger samples should systematically include additional 
somatic and psychosocial variables to analyse to what extent and how they 
account for variation in cognitive abilities. Since the majority of patients with 
NS have been bullied in youth, particularly severity and duration of bullying 
history would be of interest. The effects of a bullying history on cognitive 
development in general are, however, largely unexplored to date. 
 The studies presented here were evidently cross-sectional in nature. 
Future studies should preferably use a developmental and longitudinal design. 
Although to date none of the studies in which a full neuropsychological 
assessment was performed in children with NS has included a control group, 
findings suggest a developmental delay with respect to cognitive functions. In 
the studies of this thesis, patients ‘only’ demonstrated lowered speed of 
information processing and more problems in emotion expression than 
controls. Further larger studies are needed to study developmental change 
across the entire lifespan in NS. 
 The systematic study of affective information processing (chapter 5), that 
corroborated anecdotal evidence on social-emotional problems in NS, was 
novel. Alexithymic traits were significantly more present in adults with NS 
than in controls. Although heuristically useful, the alexithymia construct is 
complex and under debate. The concept of affectivity in general has historically 
played a subordinate role in the description of mental illness, and refinement 
in the semiology of affective experiences has not been reached (Berrios, 1985). 
In line with this, alexithymia, being a clinical construct derived from 
phenomenology, is not an established, unambiguous entity and it may be 
determined by genetic, neurophysiological, developmental and sociocultural 
factors (Lesser, 1981). In the widely used definition of alexithymia, the construct 
comprises five different aspects (diminished capacity to experience emotions, 
problems in verbalising emotions, inability to fantasise, problems in analysing 
one’s own emotions, and identifying emotions; Taylor, Ryan & Bagby, 1985). It 
may be instructive to focus research on each of these separate aspects or 
symptoms. Regarding social-emotional problems in Noonan syndrome, 
difficulty in verbalising emotions seems to be the most problematic aspect. As 
the patients in the present studies also demonstrated higher levels of social 
distress, alexithymia in this group might reflect a tendency toward introversion 
and shyness rather than an absolute inability to communicate emotions. This 
interpretation underlines earlier considerations regarding (trait) alexithymia 
as a coping strategy (Swart et al., 2009). The fact that the patients with NS did 
not have profound impairments in the perception of emotional facial 
expressions, which have been suggested to co-occur with alexithymia (see e.g., 
McDonald, Rosenfeld, Henry, Togher, Tate & Bornhofen, 2011), supports this 
for these factors. Hence, a matched control group is required as a comparison 
standard to validly interpret the performance of the patient groups. 
 With regard to patient selection the present studies relied on convenience 
samples, as it is difficult to recruit large groups of patients with this specific 
syndrome. There were various reasons for referral to the clinic, but most 
patients with NS revealed some degree of personal complaint during the 
assessment, or proxies reported a problem they had observed in the patient. 
This sample may therefore represent a cohort of patients with NS with higher 
frequencies of complaints or impairments. Future large-scale genetic cohort 
studies should replicate the results of this thesis in a representative sample of 
patients with NS.   
 Considering the genetic heterogeneity of NS, with over 10 different 
causative mutations in the Ras-MAPK pathway, it would be interesting to 
systematically compare the associated cognitive profiles. Since it has been 
demonstrated that mutations more downstream the Ras-MAPK signalling 
cascade (e.g. BRAF, MEK) induce more severe impairments in intelligence and 
adaptive behaviour than upstream mutations (e.g. PTPN11, SOS1) (Cesarini et 
al., 2009; Pierpont et al., 2009; Pierpont et al., 2010a), differences in other 
cognitive abilities could be expected as well. Concerning the present findings, 
it would for example be interesting to investigate whether mental slowness is 
a general weakness in NS across mutation types, and whether it is impaired 
relatively more profound in those patients with downstream mutations and 
lower IQs than in those with a mutated gene higher in the pathway and with 
normal or nearly normal intelligence. The NS sample presented in chapter 6 
constitutes the largest one to date in which extensive neuropsychological 
assessment has been performed (n=42). However, due to the composition of 
this sample, in which few patients with less frequent genetic mutations were 
available, subgroup analyses according to genotype were statistically not 
warranted. To investigate the specificity of the present findings, it is 
recommended that future studies not only aim to include more patients with 
NS, they should also include control groups consisting of patients with other 
genetic disorders, preferably Noonan-like genotypes and phenotypes (e.g., 
Turner syndrome, Neurofibromatosis type 1). 
 Apart from the mutation-specific profile, somatic characteristics accompanying 
NS may affect cognitive functioning because of differences in physical dispositions 
(e.g., heart defects) or through associated psychosocial differences (e.g., impact 
of frequent hospital visits and medical treatments early in life). Up to now, 
only one study included somatic and environmental predictors in their studies 
of intelligence in children and adolescents with NS (Pierpont et al., 2009). Here, 
no association was found between severity of cardiac disease and intellectual 
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 While research and care concerning NS has predominantly focused on 
somatic factors, the studies reported in this thesis indicate that neuropsycho-
logical aspects should be taken into account as well. In the diagnostic 
examination of patients with NS, both in individuals and on a group level, the 
domains speed of information processing and social cognition should be 
investigated in greater detail. Neuropsychological assessment may also contribute 
to the tailoring of education and, if necessary, intervention programs. In case 
of inconvenience due to social-emotional problems and anxiety, a modern 
cognitive behavioural approach like Acceptance and Commitment Therapy 
(ACT; Hayes, Luoma, Bond, Masuda & Lillis, 2006) may be considered, although 
no specific effect studies have been performed with this therapy in patients 
with NS yet. Finally, environmental demands should preferably be brought 
into accordance with personal speed.
idea. Therefore, the inclusion of instruments to identify personality traits and 
analyse symptoms of anxiety is recommended for future research in order to 
further elucidate the social-emotional problems in NS.
 In the assessment of alexithymia, self-report methods are used most 
frequently, but these have been criticised as well. Since the quality of the 
evaluation of one’s own emotions is the subject of interest, responses of people 
with alexithymic traits on self-report questionnaires may be biased (e.g., Lane, 
Ahern, Schwartz & Kaszniak, 1997). Although there are indications that 
correlations between self-report and observer-based evaluations are satisfactory, 
a multi-method assessment approach should be preferred (Taylor, Bagby & 
Luminet, 2000). 
 Finally, regarding future research, biomarkers (e.g., structural or functional 
MRI) could provide complementary information on the origins of mental 
slowness and alexithymic symptoms in NS, for example by relating performance 
on cognitive tests to measures of cortical thickness and white-matter volume.
Conclusion and clinical recommendations 
In this dissertation, literature on the neuropsychological profile of patients 
with Noonan syndrome was reviewed, followed-up by empirical research on 
neurobehavioural aspects of the syndrome in adults. Detailed study of the 
literature in which the neural correlates of the alexithymia construct were 
explored resulted in the conclusion that alexithymia can be associated with 
diffuse representations in the brain, and that a neuropsychological perspective 
may enhance the understanding of this complex concept. Regarding the extent 
and contents of neuropsychological assessment in NS, the research presented 
in this thesis is the most comprehensive to date. For the first time, extensive 
assessment comprising all cognitive domains has been performed in a group 
of patients with NS and results were compared with those of matched controls. 
Except for a lowered speed of information processing and higher levels of 
alexithymia, cognitive performance of the patient group was at the same level 
as that of controls. 
 In 2010, clinical guidelines for the management of Noonan syndrome have 
been published. These guidelines were developed by a European network of 
centres of expertise for dysmorphology (Dyscerne), with the aim to improve 
diagnostic standards and to provide clinical recommendations for people with 
NS and their healthcare specialists. Recommendations are based on systematic 
review of evidence and on expert consensus. They are described per organ 
system for four age groups. Although the guideline is mainly focused on the 
management of somatic symptoms, some important neuropsychological and 
behavioural considerations have been included as well (see Appendix). 
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pt
ed
 t
o 
su
it
 r
ar
e 
co
nd
it
io
ns
 w
he
re
 t
he
 e
vi
de
nc
e 
ba
se
 is
 l
im
it
ed
, 
an
d 
w
he
re
 e
xp
er
t 
co
ns
en
su
s
pl
ay
s 
a 
gr
ea
te
r 
ro
le
. 
Th
e 
m
em
be
rs
 o
f 
th
e 
gu
id
el
in
e 
de
ve
lo
pm
en
t 
gr
ou
p 
ar
e 
lis
te
d 
on
 p
ag
e 
30
. 
W
ha
t 
ar
e 
th
e 
ai
m
s 
of
 t
he
 g
ui
de
lin
es
? 
Th
e 
gu
id
el
in
es
 a
im
 t
o 
pr
ov
id
e 
cl
ea
r 
an
d 
w
he
re
ve
r 
po
ss
ib
le
, 
ev
id
en
ce
-b
as
ed
 r
ec
om
m
en
da
ti
on
s 
fo
r 
th
e 
m
an
ag
em
en
t 
of
 p
at
ie
nt
s 
w
it
h 
N
oo
na
n 
sy
nd
ro
m
e.
  
 
W
ho
 a
re
 t
he
y 
ai
m
ed
 a
t?
 
Th
es
e 
gu
id
el
in
es
 a
re
 p
ro
vi
de
d 
fo
r 
pe
op
le
 w
it
h 
N
S 
to
 u
se
 w
it
h 
th
ei
r 
pr
im
ar
y 
ca
re
 a
nd
 s
pe
ci
al
is
t 
cl
in
ic
ia
ns
 a
s 
m
an
y 
he
al
th
ca
re
 p
ro
fe
ss
io
na
ls
 
w
ill
 n
ot
 h
av
e 
ha
d 
pe
rs
on
al
 e
xp
er
ie
nc
e 
of
 m
an
ag
in
g 
N
oo
na
n 
sy
nd
ro
m
e.
 A
s 
it
 is
 a
 m
ul
ti
sy
st
em
 d
is
or
de
r,
 p
eo
pl
e 
w
it
h 
N
S 
m
ay
 r
eq
ui
re
 v
ar
io
us
 
te
st
s,
 s
cr
ee
ni
ng
, 
as
se
ss
m
en
ts
, 
re
fe
rr
al
s 
an
d 
m
ul
ti
di
sc
ip
lin
ar
y 
in
te
rv
en
ti
on
s 
at
 d
if
fe
re
nt
 s
ta
ge
s 
of
 t
he
ir
 li
ve
s.
 T
he
se
 g
ui
de
lin
es
 la
y 
ou
t 
th
es
e 
re
qu
ir
em
en
ts
 in
 a
 c
le
ar
 f
or
m
at
 t
ha
t 
is
 a
cc
es
si
bl
e 
to
 a
ny
bo
dy
 w
ho
 is
 in
vo
lv
ed
 in
 t
he
 c
ar
e 
of
 a
n 
in
di
vi
du
al
 w
it
h 
N
S.
   
H
ow
 a
re
 t
he
y 
or
ga
ni
se
d?
 
Th
e 
gu
id
el
in
es
 a
re
 d
iv
id
ed
 in
to
 r
ec
om
m
en
da
ti
on
s 
fo
r 
fo
ur
 a
ge
 g
ro
up
s:
 
Pa
ge
 4
 c
on
ta
in
s 
an
 o
ve
rv
ie
w
 o
f 
th
e 
di
ag
no
st
ic
 c
ri
te
ri
a 
an
d 
cl
in
ic
al
 f
ea
tu
re
s 
of
 N
S,
 a
nd
 p
ag
e 
5 
lis
ts
 t
he
 s
ug
ge
st
ed
 b
as
el
in
e 
in
ve
st
ig
at
io
ns
.
Su
bs
eq
ue
nt
ly
, 
th
e 
gu
id
el
in
es
 a
re
 o
rg
an
is
ed
 in
to
 s
pe
ci
fi
c 
ag
e 
gr
ou
ps
. 
 F
or
 e
ac
h 
gr
ou
p,
 m
an
ag
em
en
t 
is
su
es
 a
lo
ng
 w
it
h 
an
y 
re
co
m
m
en
de
d
te
st
s/
sc
re
en
in
gs
 a
re
 li
st
ed
, 
an
d 
fo
llo
w
-u
p 
op
ti
on
s 
de
pe
nd
in
g 
on
 t
he
 o
ut
co
m
e 
of
 t
he
 t
es
t 
or
 s
cr
ee
ni
ng
 a
re
 in
di
ca
te
d.
N
B.
 A
BN
L=
 A
bn
or
m
al
 
A 
fu
ll 
lis
t 
of
 r
ef
er
en
ce
s 
st
ar
ts
 o
n 
pa
ge
 1
9,
 o
rg
an
is
ed
 b
y 
bo
dy
 s
ys
te
m
, 
w
hi
ch
 c
an
 b
e 
us
ed
 a
s 
a 
si
gn
po
st
 t
o 
fu
rt
he
r 
in
fo
rm
at
io
n 
on
 s
pe
ci
fi
c 
 
as
pe
ct
s 
of
 N
S 
fo
r 
he
al
th
ca
re
 p
ro
fe
ss
io
na
ls
. 
Ad
di
ti
on
al
ly
, 
th
er
e 
is
 a
 l
is
t 
of
 u
se
fu
l c
on
ta
ct
s 
fo
r 
pa
re
nt
s 
an
d 
fa
m
ili
es
 a
ff
ec
te
d 
by
 N
S,
 o
n 
pa
ge
 2
9.
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Ba
se
lin
e 
in
ve
st
ig
at
io
ns
 
• 
Fu
ll 
ca
rd
ia
c 
ev
al
ua
ti
on
 a
t 
di
ag
no
si
s.
 
• 
M
on
it
or
 a
nd
 p
lo
t 
gr
ow
th
 o
n 
ap
pr
op
ri
at
e 
N
S 
an
d 
ag
e-
ba
se
d 
gr
ow
th
 
ch
ar
t.
• 
Re
fe
r 
pa
ti
en
t 
in
 s
ec
on
d 
ha
lf
 o
f 
fi
rs
t 
ye
ar
 o
r 
at
 d
ia
gn
os
is
 f
or
 f
or
m
al
 
de
ve
lo
pm
en
ta
l a
ss
es
sm
en
t.
 
• 
Ba
se
lin
e 
ne
ur
op
sy
ch
ol
og
ic
al
 a
ss
es
sm
en
t 
at
 p
ri
m
ar
y 
sc
ho
ol
 e
nt
ry
. 
• 
Re
fe
r 
fo
r 
re
na
l u
lt
ra
so
un
d 
at
 d
ia
gn
os
is
. 
• 
Ca
rr
y 
ou
t 
ba
se
lin
e 
co
ag
ul
at
io
n 
sc
re
en
in
g 
in
 p
at
ie
nt
s 
ag
ed
 5
+,
 o
r 
 
 
ea
rl
ie
r 
if
 m
aj
or
 p
ro
ce
du
re
 t
o 
be
 u
nd
er
ta
ke
n.
 (
Pr
ot
hr
om
bi
n 
Ti
m
e 
(P
T)
 
 
Ac
ti
va
te
d 
Pa
rt
ia
l T
hr
om
bo
pl
as
ti
n 
Ti
m
e 
(a
PP
T)
 a
nd
 F
XI
 a
ss
ay
.)
 
• 
Re
fe
r 
fo
r 
sp
ec
ia
lis
t 
op
ht
ha
lm
ol
og
y 
as
se
ss
m
en
t 
at
 t
he
 p
oi
nt
 o
f 
 
 
di
ag
no
si
s.
 
Cl
in
ic
al
 F
ea
tu
re
s 
of
 N
oo
na
n 
Sy
nd
ro
m
e 
• 
Co
ng
en
it
al
 h
ea
rt
 d
ef
ec
ts
 (
e.
g.
 p
ul
m
on
ar
y 
st
en
os
is
, 
hy
pe
rt
ro
ph
ic
 c
ar
di
om
yo
pa
th
y,
 
at
ri
al
 s
ep
ta
l d
ef
ec
t)
 
• 
Fa
ilu
re
 t
o 
th
ri
ve
/s
lo
w
 g
ro
w
th
 r
at
e/
fe
ed
in
g 
pr
ob
le
m
s
• 
Sh
or
t 
st
at
ur
e 
• 
D
ev
el
op
m
en
ta
l d
el
ay
 a
nd
 
ne
ur
op
sy
ch
ol
og
ic
al
/b
eh
av
io
ur
al
 is
su
es
 
• 
M
in
or
 r
en
al
 a
no
m
al
ie
s
• 
Bl
ee
di
ng
 d
is
or
de
rs
 
• 
Vi
su
al
 p
ro
bl
em
s 
(e
.g
.p
os
te
ri
or
 s
eg
m
en
t 
oc
ul
ar
 c
ha
ng
es
 a
nd
 a
nt
er
io
r 
se
gm
en
t 
 
oc
ul
ar
 a
bn
or
m
al
it
ie
s)
(w
he
re
 a
n 
in
ve
st
ig
at
io
n 
is
 n
ot
 in
di
ca
te
d 
fo
r 
a 
sp
ec
if
ic
 c
lin
ic
al
 f
ea
tu
re
, 
pl
ea
se
 r
ef
er
 t
o 
th
e 
re
le
va
nt
 a
ge
 g
ro
up
-s
pe
ci
fi
c 
pa
ge
 f
or
m
an
ag
em
en
t 
re
co
m
m
en
da
ti
on
s)
 
Re
co
m
m
en
de
d 
ba
se
lin
e 
 
in
ve
st
ig
at
io
ns
 in
 N
oo
na
n 
Sy
nd
ro
m
e
Fe
at
ur
e
 A
 =
 M
aj
or
B 
= 
M
in
or
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D
ia
gn
os
is
 a
nd
 c
lin
ic
al
 f
ea
tu
re
s 
of
 N
oo
na
n 
Sy
nd
ro
m
e
D
ia
gn
os
ti
c 
fe
at
ur
es
 o
f 
N
S 
(v
an
 d
er
 B
ur
gt
 1
99
7)
 
D
ef
in
it
iv
e 
N
S:
 
 
D
if
fe
re
nt
ia
l d
ia
gn
os
es
: 
− 
Ca
rd
io
-f
ac
io
-c
ut
an
eo
us
 s
yn
dr
om
e 
(C
FC
) 
 
− 
Co
st
el
lo
 s
yn
dr
om
e 
− 
LE
O
PA
RD
 s
yn
dr
om
e 
 
 
 
 
− 
Ki
ng
-D
en
bo
ro
ug
h 
Sy
nd
ro
m
e 
(p
he
no
ty
pi
ca
lly
 d
is
ti
nc
t.
 M
al
ig
na
nt
 h
yp
er
th
er
m
ia
 is
 n
ot
 d
es
cr
ib
ed
 in
 N
S)
 
N
B—
N
eu
ro
fi
br
om
at
os
is
-N
oo
na
n 
sy
nd
ro
m
e 
fo
rm
ed
 p
ar
t 
of
 t
he
 d
if
fe
re
nt
ia
l d
ia
gn
os
is
 in
 t
he
 p
as
t;
 it
 is
 n
ow
 k
no
w
n 
th
at
 s
om
e 
pa
ti
en
ts
 w
it
h 
ei
th
er
 o
f 
th
es
e
co
nd
it
io
ns
 w
ill
 h
av
e 
ov
er
la
pp
in
g 
cl
in
ic
al
 f
ea
tu
re
s,
 d
ue
 t
o 
th
e 
ca
us
at
iv
e 
m
ut
at
io
ns
 o
cc
ur
ri
ng
 in
 t
he
 s
am
e 
bi
ol
og
ic
al
 p
at
hw
ay
. 
1.
 F
ac
ia
l 
Ty
pi
ca
l f
ac
e 
(F
ac
ia
l f
ea
tu
re
s 
of
 N
S 
va
ry
 o
ve
r 
ti
m
e 
an
d 
m
ay
 h
av
e 
on
ly
 s
ub
tl
e 
di
ff
er
en
ce
s.
 E
xp
er
t 
as
se
ss
m
en
t 
is
 t
he
re
fo
re
  
Re
qu
ir
ed
. 
Se
e 
Al
la
ns
on
 1
98
7—
fu
ll 
re
fe
re
nc
e 
p.
19
).
 
 
Su
gg
es
ti
ve
 f
ac
e 
2.
 C
ar
di
ac
 
Pu
lm
on
ar
y 
va
lv
e 
st
en
os
is
 a
nd
/o
r 
hy
pe
rt
ro
ph
ic
 c
ar
di
om
yo
pa
th
y 
(H
CM
)
O
th
er
 c
ar
di
ac
 d
ef
ec
t 
3.
 H
ei
gh
t 
 elitnec ht01 <
 
 elitnec ht3 <
4.
 C
he
st
 w
al
l 
 xaroht daorB
 
 
mutavacxe/
mutanirac sutceP
5.
 F
am
ily
 H
is
to
ry
 
Fi
rs
t 
de
gr
ee
 r
el
at
iv
e 
w
it
h 
de
fi
ni
te
 N
S 
Fi
rs
t 
de
gr
ee
 r
el
at
iv
e 
su
gg
es
ti
ve
 o
f 
N
S 
 
6.
 O
th
er
 
M
ild
 d
ev
el
op
m
en
ta
l d
el
ay
, 
cr
yp
to
rc
hi
di
sm
 A
N
D
 ly
m
ph
at
ic
 
dy
sp
la
si
a
M
ild
 d
ev
el
op
m
en
ta
l d
el
ay
, 
cr
yp
to
rc
hi
di
sm
, 
O
R 
ly
m
ph
at
ic
 
dy
sp
la
si
a
*C
ur
re
nt
ly
, 
m
ut
at
io
n 
te
st
in
g 
w
ill
 p
ro
ve
 a
 d
ia
gn
os
is
 o
f 
N
oo
na
n 
Sy
nd
ro
m
e 
in
 7
0%
 o
f 
ca
se
s;
 in
 3
0%
 t
he
 r
es
po
ns
ib
le
 g
en
e 
re
m
ai
ns
 u
nk
no
w
n.
Th
e 
di
ag
no
si
s 
of
 N
S 
sh
ou
ld
 b
e 
co
ns
id
er
ed
 in
 p
ar
en
ts
 w
he
n 
a 
ch
ild
 is
 d
ia
gn
os
ed
 w
it
h 
th
e 
sy
nd
ro
m
e.
 
G
iv
en
 t
he
 n
um
be
r 
of
 d
if
fe
re
nt
 g
en
es
 w
he
re
 m
ut
at
io
ns
 c
an
 c
au
se
 N
S,
 t
he
 a
pp
ro
pr
ia
te
ne
ss
 a
nd
 s
eq
ue
nc
e 
of
 g
en
e 
te
st
in
g 
sh
ou
ld
 b
e 
de
ci
de
d
by
 a
 c
lin
ic
al
 g
en
et
ic
is
t.
 
Cr
it
er
io
n 
1A
 +
 
O
ne
 o
f 
2A
—
6A
 
Tw
o 
of
 2
B—
6B
 
Tw
o 
of
 2
A
—
6A
 
Th
re
e 
of
 2
B—
6B
 
Cr
it
er
io
n 
1B
 +
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0—
1
AGE
A
BN
L
A
BN
L
Re
co
m
m
en
da
ti
on
s 
fo
r 
th
e 
m
an
ag
em
en
t 
of
N
oo
na
n 
Sy
nd
ro
m
e 
~ 
in
 n
eo
na
te
s 
&
 i
nf
an
cy
 (
2)
 ~
A
BN
L
A
BN
L
Re
co
m
m
en
de
d 
Te
st
in
g/
Sc
re
en
in
g 
Cl
in
ic
al
 M
an
ag
em
en
t 
Re
co
m
m
en
da
ti
on
s 
• 
Sk
in
 p
ro
bl
em
s:
 
Ke
ra
to
si
s 
Pi
la
ri
s/
U
le
ry
th
em
a 
 
A
vo
id
 s
ki
n 
dr
yn
es
s,
 w
hi
ch
 c
an
 b
e 
w
or
se
ne
d 
by
 lo
ng
 h
ot
 b
at
hs
, p
er
fu
m
ed
 s
oa
ps
 a
nd
 
dr
y 
at
m
os
ph
er
es
. 
M
an
ag
e 
us
in
g 
em
ol
lie
nt
s,
 k
er
at
ol
yt
ic
 a
ge
nt
s 
e.
g.
 s
al
ic
yl
ic
 a
ci
d 
in
 u
re
a 
cr
ea
m
, i
f  
to
le
ra
te
d,
 o
r s
ho
rt 
co
ur
se
s 
of
 to
pi
ca
l s
te
ro
id
s 
if 
ne
ce
ss
ar
y 
(e
sp
ec
ia
lly
 if
  
er
yt
he
m
at
ou
s)
. 
W
ith
in
 a
 s
pe
ci
al
is
t d
er
m
at
ol
og
y 
se
tti
ng
, i
t s
ho
ul
d 
be
 n
ot
ed
 th
at
 re
tin
oi
ds
 m
ay
 n
ot
 b
e 
a 
fir
st
 c
ho
ic
e 
tre
at
m
en
t a
s 
th
ey
 h
av
e 
be
en
 s
ho
w
n 
no
t t
o 
w
or
k 
in
 s
om
e 
N
S
 p
at
ie
nt
s.
 
• 
Vi
si
on
 s
cr
ee
ni
ng
: 
sq
ui
nt
, 
po
st
er
io
r 
se
g-
m
en
t 
oc
ul
ar
 c
ha
ng
es
 a
nd
 a
nt
er
io
r 
se
gm
en
t 
oc
ul
ar
 a
bn
or
m
al
it
ie
s 
ha
ve
 b
ee
n 
de
sc
ri
be
d 
in
 N
S.
 
R
ef
er
 fo
r b
as
el
in
e 
ev
al
ua
tio
n 
at
 p
oi
nt
 o
f d
ia
gn
os
is
. 
O
ph
th
al
m
ic
 fo
llo
w
 u
p/
m
an
ag
em
en
t a
s 
de
em
ed
 a
pp
ro
pr
ia
te
 b
y 
th
e 
op
ht
ha
lm
ol
og
is
t. 
 
• 
Ch
ec
k 
fo
r 
cr
yp
to
rc
hi
di
sm
 
 
M
an
ag
e 
in
 th
e 
st
an
da
rd
 w
ay
 a
t t
he
 a
pp
ro
pr
ia
te
 ti
m
e.
 
• 
G
en
et
ic
 m
ut
at
io
n 
sc
re
en
in
g 
 
S
ho
ul
d 
be
 c
on
si
de
re
d 
in
 th
e 
co
nt
ex
t o
f g
en
et
ic
 m
an
ag
em
en
t—
w
hi
ch
 g
en
es
 a
re
 
te
st
ed
 fo
r s
ho
ul
d 
be
 d
ec
id
ed
 b
y 
a 
cl
in
ic
al
 g
en
et
ic
is
t. 
 
• 
 
 tne
mssessa gnirae
H
R
ef
er
 fo
r b
as
el
in
e 
ev
al
ua
tio
n 
in
 2
nd
 h
al
f o
f f
irs
t y
ea
r. 
M
an
ag
em
en
t i
n 
st
an
da
rd
 w
ay
. 
• 
Co
ag
ul
at
io
n 
sc
re
en
in
g 
 
To
 b
e 
ca
rr
ie
d 
ou
t b
ef
or
e 
an
y 
m
aj
or
 s
ur
ge
ry
 in
 n
eo
na
te
s/
in
fa
nt
s,
 a
nd
 a
t l
ea
st
 o
nc
e 
du
rin
g 
ch
ild
ho
od
. 
!  
A
na
es
th
es
ia
  
N
S
 c
an
 c
au
se
 c
oa
gu
la
tio
n 
di
ffi
cu
lti
es
 th
at
 s
ho
ul
d 
be
 e
va
lu
at
ed
 p
rio
r t
o 
su
rg
ic
al
 p
ro
ce
du
re
s 
so
 th
at
 c
ar
e,
 in
cl
ud
in
g 
an
ae
st
he
si
a,
 c
an
 b
e 
pl
an
ne
d 
ac
co
rd
in
gl
y.
 
P
at
ie
nt
s 
w
ith
 N
S
 a
nd
 h
ae
m
od
yn
am
ic
al
ly
 s
ig
ni
fic
an
t c
ar
di
ac
 in
vo
lv
em
en
t s
uc
h 
as
 s
ev
er
e 
hy
pe
rtr
op
hi
c 
ca
rd
io
m
yo
pa
th
y 
ne
ed
 to
 tr
ea
te
d
ac
co
rd
in
g 
to
 th
e 
us
ua
l p
rin
ci
pl
es
 fo
r p
at
ie
nt
s 
w
ith
 s
uc
h 
ca
rd
io
va
sc
ul
ar
 ri
sk
 fa
ct
or
s.
 
P
at
ie
nt
s 
w
ith
 N
S
 m
ay
 h
av
e 
cr
an
io
fa
ci
al
 a
nd
/o
r v
er
te
br
al
 a
no
m
al
ie
s 
th
at
 c
ou
ld
 a
ffe
ct
 in
tu
ba
tio
n 
or
 th
e 
ad
m
in
is
tra
tio
n 
of
 s
pi
na
l a
na
es
th
es
ia
. 
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0—
1
AGE
A
BN
L
A
BN
L
A
BN
L
A
BN
L
A
BN
L
A
BN
L
Re
co
m
m
en
da
ti
on
s 
fo
r 
th
e 
m
an
ag
em
en
t 
of
N
oo
na
n 
Sy
nd
ro
m
e 
~ 
in
 n
eo
na
te
s 
&
 i
nf
an
cy
 (
1)
 ~
Re
co
m
m
en
de
d 
Te
st
in
g/
Sc
re
en
in
g 
Cl
in
ic
al
 M
an
ag
em
en
t 
Re
co
m
m
en
da
ti
on
s 
• 
Fe
ed
in
g 
as
se
ss
m
en
t 
 
R
ef
er
 fo
r d
ie
ta
ry
 a
ss
es
sm
en
t a
nd
 e
va
lu
at
io
n 
of
 s
w
al
lo
w
in
g 
if 
ne
ed
ed
. 
R
ef
er
 to
 s
pe
ec
h 
th
er
ap
is
t f
or
 m
an
ag
em
en
t i
f n
ec
es
sa
ry
. 
Fr
eq
ue
nt
 v
om
iti
ng
 s
ho
ul
d 
pr
om
pt
 in
ve
st
ig
at
io
n 
fo
r g
as
tro
-o
es
op
ha
ge
al
 re
flu
x 
an
d 
m
al
ro
ta
tio
n.
Tr
ea
t w
ith
 a
nt
i-r
ef
lu
x 
m
ea
su
re
s.
 P
er
si
st
en
t v
om
iti
ng
 o
r f
oo
d 
re
fu
sa
l m
ay
 re
qu
ire
 
tu
be
 fe
ed
in
g 
(a
lth
ou
gh
 th
is
 is
 ra
re
).
• 
Fu
ll 
ca
rd
ia
c 
ev
al
ua
ti
on
 
 
A
t d
ia
gn
os
is
.  
If 
hy
pe
rtr
op
hi
c 
ca
rd
io
m
yo
pa
th
y 
(H
C
M
) i
s 
fo
un
d,
 fo
llo
w
 u
p 
ca
re
fu
lly
. 
M
an
ag
em
en
t o
f c
on
ge
ni
ta
l h
ea
rt 
di
se
as
e 
is
 a
s 
pe
r t
he
 g
en
er
al
 p
op
ul
at
io
n,
 h
ow
ev
er
 
a 
dy
sp
la
st
ic
 v
al
ve
 is
 m
or
e 
lik
el
y 
an
d 
th
er
ef
or
e 
su
rg
er
y 
m
ay
 b
e 
m
or
e 
lik
el
y 
to
 b
e 
ne
ce
ss
ar
y.
• 
G
ro
w
th
 m
on
it
or
in
g 
M
ea
su
re
 h
ei
gh
t, 
w
ei
gh
t a
nd
 o
cc
ip
ito
fro
nt
al
 c
irc
um
fe
re
nc
e 
(O
FC
) a
t b
irt
h 
an
d 
1-
3 
m
on
th
ly
.
P
lo
t o
n 
N
S
-s
pe
ci
fic
 g
ro
w
th
 c
ha
rts
. 
R
ou
tin
e 
pa
ed
ia
tri
c 
in
ve
st
ig
at
io
n s
 fo
r f
ai
lu
re
 to
 th
riv
e 
an
d 
re
du
ce
d 
gr
ow
th
 v
el
oc
ity
. 
• 
N
eu
ro
ps
yc
ho
lo
gi
ca
l a
nd
 B
eh
av
io
ur
al
  
Is
su
es
R
ef
er
 fo
r f
or
m
al
 d
ev
el
op
m
en
ta
l a
ss
es
sm
en
t i
n 
2n
d 
ha
lf 
of
 fi
rs
t y
ea
r. 
D
ev
el
op
m
en
ta
l d
el
ay
 c
au
se
d 
by
 h
yp
ot
on
ia
 w
ill
 im
pr
ov
e 
w
ith
 o
cc
up
at
io
na
l a
nd
 
ph
ys
io
th
er
ap
y.
M
an
ag
em
en
t o
f d
ev
el
op
m
en
ta
l d
el
ay
 w
ill
 b
e 
as
 p
er
 th
e 
ge
ne
ra
l p
op
ul
at
io
n.
 
• 
Re
na
l u
lt
ra
so
un
d 
 
R
ef
er
 to
 p
ae
di
at
ric
 n
ep
hr
ol
og
is
t f
or
 m
an
ag
em
en
t i
f r
en
al
 a
no
m
al
ie
s 
ar
e 
id
en
tif
ie
d 
in
 
ul
tra
so
un
d 
at
 d
ia
gn
os
is
. 
• 
N
eu
ro
lo
gy
—
po
te
nt
ia
l c
om
pl
ic
at
io
ns
 in
 N
S 
in
cl
ud
e 
se
iz
ur
es
, 
cr
an
io
sy
no
st
os
is
, 
hy
dr
oc
ep
ha
lu
s 
an
d 
Ar
no
ld
 C
hi
ar
i  
M
al
fo
rm
at
io
n.
Lo
w
 th
re
sh
ol
d 
fo
r i
nv
es
tig
at
io
n 
of
 n
eu
ro
lo
gi
ca
l s
ym
pt
om
s 
e.
g.
 c
on
si
de
r  
A
rn
ol
d-
C
hi
ar
i m
al
fo
rm
at
io
n 
an
d 
hy
dr
oc
ep
ha
lu
s 
if 
pa
tie
nt
 p
re
se
nt
s 
w
ith
 h
ea
da
ch
e 
or
 
ot
he
r n
eu
ro
lo
gi
ca
l s
ym
pt
om
s,
 a
nd
 re
fe
r f
or
 M
R
I i
f s
us
pe
ct
ed
. 
A
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L
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AGE
A
BN
L
A
BN
L
A
BN
L
A
BN
L
A
BN
L
A
BN
L
A
BN
L
A
BN
L
A
BN
L
Re
co
m
m
en
da
ti
on
s 
fo
r 
th
e 
m
an
ag
em
en
t 
of
N
oo
na
n 
Sy
nd
ro
m
e 
~ 
in
 c
hi
ld
ho
od
 (
2)
 ~
Re
co
m
m
en
de
d 
Te
st
in
g/
Sc
re
en
in
g 
Cl
in
ic
al
 M
an
ag
em
en
t 
Re
co
m
m
en
da
ti
on
s 
• 
N
eu
ro
ps
yc
ho
lo
gi
ca
l a
nd
 B
eh
av
io
ur
al
  
Is
su
es
:
hy
po
to
ni
a 
an
d 
m
ot
or
 d
el
ay
 a
re
 
co
m
m
on
 in
 N
S 
an
d 
ca
n 
ca
us
e 
 
de
ve
lo
pm
en
ta
l d
el
ay
. 
 
S
cr
ee
ni
ng
 fo
r d
ev
el
op
m
en
ta
l d
el
ay
 a
nd
 fu
ll 
ne
ur
op
sy
ch
ol
og
ic
al
 a
ss
es
sm
en
t a
t  
pr
im
ar
y 
(to
 in
cl
ud
e 
sp
ee
ch
 a
cq
ui
si
tio
n)
 a
nd
 s
ec
on
da
ry
 s
ch
oo
l e
nt
ry
, a
nd
 if
/w
he
n 
sy
m
pt
om
at
ic
.  
A
ss
es
s 
in
te
lle
ct
ua
l/c
og
ni
tiv
e 
ab
ili
tie
s 
w
ith
 s
pe
ci
al
 a
tte
nt
io
n 
fo
r l
ea
rn
in
g 
di
ffi
cu
lti
es
 a
s 
a 
re
su
lt 
of
 m
ot
or
 d
el
ay
, e
xe
cu
tiv
e 
dy
sf
un
ct
io
ns
 a
nd
 in
at
te
nt
io
n.
  
D
ev
el
op
m
en
ta
l d
el
ay
 c
au
se
d 
by
 h
yp
ot
on
ia
 w
ill
 im
pr
ov
e 
w
ith
 o
cc
up
at
io
na
l a
nd
  
ph
ys
io
th
er
ap
y.
R
ef
er
ra
l f
or
 s
pe
ec
h 
th
er
ap
y 
if 
ac
qu
is
iti
on
 is
 d
el
ay
ed
. 
M
an
ag
em
en
t o
f d
ev
el
op
m
en
ta
l d
el
ay
 w
ill
 b
e 
as
 p
er
 th
e 
ge
ne
ra
l p
op
ul
at
io
n.
 
O
ng
oi
ng
 re
vi
ew
 a
nd
 s
up
po
rt 
of
 le
ar
ni
ng
 a
nd
 d
ev
el
op
m
en
t w
ith
 fu
rth
er
 a
ss
es
sm
en
t 
of
 s
pe
ci
al
 e
du
ca
tio
na
l n
ee
ds
 a
s 
re
qu
ire
d.
   
 
• 
N
eu
ro
lo
gy
—
po
te
nt
ia
l c
om
pl
ic
at
io
ns
 in
 N
S 
in
cl
ud
e 
se
iz
ur
es
, 
cr
an
io
sy
no
st
os
is
, 
hy
dr
oc
ep
ha
lu
s 
an
d 
Ar
no
ld
 C
hi
ar
i  
M
al
fo
rm
at
io
n.
 
Lo
w
 th
re
sh
ol
d 
fo
r i
nv
es
tig
at
io
n 
of
 n
eu
ro
lo
gi
ca
l s
ym
pt
om
s 
e.
g.
 c
on
si
de
r  
A
rn
ol
d-
C
hi
ar
i m
al
fo
rm
at
io
n 
an
d 
hy
dr
oc
ep
ha
lu
s 
if 
pa
tie
nt
 p
re
se
nt
s 
w
ith
 h
ea
da
ch
e 
or
 
ot
he
r n
eu
ro
lo
gi
ca
l s
ym
pt
om
s,
 a
nd
 re
fe
r f
or
 M
R
I i
f s
us
pe
ct
ed
. 
• 
M
us
cu
lo
sk
el
et
al
 
 
M
on
ito
r f
or
 s
co
lio
si
s.
 B
e 
aw
ar
e 
th
at
 it
 c
an
 w
or
se
n 
w
ith
 G
H
T.
 
Ta
lip
es
 o
cc
ur
s 
in
 5
 %
 o
f N
S
 p
at
ie
nt
s 
an
d 
sh
ou
ld
 b
e 
m
an
ag
ed
 a
s 
pe
r t
he
 g
en
er
al
 
po
pu
la
tio
n.
R
ef
er
 fo
r o
cc
up
at
io
na
l t
he
ra
py
 fo
r m
an
ag
em
en
t o
f h
yp
er
m
ob
ili
ty
. 
• 
Fe
ed
in
g 
as
se
ss
m
en
t:
 if
 n
ec
es
sa
ry
—
m
os
t 
fe
ed
in
g 
is
su
es
 w
ill
 h
av
e 
re
so
lv
ed
 b
y 
18
 
m
on
th
s.
 
R
ef
er
 fo
r d
ie
ta
ry
 a
ss
es
sm
en
t a
nd
 e
va
lu
at
io
n 
of
 s
w
al
lo
w
in
g 
if 
ne
ed
ed
. 
R
ef
er
 to
 s
pe
ec
h 
th
er
ap
is
t f
or
 m
an
ag
em
en
t i
f n
ec
es
sa
ry
. 
Fr
eq
ue
nt
 v
om
iti
ng
 s
ho
ul
d 
pr
om
pt
 in
ve
st
ig
at
io
n 
fo
r g
as
tro
-o
es
op
ha
ge
al
 re
flu
x 
an
d 
m
al
ro
ta
tio
n.
Tr
ea
t w
ith
 a
nt
i-r
ef
lu
x 
m
ea
su
re
s.
 P
er
si
st
en
t v
om
iti
ng
 o
r f
oo
d 
re
fu
sa
l m
ay
 re
qu
ire
 tu
be
 
fe
ed
in
g 
(a
lth
ou
gh
 th
is
 is
 ra
re
).
• 
Ch
ec
k 
fo
r 
cr
yp
to
rc
hi
di
sm
 
 
M
an
ag
e 
in
 th
e 
st
an
da
rd
 w
ay
 a
t t
he
 a
pp
ro
pr
ia
te
 ti
m
e.
 
• 
Ly
m
ph
oe
de
m
a:
 T
he
r e
 is
 a
n 
in
cr
ea
se
d 
ri
sk
 
of
 d
ev
el
op
in
g 
ly
m
ph
oe
de
m
a 
in
 N
S,
 
th
ro
ug
ho
ut
 c
hi
ld
ho
od
 a
nd
 la
te
r 
lif
e.
 
M
an
ag
em
en
t s
ho
ul
d 
be
 th
e 
sa
m
e 
as
 fo
r g
en
er
al
 p
op
ul
at
io
n.
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AGE
A
BN
L
A
BN
L
A
BN
L
A
BN
L
Re
co
m
m
en
da
ti
on
s 
fo
r 
th
e 
m
an
ag
em
en
t 
of
N
oo
na
n 
Sy
nd
ro
m
e 
~ 
in
 c
hi
ld
ho
od
 (
1)
 ~
Re
co
m
m
en
de
d 
Te
st
in
g/
Sc
re
en
in
g 
Cl
in
ic
al
 M
an
ag
em
en
t 
Re
co
m
m
en
da
ti
on
s 
• 
Ec
ho
ca
rd
io
gr
am
 (
EC
H
O
) 
 
A
nn
ua
lly
 u
nt
il 
th
e 
ag
e 
of
 3
 a
nd
 th
en
 a
t 5
 a
nd
 1
0 
ye
ar
s 
ol
d,
 to
 a
ss
es
s 
fo
r o
ns
et
 o
f  
H
C
M
.
If 
re
su
lts
 in
di
ca
te
 H
C
M
, f
ol
lo
w
-u
p 
re
gu
la
rly
. 
M
an
ag
em
en
t o
f c
on
ge
ni
ta
l h
ea
rt 
di
se
as
e 
is
 a
s 
pe
r t
he
 g
en
er
al
 p
op
ul
at
io
n,
 h
ow
ev
er
 a
 
dy
sp
la
st
ic
 v
al
ve
 is
 m
or
e 
lik
el
y 
an
d 
su
rg
er
y 
m
ay
 b
e 
m
or
e 
lik
el
y 
to
 b
e 
ne
ce
ss
ar
y.
 
If 
E
C
H
O
 re
su
lts
 a
re
 n
or
m
al
 a
t t
he
 a
ge
 o
f 1
0 
ye
ar
s 
ol
d 
an
d 
ol
de
r, 
ca
rd
ia
c 
fo
llo
w
 u
p 
re
m
ai
ns
 n
ec
es
sa
ry
 d
ue
 to
 th
e 
on
go
in
g 
in
cr
ea
se
d 
ris
k 
of
 c
ar
di
om
yo
pa
th
y.
 
• 
G
ro
w
th
 a
ss
es
sm
en
t 
G
ro
w
th
 h
or
m
on
e 
(G
H
) 
ax
is
 e
va
lu
at
io
n 
G
H
 &
 h
yp
er
tr
op
hi
c 
ca
rd
io
m
yo
pa
th
y 
(H
CM
) 
 
N
ea
rly
 h
al
f o
f c
hi
ld
re
n 
w
ith
 N
S
 w
ill
 re
ac
h 
a 
he
ig
ht
 w
ith
in
 th
e 
no
rm
al
 ra
ng
e 
w
ith
ou
t 
gr
ow
th
 h
or
m
on
e 
(G
H
) i
nt
er
ve
nt
io
n.
 
M
od
es
t r
es
po
ns
e 
to
 g
ro
w
th
 h
or
m
on
e 
th
er
ap
y 
(G
H
T)
 h
as
 b
ee
n 
do
cu
m
en
te
d 
bu
t 
so
m
e 
N
S
 p
at
ie
nt
s 
w
ill
 c
on
tin
ue
 to
 g
ro
w
 in
to
 th
ei
r l
at
e 
te
en
s/
ea
rly
 tw
en
tie
s 
(b
ec
au
se
 
of
 la
te
 p
ub
er
ty
) a
nd
 th
er
eb
y 
re
ac
h 
no
rm
al
 ra
ng
e.
  
Fi
na
l h
ei
gh
t m
ay
 a
ls
o 
be
 in
flu
en
ce
d 
by
 p
ar
en
ta
l h
ei
gh
t. 
P
lo
t g
ro
w
th
 o
n 
N
S
 g
ro
w
th
 c
ha
rts
. 
A
ll 
ch
ild
re
n 
w
ith
 a
 h
ei
gh
t b
el
ow
 th
e 
m
ea
n 
fo
r N
S
 s
ho
ul
d 
be
 re
fe
rr
ed
 to
 a
 p
ae
di
at
ric
 
en
do
cr
in
ol
og
is
t f
or
 a
ss
es
sm
en
t. 
 
If 
he
ig
ht
 is
 b
el
ow
 2
.5
 s
ta
nd
ar
d 
de
vi
at
io
ns
 (S
D
) f
ro
m
 th
e 
m
ea
n 
on
 s
ta
nd
ar
d 
ch
ild
ho
od
 
ch
ar
ts
, G
H
T 
m
ay
 b
e 
co
ns
id
er
ed
 w
ith
ou
t e
va
lu
at
io
n 
of
 th
e 
G
H
 a
xi
s.
 
If 
IG
F-
1 
le
ve
ls
 a
re
 lo
w
, t
es
tin
g 
of
 th
e 
G
H
 a
xi
s 
sh
ou
ld
 b
e 
co
ns
id
er
ed
 to
 s
ho
w
 g
ro
w
th
  
ho
rm
on
e 
de
fic
ie
nc
y 
(G
H
D
). 
N
B
.W
hi
le
 m
an
y 
co
ns
id
er
 e
xi
st
in
g 
H
C
M
 o
r m
al
ig
na
nc
y 
as
 re
la
tiv
e 
co
nt
ra
in
di
ca
tio
ns
 
to
 G
H
T,
 th
er
e 
ar
e 
no
 d
at
a 
to
 s
up
po
rt 
th
is
 c
la
im
. 
A
dd
iti
on
al
ly
, t
he
re
 is
 n
o 
ev
id
en
ce
 o
f a
n 
in
cr
ea
se
d 
ris
k 
of
 H
C
M
 o
r m
al
ig
na
nc
y 
 
de
ve
lo
pi
ng
 in
 p
eo
pl
e 
w
ith
 N
S
 u
nd
er
ta
ki
ng
 G
H
T.
  
• 
Co
ag
ul
at
io
n 
sc
re
en
in
g 
 
S
ho
ul
d 
be
 c
ar
rie
d 
ou
t a
t l
ea
st
 o
nc
e 
du
rin
g 
m
id
/la
te
 c
hi
ld
ho
od
 (5
—
11
 y
ea
rs
 o
ld
), 
an
d 
be
fo
re
 m
aj
or
 s
ur
ge
ry
. 
A
sp
iri
n 
sh
ou
ld
 b
e 
w
ith
he
ld
 b
ef
or
e 
an
y 
su
rg
ic
al
 in
te
rv
en
tio
ns
, a
s 
pe
r s
ta
nd
ar
d 
 
pr
ac
tic
e.
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AGE
11
—
18
A
BN
L
A
BN
L
Re
co
m
m
en
da
ti
on
s 
fo
r 
th
e 
m
an
ag
em
en
t 
of
N
oo
na
n 
Sy
nd
ro
m
e 
~ 
in
 a
do
le
sc
en
ce
 (
1)
 ~
Re
co
m
m
en
de
d 
Te
st
in
g/
Sc
re
en
in
g 
Cl
in
ic
al
 M
an
ag
em
en
t 
Re
co
m
m
en
da
ti
on
s 
• 
Ec
ho
ca
rd
io
gr
am
 (
EC
H
O
) 
 
A
n 
E
C
H
O
 in
 a
do
le
sc
en
ce
 is
 re
co
m
m
en
de
d 
as
 th
is
 is
 w
he
n 
fa
m
ili
al
 H
C
M
 m
ay
 fi
rs
t 
be
 id
en
tif
ie
d.
 
C
on
tin
ue
d 
ca
rd
ia
c 
fo
llo
w
 u
p 
th
ro
ug
ho
ut
 a
do
le
sc
en
ce
 is
 im
po
rta
nt
. 
• 
 
 ytrebuP
Th
e 
lik
el
ih
oo
d 
of
 d
el
ay
ed
 p
ub
er
ty
 s
ho
ul
d 
be
 a
nt
ic
ip
at
ed
, a
nd
 a
pp
ro
pr
ia
te
 e
du
ca
tio
n 
an
d 
co
un
se
lli
ng
 p
ro
vi
de
d 
ar
ou
nd
 th
is
 is
su
e.
 
• 
N
eu
ro
ps
yc
ho
lo
gi
ca
l a
nd
 B
eh
av
io
ur
al
  
Is
su
es
 
A
cc
es
s 
to
 s
oc
ia
l s
ki
lls
 tr
ai
ni
ng
, a
nd
 p
ro
gr
am
m
es
 to
 te
ac
h 
ba
si
c 
se
lf 
he
lp
 a
nd
 d
ai
ly
 
liv
in
g 
sk
ill
s,
 if
 re
qu
ire
d.
 
S
cr
ee
n 
fo
r m
oo
d 
an
d 
an
xi
et
y 
di
so
rd
er
s 
if 
su
sp
ec
te
d.
 
If 
ne
ce
ss
ar
y,
 c
on
si
de
r p
ha
rm
ac
ol
og
ic
al
 m
an
ag
em
en
t. 
• 
N
eu
ro
lo
gy
—
po
te
nt
ia
l c
om
pl
ic
at
io
ns
 in
 N
S 
in
cl
ud
e 
se
iz
ur
es
, 
cr
an
io
sy
no
st
os
is
, 
hy
dr
oc
ep
ha
lu
s 
an
d 
Ar
no
ld
 C
hi
ar
i  
m
al
fo
rm
at
io
n)
 
N
o 
ro
ut
in
e 
sc
re
en
in
g 
is
 re
co
m
m
en
de
d,
 h
ow
ev
er
 th
er
e 
sh
ou
ld
 b
e 
a 
lo
w
 th
re
sh
ol
d 
fo
r 
in
ve
s t
ig
at
io
n 
of
 n
eu
ro
lo
gi
ca
l s
ym
pt
om
s 
e.
g.
 c
on
si
de
r A
rn
ol
d-
C
hi
ar
i m
al
fo
rm
at
io
n 
an
d 
hy
dr
oc
ep
ha
lu
s 
if 
pa
tie
nt
 p
re
se
nt
s 
w
ith
 h
ea
da
ch
e 
or
 o
th
er
 n
eu
ro
lo
gi
ca
l  
sy
m
pt
om
s,
 a
nd
 re
fe
r f
or
 M
R
I i
f s
us
pe
ct
ed
. 
M
an
ag
em
en
t o
f s
pe
ci
fic
 c
om
pl
ic
at
io
ns
, i
nc
lu
di
ng
 e
pi
le
ps
y,
 w
ill
 b
e 
as
 p
er
 th
e 
 
ge
ne
ra
l p
op
ul
at
io
n.
 
• 
Co
ag
ul
at
io
n 
sc
re
en
in
g 
 
S
cr
ee
n 
be
fo
re
 a
ny
 s
ur
gi
ca
l i
nt
er
ve
nt
io
n,
 a
nd
 w
ith
ho
ld
 a
sp
iri
n 
pr
io
r t
o 
su
rg
er
y,
 a
s 
pe
r s
ta
nd
ar
d 
pr
ac
tic
e.
 
• 
M
us
cu
lo
sk
el
et
al
 
 
M
on
ito
r f
or
 s
co
lio
si
s.
 
B
e 
aw
ar
e 
th
at
 s
co
lio
si
s 
ca
n 
w
or
se
n 
w
ith
 G
H
T 
an
d 
in
 a
do
le
sc
en
ce
. 
• 
Th
yr
oi
d 
sc
re
en
in
g 
 
S
cr
ee
n 
bl
oo
d 
fo
r t
hy
ro
id
 a
bn
or
m
al
iti
es
 e
ve
ry
 3
—
5 
ye
ar
s 
in
 o
ld
er
 c
hi
ld
re
n 
an
d 
ad
ul
ts
.
M
an
ag
e 
an
om
al
ie
s 
as
 in
 g
en
er
al
 p
op
ul
at
io
n.
 
• 
Ly
m
ph
oe
de
m
a 
 
Th
er
e 
is
 a
n 
in
cr
ea
se
d 
ris
k 
of
 d
ev
el
op
in
g 
ly
m
ph
oe
de
m
a 
in
 N
S
, t
hr
ou
gh
ou
t c
hi
ld
ho
od
 
an
d 
la
te
r l
ife
. 
M
an
ag
em
en
t s
ho
ul
d 
be
 th
e 
sa
m
e 
as
 fo
r g
en
er
al
 p
op
ul
at
io
n.
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AGE
A
BN
L
A
BN
L
A
BN
L
!  
A
na
es
th
es
ia
  
N
S
 c
an
 c
au
se
 c
oa
gu
la
tio
n 
di
ffi
cu
lti
es
 th
at
 s
ho
ul
d 
be
 e
va
lu
at
ed
 p
rio
r t
o 
su
rg
ic
al
 p
ro
ce
du
re
s 
so
 th
at
 c
ar
e,
 in
cl
ud
in
g 
an
ae
st
he
si
a,
 c
an
 b
e 
pl
an
ne
d 
ac
co
rd
in
gl
y.
 
P
at
ie
nt
s 
w
ith
 N
S
 a
nd
 h
ae
m
od
yn
am
ic
al
ly
 s
ig
ni
fic
an
t c
ar
di
ac
 in
vo
lv
em
en
t s
uc
h 
as
 s
ev
er
e 
hy
pe
rtr
op
hi
c 
ca
rd
io
m
yo
pa
th
y 
ne
ed
 to
 tr
ea
te
d
ac
co
rd
in
g 
to
 th
e 
us
ua
l p
rin
ci
pl
es
 fo
r p
at
ie
nt
s 
w
ith
 s
uc
h 
ca
rd
io
va
sc
ul
ar
 ri
sk
 fa
ct
or
s.
 
P
at
ie
nt
s 
w
ith
 N
S
 m
ay
 h
av
e 
cr
an
io
fa
ci
al
 a
nd
/o
r v
er
te
br
al
 a
no
m
al
ie
s 
th
at
 c
ou
ld
 a
ffe
ct
 in
tu
ba
tio
n 
or
 th
e 
ad
m
in
is
tra
tio
n 
of
 s
pi
na
l a
na
es
th
es
ia
. 
Re
co
m
m
en
da
ti
on
s 
fo
r 
th
e 
m
an
ag
em
en
t 
of
N
oo
na
n 
Sy
nd
ro
m
e 
~ 
in
 c
hi
ld
ho
od
 (
3)
 ~
Re
co
m
m
en
de
d 
Te
st
in
g/
Sc
re
en
in
g 
Cl
in
ic
al
 M
an
ag
em
en
t 
Re
co
m
m
en
da
ti
on
s 
• 
Vi
si
on
 s
cr
ee
ni
ng
: 
sq
ui
nt
, 
po
st
er
io
r 
 s
eg
m
en
t 
oc
ul
ar
 c
ha
ng
es
 a
nd
 a
nt
er
io
r 
 
 s
eg
m
en
t 
oc
ul
ar
 a
bn
or
m
al
it
ie
s 
ar
e 
 
 f
re
qu
en
t 
in
 N
S.
 
U
nl
es
s 
al
re
ad
y 
un
de
r o
ph
th
al
m
ic
 m
an
ag
em
en
t, 
N
S
 p
at
ie
nt
s 
sh
ou
ld
 b
e 
re
fe
rr
ed
 to
 
an
 o
ph
th
al
m
ol
og
is
t f
or
 a
ss
es
sm
en
t i
f/a
s 
ap
pr
op
ria
te
. 
• 
H
ea
ri
ng
 a
ss
es
sm
en
ts
: 
N
S 
pa
ti
en
ts
 h
av
e 
an
 
in
cr
ea
se
d 
ri
sk
 o
f 
co
nd
uc
ti
ve
 h
ea
ri
ng
 lo
ss
.
Se
ns
or
in
eu
ra
l h
ea
ri
ng
 lo
ss
 is
 r
ar
e 
bu
t 
ha
s 
be
en
 d
es
cr
ib
ed
. 
 
M
on
ito
r h
ea
rin
g 
an
nu
al
ly
 fr
om
 1
—
11
 y
ea
rs
 o
ld
 to
 p
re
ve
nt
 s
pe
ec
h 
de
ve
lo
pm
en
t 
pr
ob
le
m
s.
• 
D
en
ta
l s
cr
ee
ni
ng
 
G
ia
nt
 c
el
l l
es
io
ns
 o
f 
th
e 
ja
w
 
 
P
ub
lis
he
d 
ev
id
en
ce
 o
n 
th
e 
m
an
ag
em
en
t o
f r
ou
tin
e 
de
nt
al
 p
ro
bl
em
s 
in
 N
S
 is
 li
m
ite
d.
 
E
nr
ol
 p
at
ie
nt
 in
 a
n 
in
di
vi
du
al
is
ed
 p
re
ve
nt
at
iv
e 
or
al
 h
ea
lth
ca
re
 p
ro
gr
am
m
e 
fro
m
 a
n 
ea
rly
 a
ge
. 
R
ou
tin
e 
fo
llo
w
 u
p 
an
d 
re
gu
la
r d
en
ta
l e
xa
m
in
at
io
ns
 b
y 
a 
fa
m
ily
 d
en
tis
t o
r l
oc
al
  
co
m
m
un
ity
 d
en
ta
l s
er
vi
ce
s 
ar
e 
es
se
nt
ia
l. 
M
is
si
ng
 te
et
h/
m
al
oc
cl
us
io
n/
ot
he
r d
en
ta
l a
no
m
al
ie
s:
 re
fe
r t
o 
a 
co
ns
ul
ta
nt
 in
  
pa
ed
ia
tri
c 
de
nt
is
try
 fo
r m
ul
tid
is
ci
pl
in
ar
y 
m
an
ag
em
en
t. 
R
ef
er
 to
 O
ra
l/M
ax
ill
of
ac
ia
l/H
ea
d 
&
 N
ec
k 
S
ur
ge
on
 o
r e
xp
er
t d
en
ta
l c
ar
e 
ce
nt
re
. 
• 
Sk
in
 p
ro
bl
em
s:
 
Ke
ra
to
si
s 
Pi
la
ri
s/
U
le
ry
th
em
a 
 
A
vo
id
 s
ki
n 
dr
yn
es
s,
 w
hi
ch
 c
an
 b
e 
w
or
se
ne
d 
by
 lo
ng
 h
ot
 b
at
hs
, p
er
fu
m
ed
 s
oa
ps
 a
nd
 
dr
y 
at
m
os
ph
er
es
. 
M
an
ag
e 
us
in
g 
em
ol
lie
nt
s,
 k
er
at
ol
yt
ic
 a
ge
nt
s 
e.
g.
 s
al
ic
yl
ic
 a
ci
d 
in
 u
re
a 
cr
ea
m
, i
f  
to
le
ra
te
d,
 o
r s
ho
rt 
co
ur
se
s 
of
 to
pi
ca
l s
te
ro
id
s 
if 
ne
ce
ss
ar
y 
(e
sp
ec
ia
lly
 if
  
er
yt
he
m
at
ou
s)
. 
W
ith
in
 a
 s
pe
ci
al
is
t d
er
m
at
ol
og
y 
se
tti
ng
, i
t s
ho
ul
d 
be
 n
ot
ed
 th
at
 re
tin
oi
ds
 m
ay
 n
ot
 b
e 
a 
fir
st
 c
ho
ic
e 
tre
at
m
en
t a
s 
th
ey
 h
av
e 
be
en
 s
ho
w
n 
no
t t
o 
w
or
k 
in
 s
om
e 
N
S
 p
at
ie
nt
s.
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AGE
Re
co
m
m
en
da
ti
on
s 
fo
r 
th
e 
m
an
ag
em
en
t 
of
N
oo
na
n 
Sy
nd
ro
m
e 
~ 
in
 a
du
lt
ho
od
 (
1)
 ~
A
BN
L
A
BN
L
A
BN
L
Re
co
m
m
en
de
d 
Te
st
in
g/
Sc
re
en
in
g 
Cl
in
ic
al
 M
an
ag
em
en
t 
Re
co
m
m
en
da
ti
on
s 
• 
G
en
et
ic
 c
ou
ns
el
lin
g 
 
R
ef
er
 fo
r g
en
et
ic
 c
ou
ns
el
lin
g,
 m
ut
at
io
n 
te
st
in
g 
an
d 
di
sc
us
si
on
 o
f r
is
ks
 to
 c
hi
ld
re
n 
an
d 
op
tio
ns
 in
 p
re
gn
an
cy
. 
• 
Fe
rt
ili
ty
 is
su
es
 
 
C
ar
e 
pr
ov
id
er
s 
sh
ou
ld
 b
e 
m
ad
e 
aw
ar
e 
of
 th
e 
in
cr
ea
se
d 
ris
k 
of
 in
fe
rti
lit
y 
in
 m
al
es
 w
ith
 
N
S
, a
nd
 n
ot
 ju
st
 in
 th
os
e 
w
ith
 c
ry
pt
or
ch
id
is
m
. 
R
ef
er
 to
 a
 fe
rti
lit
y 
cl
in
ic
 o
r e
nd
oc
rin
ol
og
is
t i
f n
ec
es
sa
ry
. 
• 
In
 p
re
gn
an
cy
 
Fe
ta
l c
on
si
de
ra
ti
on
s 
M
at
er
na
l c
on
si
de
ra
ti
on
s 
 
P
re
na
ta
l f
ea
tu
re
s 
in
cl
ud
e;
 p
ol
yh
yd
ra
m
ni
os
, i
nc
re
as
ed
 n
uc
ha
l t
ra
ns
lu
ce
nc
y,
  
hy
dr
op
s 
fe
ta
lis
 a
nd
 c
ys
tic
 h
yg
ro
m
a,
 w
ith
 o
r w
ith
ou
t a
ss
oc
ia
te
d 
as
ci
te
s,
 p
le
ur
al
  
ef
fu
si
on
, r
en
al
 a
bn
or
m
al
iti
es
 a
nd
 c
on
ge
ni
ta
l h
ea
rt 
de
fe
ct
s.
 
C
ho
rio
ni
c 
vi
llu
s 
sa
m
pl
in
g 
(C
V
S
) o
r a
m
ni
oc
en
te
si
s 
is
 p
os
si
bl
e—
re
fe
rr
al
 to
 a
 c
lin
ic
al
 
ge
ne
tic
s 
se
rv
ic
e 
pr
ec
on
ce
pt
ua
lly
 is
 id
ea
l—
 if
 p
ar
en
ta
l m
ut
at
io
n 
is
 k
no
w
n 
an
d 
co
up
le
 
w
is
h 
fo
r a
 p
re
na
ta
l d
ia
gn
os
is
. 
U
ltr
as
ou
nd
s 
at
 1
2—
14
 a
nd
 2
0 
w
ee
ks
 a
nd
 u
nd
er
ta
ke
 m
ut
at
io
n 
an
al
ys
is
 if
 p
ar
en
ta
l  
m
ut
at
io
n 
kn
ow
n 
an
d 
cl
in
ic
al
 fe
at
u r
es
 a
re
 s
ug
ge
st
iv
e,
 if
 re
qu
ire
d.
 
P
ot
en
tia
l d
iff
ic
ul
tie
s,
 fo
r e
xa
m
pl
e 
th
os
e 
ar
is
in
g 
fro
m
 c
oa
gu
la
tio
n 
de
fe
ct
s 
du
rin
g 
 
ch
ild
bi
rth
, s
ho
ul
d 
be
 c
on
si
de
re
d 
an
d 
pl
an
ne
d 
fo
r a
s 
ap
pr
op
ria
te
. 
• 
N
eu
ro
ps
yc
ho
lo
gi
ca
l a
nd
 B
eh
av
io
ur
al
  
Is
su
es
R
ep
ea
t n
eu
ro
ps
yc
ho
lo
gi
ca
l a
ss
es
sm
en
t i
f p
at
ie
nt
 is
 s
ym
pt
om
at
ic
 o
f m
oo
d/
an
xi
et
y 
 
di
so
rd
er
(s
), 
or
 if
 c
og
ni
tiv
e 
im
pa
irm
en
ts
 a
re
 s
us
pe
ct
ed
.  
P
ay
 e
xt
ra
 a
tte
nt
io
n 
to
 th
e 
ev
al
ua
tio
n 
of
 s
oc
ia
l c
og
ni
tio
n 
an
d 
so
ci
al
 e
m
be
dd
in
g.
  
C
on
si
de
r t
he
 ri
sk
 o
f u
nd
er
-d
ia
gn
os
in
g 
be
ca
us
e 
of
 p
ro
bl
em
s 
in
 e
xp
re
ss
in
g 
em
ot
io
ns
. 
If 
ne
ce
ss
ar
y,
 c
on
si
de
r p
ha
rm
ac
ol
og
ic
al
 m
an
ag
em
en
t. 
Fa
ci
lit
at
e 
ac
ce
ss
 to
 s
up
po
rt 
fo
r e
m
pl
oy
m
en
t, 
se
lf 
he
lp
 a
nd
 in
de
pe
nd
en
t l
iv
in
g.
 
S
oc
ia
l s
ki
lls
 in
te
rv
en
tio
n 
as
 n
ee
de
d.
  
• 
N
eu
ro
lo
gy
—
po
te
nt
ia
l c
om
pl
ic
at
io
ns
 in
 N
S 
in
cl
ud
e 
se
iz
ur
es
, 
cr
an
io
sy
no
st
os
is
, 
hy
dr
oc
ep
ha
lu
s 
an
d 
Ar
no
ld
 C
hi
ar
i  
m
al
fo
rm
at
io
n)
Lo
w
 th
re
sh
ol
d 
fo
r i
nv
es
tig
at
io
n 
of
 n
eu
ro
lo
gi
ca
l s
ym
pt
om
s 
e.
g.
 c
on
si
de
r  
A
rn
ol
d-
C
hi
ar
i m
al
fo
rm
at
io
n 
an
d 
hy
dr
oc
ep
ha
lu
s 
if 
pa
tie
nt
 p
re
se
nt
s 
w
ith
 h
ea
da
ch
e 
or
 
ot
he
r n
eu
ro
lo
gi
ca
l s
ym
pt
om
s,
 a
nd
 re
fe
r f
or
 M
R
I i
f s
us
pe
ct
ed
. 
M
an
ag
em
en
t o
f s
pe
ci
fic
 c
om
pl
ic
at
io
ns
, i
nc
lu
di
ng
 e
pi
le
ps
y,
 w
ill
 b
e 
as
 p
er
 th
e 
ge
ne
ra
l 
po
pu
la
tio
n.
• 
Co
ag
ul
at
io
n 
sc
re
en
in
g 
 
S
cr
ee
n 
be
fo
re
 a
ny
 s
ur
gi
ca
l i
nt
er
ve
nt
io
n,
 a
nd
 w
ith
ho
ld
 a
sp
iri
n 
pr
io
r t
o 
su
rg
er
y,
 a
s 
pe
r 
st
an
da
rd
 p
ra
ct
ic
e.
 
• 
Ca
rd
ia
c 
sc
re
en
in
g 
Pu
lm
on
ar
y 
ar
te
ry
 in
te
rv
en
ti
on
 
 
N
ew
ly
 d
ia
gn
os
ed
 a
du
lts
: f
ul
l c
ar
di
ac
 e
va
lu
at
io
n 
in
cl
ud
in
g 
E
C
H
O
. 
P
re
vi
ou
sl
y 
di
ag
no
se
d 
ad
ul
ts
: r
eg
ul
ar
 c
ar
di
ac
 a
ss
es
sm
en
t o
f e
xi
st
in
g 
he
ar
t d
is
ea
se
, o
r 
ca
rd
ia
c 
ev
al
ua
tio
n 
in
ca
se
 a
or
tic
 d
is
ea
se
 m
is
se
d 
pr
ev
io
us
ly
. 
Fo
llo
w
 u
p 
fo
r p
ul
m
on
ar
y 
va
lv
e 
in
su
ffi
ci
en
cy
. 
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—
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A
BN
L
A
BN
L
A
BN
L
Re
co
m
m
en
da
ti
on
s 
fo
r 
th
e 
m
an
ag
em
en
t 
of
N
oo
na
n 
Sy
nd
ro
m
e 
~ 
in
 a
do
le
sc
en
ce
 (
2)
 ~
Re
co
m
m
en
de
d 
Te
st
in
g/
Sc
re
en
in
g 
Cl
in
ic
al
 M
an
ag
em
en
t 
Re
co
m
m
en
da
ti
on
s 
• 
D
en
ta
l s
cr
ee
ni
ng
 
G
ia
nt
 c
el
l l
es
io
ns
 o
f 
th
e 
ja
w
 
 
P
ub
lis
he
d 
ev
id
en
ce
 o
n 
th
e 
m
an
ag
em
en
t o
f r
ou
tin
e 
de
nt
al
 p
ro
bl
em
s 
in
 N
S
 is
 li
m
ite
d.
 
R
ou
tin
e 
fo
llo
w
 u
p 
an
d 
re
gu
la
r d
en
ta
l e
xa
m
in
at
io
ns
 b
y 
a 
fa
m
ily
 d
en
tis
t o
r l
oc
al
  
co
m
m
un
ity
 d
en
ta
l s
er
vi
ce
s 
ar
e 
es
se
nt
ia
l. 
M
is
si
ng
 te
et
h/
m
al
oc
cl
us
io
n/
ot
he
r d
en
ta
l a
no
m
al
ie
s:
 re
fe
r t
o 
a 
co
ns
ul
ta
nt
 in
  
pa
ed
ia
tri
c 
de
nt
is
try
 fo
r m
ul
tid
is
ci
pl
in
ar
y 
m
an
ag
em
en
t. 
R
ef
er
 to
 O
ra
l/M
ax
ill
of
ac
ia
l/H
ea
d 
&
 N
ec
k 
S
ur
ge
on
 o
r e
xp
er
t d
en
ta
l c
ar
e 
ce
nt
re
. 
• 
G
en
et
ic
 c
ou
ns
el
lin
g 
R
ef
er
 fo
r g
en
et
ic
 c
ou
ns
el
lin
g,
 m
ut
at
io
n 
te
st
in
g 
an
d 
di
sc
us
si
on
 o
f r
is
ks
 to
 c
hi
ld
re
n 
an
d 
op
tio
ns
 in
 p
re
gn
an
cy
, a
t a
n 
ap
pr
op
ria
te
 ti
m
e.
 
• 
Vi
si
on
 s
cr
ee
ni
ng
: 
sq
ui
nt
, 
po
st
er
io
r 
se
gm
en
t 
oc
ul
ar
 c
ha
ng
es
 a
nd
 a
nt
er
io
r 
 
se
gm
en
t 
oc
ul
ar
 a
bn
or
m
al
it
ie
s 
ha
ve
 b
ee
n 
de
sc
ri
be
d 
in
 N
S.
 
U
nl
es
s 
al
re
ad
y 
un
de
r o
ph
th
al
m
ic
 m
an
ag
em
en
t, 
N
S
 p
at
ie
nt
s 
sh
ou
ld
 b
e 
re
fe
rr
ed
 to
 
an
 o
ph
th
al
m
ol
og
is
t f
or
 a
ss
es
sm
en
t i
f/a
s 
ap
pr
op
ria
te
. 
• 
Sk
in
 p
ro
bl
em
s:
 
Ke
ra
to
si
s 
Pi
la
ri
s/
U
le
ry
th
em
a 
 
A
vo
id
 s
ki
n 
dr
yn
es
s,
 w
hi
ch
 c
an
 b
e 
w
or
se
ne
d 
by
 lo
ng
 h
ot
 b
at
hs
, p
er
fu
m
ed
 s
oa
ps
 a
nd
 
dr
y 
at
m
os
ph
er
es
. 
M
an
ag
e 
us
in
g 
em
ol
lie
nt
s,
 k
er
at
ol
yt
ic
 a
ge
nt
s 
e.
g.
 s
al
ic
yl
ic
 a
ci
d 
in
 u
re
a 
cr
ea
m
, i
f  
to
le
ra
te
d,
 o
r s
ho
rt 
co
ur
se
s 
of
 to
pi
ca
l s
te
ro
id
s 
if 
ne
ce
ss
ar
y 
(e
sp
ec
ia
lly
 if
  
er
yt
he
m
at
ou
s)
. 
W
ith
in
 a
 s
pe
ci
al
is
t d
er
m
at
ol
og
y 
se
tti
ng
, i
t s
ho
ul
d 
be
 n
ot
ed
 th
at
 re
tin
oi
ds
 m
ay
 n
ot
 b
e 
a 
fir
st
 c
ho
ic
e 
tre
at
m
en
t a
s 
th
ey
 h
av
e 
be
en
 s
ho
w
n 
no
t t
o 
w
or
k 
in
 s
om
e 
N
S
 p
at
ie
nt
s.
 
!  
A
na
es
th
es
ia
  
N
S
 c
an
 c
au
se
 c
oa
gu
la
tio
n 
di
ffi
cu
lti
es
 th
at
 s
ho
ul
d 
be
 e
va
lu
at
ed
 p
rio
r t
o 
su
rg
ic
al
 p
ro
ce
du
re
s 
so
 th
at
 c
ar
e,
 in
cl
ud
in
g 
an
ae
st
he
si
a,
 c
an
 b
e 
pl
an
ne
d 
ac
co
rd
in
gl
y.
 
P
at
ie
nt
s 
w
ith
 N
S
 a
nd
 h
ae
m
od
yn
am
ic
al
ly
 s
ig
ni
fic
an
t c
ar
di
ac
 in
vo
lv
em
en
t s
uc
h 
as
 s
ev
er
e 
hy
pe
rtr
op
hi
c 
ca
rd
io
m
yo
pa
th
y 
ne
ed
 to
 tr
ea
te
d
ac
co
rd
in
g 
to
 th
e 
us
ua
l p
rin
ci
pl
es
 fo
r p
at
ie
nt
s 
w
ith
 s
uc
h 
ca
rd
io
va
sc
ul
ar
 ri
sk
 fa
ct
or
s.
 
P
at
ie
nt
s 
w
ith
 N
S
 m
ay
 h
av
e 
cr
an
io
fa
ci
al
 a
nd
/o
r v
er
te
br
al
 a
no
m
al
ie
s 
th
at
 c
ou
ld
 a
ffe
ct
 in
tu
ba
tio
n 
or
 th
e 
ad
m
in
is
tra
tio
n 
of
 s
pi
na
l a
na
es
th
es
ia
. 
N
oonan Syndrom
e Clinical M
anagem
ent G
uidelines
140 141
Noonan Syndrome Clinical Management Guidelines 
15
Noonan Syndrome Clinical Management Guidelines 
18
+
AGE
A
BN
L
A
BN
L
A
BN
L
A
BN
L
A
BN
L
Re
co
m
m
en
da
ti
on
s 
fo
r 
th
e 
m
an
ag
em
en
t 
of
N
oo
na
n 
Sy
nd
ro
m
e 
~ 
in
 a
du
lt
ho
od
 (
2)
 ~
Re
co
m
m
en
de
d 
Te
st
in
g/
Sc
re
en
in
g 
Cl
in
ic
al
 M
an
ag
em
en
t 
Re
co
m
m
en
da
ti
on
s 
• 
Th
yr
oi
d 
sc
re
en
in
g 
 
S
cr
ee
n 
bl
oo
d 
fo
r t
hy
ro
id
 a
bn
or
m
al
iti
es
 e
ve
ry
 3
—
5 
ye
ar
s.
 
M
an
ag
e 
an
om
al
ie
s 
as
 in
 g
en
er
al
 p
op
ul
at
io
n.
 
• 
Ly
m
ph
oe
de
m
a 
 
Th
er
e 
is
 a
n 
in
cr
ea
se
d 
ris
k 
of
 d
ev
el
op
in
g 
ly
m
ph
oe
de
m
a 
in
 N
S
, t
hr
ou
gh
ou
t  
ad
ul
th
oo
d.
M
an
ag
em
en
t s
ho
ul
d 
be
 th
e 
sa
m
e 
as
 fo
r g
en
er
al
 p
op
ul
at
io
n.
 
• 
Sk
in
 p
ro
bl
em
s:
 
Ke
ra
to
si
s 
Pi
la
ri
s/
U
le
ry
th
em
a 
 
A
vo
id
 s
ki
n 
dr
yn
es
s,
 w
hi
ch
 c
an
 b
e 
w
or
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Nederlandse samenvatting
In dit proefschrift worden vijf studies beschreven die tot doel hebben het 
cognitieve en emotionele functioneren van volwassenen met het syndroom 
van Noonan te onderzoeken. Daartoe worden allereerst, in hoofdstuk 1, enkele 
begrippen en aan het syndroom gerelateerde kenmerken geïntroduceerd.
Het syndroom van Noonan
Het noonansyndroom (NS) werd voor het eerst beschreven door de Amerikaanse 
kindercardioloog Jacqueline Anne Noonan in de jaren zestig van de vorige 
eeuw. Het is in vergelijking met andere genetische syndromen een vrij 
onbekende aandoening, terwijl de prevalentie relatief hoog is (1:1000-2500). De 
diagnose wordt gesteld met behulp van een scoringssysteem dat gebaseerd is 
op uiterlijke kenmerken. De belangrijkste daarvan zijn karakteristieke gelaats-
trekken, aangeboren hartafwijkingen en een geringe lengte. In de vroege jeugd 
treden vaak voedingsproblemen op en de ontwikkeling van taal en motoriek 
verloopt veelal vertraagd. De intelligentie is gemiddeld gezien licht verlaagd 
en ongeveer de helft van de kinderen met NS volgt speciaal onderwijs. De 
variatie in uiterlijke verschijning en in ontwikkelingsniveau is groot. Met het 
vorderen van de leeftijd worden de typische uiterlijke kenmerken vaak minder 
goed zichtbaar. 
 De meeste gevallen van NS ontstaan op basis van een spontane, nieuwe 
(de novo) mutatie. Overerving volgt een autosomaal dominant patroon, wat 
inhoudt dat zowel mannen als vrouwen ontvankelijk zijn en dat een kind van 
iemand met NS 50% kans heeft om de aandoening ook te hebben. Bij ongeveer 
75% van de patiënten met klinische kenmerken van NS kan via moleculaire 
diagnostiek een genafwijking worden gevonden. Een mutatieanalyse, die 
tegenwoordig al tijdens de zwangerschap kan worden verricht, kan worden 
uitgevoerd op afgenomen bloed, placentaweefsel of vruchtwater. In 1994 werd 
op basis van linkage-onderzoek vermoed dat een genetische mutatie gevonden 
kon worden op de lange arm van chromosoom 12. In 2001 werd op deze locatie 
inderdaad het eerste gen voor NS gevonden: PTPN11 (12q24.1). Bij ongeveer de 
helft van de patiënten met NS wordt in dit gen een mutatie aangetroffen. 
Inmiddels zijn daarnaast NS-gerelateerde mutaties gevonden in acht andere 
genen: SOS1 (circa 10% van de klinisch gediagnosticeerde patiënten), RAF1 
(5-15%), KRAS (2-5%), NRAS (<2-5%), BRAF (<2%), SHOC2 (<2%), MAP2K1 
(MEK1) (<2%) en CBL (<2%). Het betreft activerende mutaties in genen die 
coderen voor eiwitten in de Ras mitogen-activated protein kinase (Ras-MAPK) 
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Affectieve informatieverwerking
Aangezien er anekdotische aanwijzingen zijn voor problemen in sociaal- 
emotionele processen bij patiënten met NS, is dit gebied opgenomen en 
uitgelicht in twee van de onderhavige studies. Het begrip ‘affectieve informatie-
verwerking’ wordt hierbij gehanteerd als een verzamelnaam voor de cognitieve 
verwerking van alle soorten emotionele informatie, zowel in intrapersoonlijke 
situaties als in interpersoonlijke (sociale) situaties. Sociale cognitie kan 
beschouwd worden als een onderdeel van dit brede begrip en heeft primair 
betrekking op de laatstgenoemde situaties, waarin het gaat om de mentale 
verwerking van emoties in intermenselijke relaties. 
 Het interpreteren van lichaamstaal, het anticiperen op reacties en het 
herkennen van emoties in gezichtsuitdrukkingen van anderen zijn voorbeelden 
van affectieve processen in een interpersoonlijke context. Het kunnen 
herkennen, benoemen en verklaren van eigen emoties kan gezien worden als 
een intrapersoonlijk affectief proces. Wanneer hierin problemen optreden, 
wordt gesproken van alexithymie. Dit concept werd in 1973 geïntroduceerd 
door Sifneos als ‘het ontbreken van woorden voor emoties’. Het stamt 
oorspronkelijk uit de psychodynamische traditie en werd aanvankelijk 
voornamelijk onderzocht bij patiënten met psychosomatische stoornissen. 
Alexithymie komt bij circa 10% van de bevolking voor, vormt een belemmering 
voor effectieve emotieregulatie en vergroot het risico op lichamelijke klachten 
en psychopathologie, waaronder angst- en stemmingsstoornissen. Binnen een 
neuropsychologisch referentiekader kan alexithymie worden beschouwd als 
een affectief informatieverwerkingsprobleem.
De eerste twee studies in dit proefschrift betreffen literatuuronderzoek, ter 
voorbereiding op de daaropvolgende empirische studies. In hoofdstuk 2 wordt 
een samenvatting gegeven van het beschikbare onderzoek naar het neuropsy-
chologisch functioneren en psychopathologie bij NS. Uit dit hoofdstuk blijkt 
dat hiernaar nog weinig systematisch onderzoek is gedaan, terwijl het toch om 
een relatief veel voorkomende aandoening gaat die nogal eens gepaard blijkt 
te gaan met leerproblemen. De meeste publicaties bevatten gevalsbeschrijvin-
gen of kleine groepsstudies bij kinderen en adolescenten met NS. Veel van deze 
studies kennen methodologische beperkingen, zoals het ontbreken van een 
controlegroep en het gebruik van een weinig gedifferentieerd instrumentarium. 
Hoewel hierdoor de validiteit en generaliseerbaarheid van de bevindingen 
niet altijd optimaal is, kan voorzichtig gesteld worden dat het cognitief profiel 
van kinderen en adolescenten met NS gekenmerkt wordt door gespreide, maar 
gemiddeld licht verlaagde intellectuele capaciteiten, een vertraagde ontwikkeling 
pathway, een signaalketen die betrokken is bij de regulatie van ontwikkelings-
processen, waaronder groei en migratie van celweefsel. De zoektocht naar 
andere mutaties is nog gaande.
 Er is een aantal syndromen met pathogenetische overeenkomsten met NS. 
Voorbeelden hiervan zijn het cardio-facio-cutaan syndroom, het costellosyn-
droom, neurofibromatose type 1 (NF1), het LEOPARD-syndroom en het 
Noonan-like syndrome with loose anagen hair. Deze aandoeningen zijn allen 
gerelateerd aan genafwijkingen binnen de genoemde Ras-MAPK pathway en 
worden gegroepeerd in de familie van neurocardiofaciocutane syndromen, 
ofwel de ‘rasopathieën’. Anderzijds zijn er ook aandoeningen die een heel 
ander genotype kennen, maar wel fenotypische overeenkomsten hebben met 
NS. Voorbeelden hiervan zijn het turnersyndroom en het syndroom van 
Williams.    
 Over de informatieverwerking en het welzijn van mensen met NS is de 
beschikbare informatie beperkt; veel onderzoek richt zich op genetische 
aspecten en op somatische complicaties die kunnen optreden bij deze 
aandoening. Hartaandoeningen komen veelvuldig voor bij NS. Het betreft 
hier voornamelijk valvulaire pulmonalisstenose (65%), hypertrofische cardio-
myopathie en atriumseptumdefecten. Hoewel het meestal gaat om lichte 
aandoeningen, zouden als gevolg van deze cardiale afwijkingen, die de door- 
bloeding van de hersenen kunnen beïnvloeden, cognitieve problemen verwacht 
kunnen worden. Op grond van de disregulatie van de hierboven beschreven 
Ras-MAPK-signaaltransductie zou bij NS de ontwikkeling van de hersenen en 
van de cognitieve functies eveneens anders kunnen verlopen. Een lagere 
intelligentie en verminderde zelfredzaamheid in vergelijking met kinderen die 
zich gewoon ontwikkelen, zijn eerder in verband gebracht met veranderingen 
in de werking van deze pathway. Voorts zijn er enkele studies die ontwikkelings-
problemen en leerproblemen bij kinderen met NS rapporteren. In deze studies 
wordt vaak melding gemaakt van observaties die wijzen op problemen in de 
sociale vaardigheid en in het benoemen en uiten van gevoelens. Bij kinderen 
wordt een vertraagde sociaal-emotionele ontwikkeling waargenomen. Systematisch 
en gecontroleerd onderzoek van de cognitieve functies met inbegrip van de 
sociaal-emotionele capaciteiten, hetgeen zeker voor volwassenen met NS nog 
goeddeels ontbrak, vormt de kern van dit proefschrift. 
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In het tweede deel van dit proefschrift, in de hoofdstukken 4 tot en met 6, 
worden verschillende empirische studies naar het neuropsychologisch 
functioneren van volwassenen met NS beschreven. Hoofdstuk 4 geeft de 
bevindingen weer van een verkennende pilotstudie naar het neuropsycholo-
gisch functioneren en psychopathologie bij tien volwassenen met NS. In deze 
steekproef ligt, in vergelijking met normatieve waarden, de intelligentie op 
een laaggemiddeld niveau en de Bermond-Vorst Alexithymia Questionnaire 
laat verhogingen zien op schalen die cognitieve aspecten van alexithymie in 
kaart brengen. Evenzo zijn er enige aanwijzingen voor problemen in de 
herkenning van emoties bij anderen. Hoewel niet opvallend sterk, lijken de 
volwassenen met NS ten opzichte van een normatieve steekproef meer klachten 
te ervaren en te rapporteren terwijl zij hun kwaliteit van leven als gemiddeld 
tot goed beoordelen. Bij de meeste patiënten wordt een opvallend meegaande, 
sociaal wenselijke opstelling geobserveerd. Slechts bij één van de tien patiënten 
is sprake van psychopathologie in de zin van een classificatie volgens de 
DSM-IV, terwijl lichte verschijnselen van depressie en angst de groep als 
geheel kenmerken.
 In de hoofdstukken 5 en 6 worden twee uitgebreide empirische vervolgstudies 
van het cognitief en sociaal-emotioneel functioneren bij volwassenen met NS 
beschreven. In de eerste plaats wordt de emotieherkenning bij anderen en bij 
zichzelf onderzocht, door vergelijking van bevindingen op een emotieherken-
ningstest en op verschillende alexithymievragenlijsten bij 40 volwassen 
patiënten met NS met die van 40 op leeftijd en opleidingsniveau gematchte 
controleproefpersonen (hoofdstuk 5). De resultaten laten weliswaar een klein 
groepseffect zien op de emotieherkenningstest in het nadeel van de patiënten, 
maar de herkenning van emoties bij anderen lijkt kwalitatief gezien niet 
wezenlijk anders te verlopen en er worden geen emotiespecifieke verschillen 
in perceptie gevonden. De patiënten met NS rapporteren wel significant meer 
alexithyme kenmerken dan de controleproefpersonen. Ook maken zij kenbaar 
meer klachten ten aanzien van hun cognitieve functioneren te hebben en 
geven zij aan in sociale situaties hogere stressniveaus te ervaren. 
 Ten slotte wordt in hoofdstuk 6 het functioneren op andere relevante 
cognitieve domeinen in kaart gebracht bij 42 personen met NS. De prestaties 
op de verschillende domeinen zijn hier vergeleken met die van 42 controle-
proefpersonen die wat betreft opleiding en leeftijd vergelijkbaar waren met de 
NS-groep en met beschikbare normatieve waarden. De snelheid van informa-
tieverwerking, verschillende geheugenaspecten, de executieve functies en vi-
suoconstructieve vermogens worden voor deze groepen beschreven aan de 
hand van verschillende tests. Patiënten met NS blijken in vergelijking met de 
controleproefpersonen alleen significant lager te presteren in het domein 
van de taalfuncties en motoriek die normaliseert in de volwassenheid, afwijkingen 
in de aandachtsfuncties en enige problemen in de ontwikkeling van plannings- 
en organisatievaardigheden. Daarnaast zijn er aanwijzingen voor een 
vertraagde sociaal-emotionele ontwikkeling en problemen in de communicatie 
van emoties (alexithymie). Bij kinderen wordt een verhoogd risico op gedrags-
problemen opgemerkt, waarbij naast de genoemde sociale problemen ook 
impulsiviteit en stemmingswisselingen worden genoemd. De verschillende 
studies wijzen op een grote variatie in de vaardigheden en het functioneren 
van patiënten met NS en één cognitief fenotype lijkt dan ook niet aan de orde. 
 Hoofdstuk 3 beschrijft eveneens een literatuurstudie, waarin getracht wordt 
meer zicht te krijgen op het neurale substraat van alexithymie. De aanleiding 
hiervoor is enerzijds gelegen in het feit dat er aanwijzingen zijn voor alexithyme 
kenmerken bij patiënten met NS, terwijl het construct alexithymie ter discussie 
kan worden gesteld. Anderzijds zijn eventuele onderliggende mechanismen in 
de hersenen voor deze (of andere) cognitieve problemen bij NS niet of 
nauwelijks onderzocht, terwijl het onderzoek naar een neurale basis van 
alexithymie in het algemeen inmiddels een aardige historie kent. Historisch 
zijn aanvankelijk en met name de rechterhemisfeer en het corpus callosum 
genoemd en onderzocht op hun bijdrage aan alexithymie. In het bijzonder bij 
mannelijke proefpersonen met alexithymie is herhaaldelijk aangetoond dat de 
activiteit van de rechterhersenhelft verlaagd was ten opzichte van personen 
zonder alexithymie. Verder worden laesies in het corpus callosum in verband 
gebracht met een disconnectie van emotionele belevingen en de cognitieve 
verwerking daarvan (bijvoorbeeld het verbaliseren van ervaren gevoelens). 
Uit onderzoek naar de cortex cingularis anterior, bekend om zijn betrokkenheid 
bij motivationele processen, komt naar voren dat alexithyme kenmerken 
geassocieerd zijn met een verminderde activatie van deze hersenstructuur, 
met name bij inductie van negatieve emoties. Een verminderde activiteit van 
de cortex cingularis posterior lijkt gerelateerd aan de met alexithymie gepaard 
gaande problemen in verbeelding of fantaseren. Laesies in de cortex insularis 
anterior, bekend om zijn functie in de integratie van lichaamssignalen en de 
bewuste representatie van gevoelens, kunnen leiden tot verminderde 
empathische vermogens en tot alexithymie. Al met al blijken meerdere hersen-
structuren (en mogelijk meerdere netwerken) betrokken te zijn bij alexithymie 
en lijkt een eenzijdige neurale benadering het construct niet voldoende te 
kunnen verklaren. Alexithymie kan waarschijnlijk beter begrepen worden als 
een multifactorieel bepaalde aandoening, waarbij een ontwikkelingsparadig-
ma dat gebruik maakt van gecombineerde neurobiologische, neuropsycholo-
gische en leertheoretische inzichten, behulpzaam kan zijn om tot een beter 
begrip te komen.                                             
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 Deze bevindingen onderstrepen het belang van individueel neuropsycho-
logisch onderzoek op verschillende momenten in de ontwikkeling van 
patiënten met NS. In het bijzonder de domeinen snelheid van informatie-
verwerking en affectieve informatieverwerking verdienen extra aandacht, 
zowel in diagnostisch onderzoek in dienst van de patiëntenzorg als in toekomstig 
wetenschappelijk onderzoek. Hoewel het verrichten van gecontroleerd, toegepast 
wetenschappelijk onderzoek bij genetische aandoeningen niet eenvoudig is, 
zou dit type onderzoek bij voorkeur gebaseerd moeten zijn op een ontwikke-
lingsmodel waarin genetische, somatische, en contextuele variabelen worden 
opgenomen, met als doel inzicht te krijgen in de bijdrage daarvan aan de 
ontwikkeling van cognitie en gedrag. Naast het opnemen van gezonde en op 
relevante kenmerken vergelijkbare controlegroepen zou het interessant zijn 
om controlegroepen te includeren van patiënten met genetische aandoeningen 
met overlappende genotypische of fenotypische kenmerken, om na te gaan in 
hoeverre de hier gepresenteerde uitkomsten specifiek zijn voor het syndroom 
van Noonan.
snelheid van informatieverwerking. Op de uitgestelde herinnering is de 
prestatie van de patiëntgroep juist iets beter dan die van de controlegroep. 
Naast deze objectieve maten voor het cognitief functioneren wordt de 
subjectieve ervaring van cognitieve klachten (uitgebreider dan in hoofdstuk 5) 
en van het algemene klachtenniveau onderzocht. Ten aanzien van het algemene 
klachtenniveau worden geen verschillen gevonden met de controlegroep, 
maar patiënten met NS rapporteren (opnieuw) meer klachten van cognitieve 
aard dan de controleproefpersonen. Er is hierbij geen correlatie aangetoond 
tussen de vastgestelde snelheidsproblemen en de subjectieve beleving van 
klachten op het gebied van de informatieverwerking. 
 Voor de gevonden problemen in de affectieve informatieverwerking 
(alexithyme kenmerken) en de achterblijvende snelheid worden in de hoofd - 
stukken 5 en 6 verklaringen gesuggereerd van genetische, somatische, cognitieve 
en psychosociale aard. Er zou sprake kunnen zijn van een veranderde aanleg 
en/of functie van de hersenen als direct gevolg van de genetische afwijking, 
maar ook de veel voorkomende congenitale hartaandoeningen zouden cognitieve 
complicaties met zich mee kunnen brengen. Voorts is aannemelijk, zeker met 
betrekking tot de sociaal-cognitieve problemen, dat de ontwikkelingsgeschie-
denis een rol speelt. Een meerderheid van de kinderen met NS is tijdens de 
jeugd gepest en daarnaast is er, vanwege syndroomgebonden somatische 
problematiek, vaak sprake van frequent ziekenhuisbezoek vanaf de vroege 
jeugd. Het is goed denkbaar dat deze factoren de sociaal-emotionele 
ontwikkeling in negatieve zin beïnvloeden. Het sociaal-cognitieve profiel zou 
dan niet specifiek zijn voor NS, maar zou waarschijnlijk, tenminste gedeeltelijk, 
samenvallen met een profiel dat verwacht kan worden bij diverse genetische 
aandoeningen met een overlappend fenotype. 
Tot besluit
Concluderend kan gesteld worden dat de beschikbare studies bij kinderen en 
adolescenten met NS suggereren dat hun neuropsychologisch profiel gekenmerkt 
wordt door een vertraagde ontwikkeling, aandachts- en planningsproblemen, 
alsmede sociaal-emotionele problemen. In de in dit proefschrift beschreven 
empirische studies zijn voor het eerst alle cognitieve functies onderzocht bij 
een groep volwassenen met NS en de resultaten vergeleken met die van een 
vergelijkbare controlegroep. Een verminderde verwerkingssnelheid en problemen 
in de affectieve informatieverwerking konden hierbij worden geobjectiveerd. 
De volwassen patiënten ervaren cognitieve klachten die niet geheel verklaard 
lijken te kunnen worden door de objectieve stoornissen. 
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dankzij velen.  
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gekomen. Wat ben ik trots en blij dat ik bij jou mag promoveren!   
Prof. dr. Kessels, beste Roy, dank je wel voor je enthousiasme, je voortvarend-
heid en alle mentale en praktische ondersteuning, zelfs vanuit Australië. Jouw 
feedback heeft bijgedragen aan de sjiekste publicaties.      
Prof. dr. Verhoeven, beste Willem, dank voor je belangrijke rol bij de start van 
het onderzoek en voor je geduld, toen jij al wel en ik nog niet wist dat ik dit 
ging doen. Onze gezamenlijke consulten heb ik als zeer leerzaam ervaren.
Co-promotor dr. van der Burgt, beste Ineke, jij liet me kennismaken met 
mensen met het noonansyndroom, waardoor mijn werk werd verrijkt en het 
onderzoek kon floreren. In dit verband bedank ik graag ook dr. Joep Tuerlings, 
die mede aan de basis stond voor dit project van de researchgroep Psychopa-
thologie en Genetica, een samenwerking van het Topklinisch Centrum voor 
Neuropsychiatrie en de afdeling klinische genetica van het UMC St Radboud. 
Ook dr. Siegfried Tuinier ben ik dank verschuldigd voor zijn betrokkenheid bij 
de start van het onderzoek.   
Graag bedank ik het voormalige en het huidige bestuur van Vincent van Gogh 
voor het gestaag faciliteren en stimuleren van wetenschappelijk onderzoek 
binnen onze GGZ-instelling. Mijn dank strekt zich ook uit naar mr. drs. Ton 
Ederveen en de andere bestuursleden van de Stichting ter Bevordering van 
Wetenschappelijk Onderzoek. Het bestuur van de Stichting Noonan Syndroom 
bedank ik graag voor de hulp bij de werving van deelnemers. De medische 
adviesraad dank ik voor de waardevolle uitwisselingen in de afgelopen jaren. 
Mijn grote dank gaat uit naar alle mensen met het syndroom van Noonan en 
alle controleproefpersonen die zich zo bereidwillig hebben ingezet.
I thank the Dyscerne Network, in particular the Development Group for the 
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en dank familie Christiaans, ook bij jullie ben ik thuis. Dank ook aan mijn 
nieuwste Limburgse familie, die Timo en mij zo warm onthaalde.  
Mijn ouders, Theo Wingbermühle en Nelleke Wingbermühle-Prins, dank je 
wel voor het liefdevolle thuis waar ik opgroeide, waardoor ik uiteindelijk in de 
psychologie mijn werk kon vinden. Pap, wat ben ik blij dat jij er bent en wat 
zou mama dit mooi gevonden hebben! Liefste Jan-Willem ten slotte, wat een 
voorrecht dat jij altijd naast me staat. Jouw kijk op de dingen maakt alles 
spannender én lichter. Ik beloof je dat het nu een beetje rustiger wordt. Nah ja, 
tot ik weer eens iets bedenk en jij zegt: tja, doen, natuurlijk!
Voor hun enthousiaste assistentie bij de dataverzameling bedank ik drs. Loes 
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